{"idB": "1316175_12_item1_p138_s0", "idA": "1316175_11_item1_p106_s0", "sentA": "In December 2007, we completed a randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating two doses of varespladib versus placebo amongst 138 patients with stable CAD.", "sentB": "In December 2011, we completed the technology transfer from Amgen and manufacturing scale up to 3,000 liters at our contract manufacturing organization, or CRO (Fujifilm Diosynth Bioservices or \"Fujifilm\").", "type": 1, "words": ["<tag1>", "In", "December", "2007,", "we", "completed", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2", "clinical", "study", "evaluating", "two", "doses", "of", "varespladib", "versus", "placebo", "amongst", "138", "patients", "with", "stable", "CAD.", "<tag2>", "In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CRO", "(Fujifilm", "Diosynth", "Bioservices", "or", "\"Fujifilm\").", "<tag3>"], "wordsA": ["In", "December", "2007,", "we", "completed", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2", "clinical", "study", "evaluating", "two", "doses", "of", "varespladib", "versus", "placebo", "amongst", "138", "patients", "with", "stable", "CAD."], "wordsB": ["In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CRO", "(Fujifilm", "Diosynth", "Bioservices", "or", "\"Fujifilm\")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p157_s3", "idA": "1316175_11_item1_p120_s0", "sentA": "Approximately 150 preclinical pharmacology and toxicology studies have been completed with varespladib and A-001, including two-year rat and mouse carcinogenicity studies, one-year primate study and three-month rat study in combination with Lipitor (atorvastatin).", "sentB": "This damage is more commonly labeled as VOC.", "type": 1, "words": ["<tag1>", "Approximately", "150", "preclinical", "pharmacology", "and", "toxicology", "studies", "have", "been", "completed", "with", "varespladib", "and", "A-001,", "including", "two-year", "rat", "and", "mouse", "carcinogenicity", "studies,", "one-year", "primate", "study", "and", "three-month", "rat", "study", "in", "combination", "with", "Lipitor", "(atorvastatin).", "<tag2>", "This", "damage", "is", "more", "commonly", "labeled", "as", "VOC.", "<tag3>"], "wordsA": ["Approximately", "150", "preclinical", "pharmacology", "and", "toxicology", "studies", "have", "been", "completed", "with", "varespladib", "and", "A-001,", "including", "two-year", "rat", "and", "mouse", "carcinogenicity", "studies,", "one-year", "primate", "study", "and", "three-month", "rat", "study", "in", "combination", "with", "Lipitor", "(atorvastatin)."], "wordsB": ["This", "damage", "is", "more", "commonly", "labeled", "as", "VOC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p140_s2", "idA": "1316175_11_item1_p135_s0", "sentA": "In November 2010, we placed a voluntary hold on the PEARL-SC study due to problems found with vials.", "sentB": "It was determined the vial breakage was due to low temperature shipping conditions.", "type": 1, "words": ["<tag1>", "In", "November", "2010,", "we", "placed", "a", "voluntary", "hold", "on", "the", "PEARL-SC", "study", "due", "to", "problems", "found", "with", "vials.", "<tag2>", "It", "was", "determined", "the", "vial", "breakage", "was", "due", "to", "low", "temperature", "shipping", "conditions.", "<tag3>"], "wordsA": ["In", "November", "2010,", "we", "placed", "a", "voluntary", "hold", "on", "the", "PEARL-SC", "study", "due", "to", "problems", "found", "with", "vials."], "wordsB": ["It", "was", "determined", "the", "vial", "breakage", "was", "due", "to", "low", "temperature", "shipping", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p138_s1", "idA": "1316175_11_item1_p136_s1", "sentA": "Manufacturing was conducted per current good manufacturing practices, or cGMP, and the product was released to clinical sites in July 2010.", "sentB": "Two (2) batches of blisibimod produced under US FDA good manufacturing procedures, or GMP, at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "type": 1, "words": ["<tag1>", "Manufacturing", "was", "conducted", "per", "current", "good", "manufacturing", "practices,", "or", "cGMP,", "and", "the", "product", "was", "released", "to", "clinical", "sites", "in", "July", "2010.", "<tag2>", "Two", "(2)", "batches", "of", "blisibimod", "produced", "under", "US", "FDA", "good", "manufacturing", "procedures,", "or", "GMP,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag3>"], "wordsA": ["Manufacturing", "was", "conducted", "per", "current", "good", "manufacturing", "practices,", "or", "cGMP,", "and", "the", "product", "was", "released", "to", "clinical", "sites", "in", "July", "2010."], "wordsB": ["Two", "(2)", "batches", "of", "blisibimod", "produced", "under", "US", "FDA", "good", "manufacturing", "procedures,", "or", "GMP,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p87_s2", "idA": "1316175_11_item1_p255_s0", "sentA": "Human clinical studies are typically conducted in three sequential phases that may overlap or be combined:", "sentB": "P-values below 0.05 are typically referred to as statistically significant.", "type": 1, "words": ["<tag1>", "Human", "clinical", "studies", "are", "typically", "conducted", "in", "three", "sequential", "phases", "that", "may", "overlap", "or", "be", "combined:", "<tag2>", "P-values", "below", "0.05", "are", "typically", "referred", "to", "as", "statistically", "significant.", "<tag3>"], "wordsA": ["Human", "clinical", "studies", "are", "typically", "conducted", "in", "three", "sequential", "phases", "that", "may", "overlap", "or", "be", "combined:"], "wordsB": ["P-values", "below", "0.05", "are", "typically", "referred", "to", "as", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p137_s0", "idA": "1316175_11_item1_p275_s2", "sentA": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued Written Request for such a study.", "sentB": "Upon completion of PEARL-SC, patients may be invited to enroll in an open-label extension study in which patients will receive active study drug (blisibimod) for the primary objective of monitoring long-term safety.", "type": 1, "words": ["<tag1>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study.", "<tag2>", "Upon", "completion", "of", "PEARL-SC,", "patients", "may", "be", "invited", "to", "enroll", "in", "an", "open-label", "extension", "study", "in", "which", "patients", "will", "receive", "active", "study", "drug", "(blisibimod)", "for", "the", "primary", "objective", "of", "monitoring", "long-term", "safety.", "<tag3>"], "wordsA": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study."], "wordsB": ["Upon", "completion", "of", "PEARL-SC,", "patients", "may", "be", "invited", "to", "enroll", "in", "an", "open-label", "extension", "study", "in", "which", "patients", "will", "receive", "active", "study", "drug", "(blisibimod)", "for", "the", "primary", "objective", "of", "monitoring", "long-term", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p3_s1", "idA": "1316175_11_item1_p288_s1", "sentA": "The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug or biological product.", "sentB": "After review of the totality of evidence, including the emerging unblinded data from VISTA-16, the DSMB was unanimous in its view that there was cogent evidence to recommend early termination of the trial.", "type": 1, "words": ["<tag1>", "The", "cGMP", "requirements", "apply", "to", "all", "stages", "of", "the", "manufacturing", "process,", "including", "the", "production,", "processing,", "sterilization,", "packaging,", "labeling,", "storage", "and", "shipment", "of", "the", "drug", "or", "biological", "product.", "<tag2>", "After", "review", "of", "the", "totality", "of", "evidence,", "including", "the", "emerging", "unblinded", "data", "from", "VISTA-16,", "the", "DSMB", "was", "unanimous", "in", "its", "view", "that", "there", "was", "cogent", "evidence", "to", "recommend", "early", "termination", "of", "the", "trial.", "<tag3>"], "wordsA": ["The", "cGMP", "requirements", "apply", "to", "all", "stages", "of", "the", "manufacturing", "process,", "including", "the", "production,", "processing,", "sterilization,", "packaging,", "labeling,", "storage", "and", "shipment", "of", "the", "drug", "or", "biological", "product."], "wordsB": ["After", "review", "of", "the", "totality", "of", "evidence,", "including", "the", "emerging", "unblinded", "data", "from", "VISTA-16,", "the", "DSMB", "was", "unanimous", "in", "its", "view", "that", "there", "was", "cogent", "evidence", "to", "recommend", "early", "termination", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p78_s1", "idA": "1316175_11_item1_p288_s1", "sentA": "The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug or biological product.", "sentB": "After review of the totality of evidence, including the emerging unblinded data from VISTA-16, the DSMB was unanimous in its view that there was cogent evidence to recommend early termination of the trial.", "type": 1, "words": ["<tag1>", "The", "cGMP", "requirements", "apply", "to", "all", "stages", "of", "the", "manufacturing", "process,", "including", "the", "production,", "processing,", "sterilization,", "packaging,", "labeling,", "storage", "and", "shipment", "of", "the", "drug", "or", "biological", "product.", "<tag2>", "After", "review", "of", "the", "totality", "of", "evidence,", "including", "the", "emerging", "unblinded", "data", "from", "VISTA-16,", "the", "DSMB", "was", "unanimous", "in", "its", "view", "that", "there", "was", "cogent", "evidence", "to", "recommend", "early", "termination", "of", "the", "trial.", "<tag3>"], "wordsA": ["The", "cGMP", "requirements", "apply", "to", "all", "stages", "of", "the", "manufacturing", "process,", "including", "the", "production,", "processing,", "sterilization,", "packaging,", "labeling,", "storage", "and", "shipment", "of", "the", "drug", "or", "biological", "product."], "wordsB": ["After", "review", "of", "the", "totality", "of", "evidence,", "including", "the", "emerging", "unblinded", "data", "from", "VISTA-16,", "the", "DSMB", "was", "unanimous", "in", "its", "view", "that", "there", "was", "cogent", "evidence", "to", "recommend", "early", "termination", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p79_s0", "idA": "1316175_11_item1_p306_s0", "sentA": "The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest.", "sentB": "prespecified primary and secondary endpoints even if the trial continues to its scheduled termination.", "type": 1, "words": ["<tag1>", "The", "cost", "of", "pharmaceuticals", "continues", "to", "generate", "substantial", "governmental", "and", "third-party", "payor", "interest.", "<tag2>", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continues", "to", "its", "scheduled", "termination.", "<tag3>"], "wordsA": ["The", "cost", "of", "pharmaceuticals", "continues", "to", "generate", "substantial", "governmental", "and", "third-party", "payor", "interest."], "wordsB": ["prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continues", "to", "its", "scheduled", "termination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p213_s2", "idA": "1316175_11_item1_p313_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "If we were to challenge the validity of any issued United States patent in court, we would need to overcome the presumption of validity that attaches to every United States patent by presenting clear and convincing evidence as to the invalidity of the patent's claims.", "type": 1, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "United", "States", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "United", "States", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent's", "claims.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "United", "States", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "United", "States", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent's", "claims."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p142_s0", "idA": "1316175_11_item1_p31_s1", "sentA": "These emboli are substrates for sPLA 2 enzymes and provide fuel for an already established inflammatory response, increasing lung injury.", "sentB": "SLE response index and to include an option for an interim efficacy analysis.", "type": 1, "words": ["<tag1>", "These", "emboli", "are", "substrates", "for", "sPLA", "2", "enzymes", "and", "provide", "fuel", "for", "an", "already", "established", "inflammatory", "response,", "increasing", "lung", "injury.", "<tag2>", "SLE", "response", "index", "and", "to", "include", "an", "option", "for", "an", "interim", "efficacy", "analysis.", "<tag3>"], "wordsA": ["These", "emboli", "are", "substrates", "for", "sPLA", "2", "enzymes", "and", "provide", "fuel", "for", "an", "already", "established", "inflammatory", "response,", "increasing", "lung", "injury."], "wordsB": ["SLE", "response", "index", "and", "to", "include", "an", "option", "for", "an", "interim", "efficacy", "analysis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p166_s2", "idA": "1316175_11_item1_p65_s1", "sentA": "Results from large clinical outcome studies demonstrate achieving incrementally lower LDL-C levels reduces the risk of future cardiovascular events and provides continued patient benefit.", "sentB": "The Company believes that the DSMB's decision was based on the belief that the risk profile of the drug would not outweigh any benefit.", "type": 1, "words": ["<tag1>", "Results", "from", "large", "clinical", "outcome", "studies", "demonstrate", "achieving", "incrementally", "lower", "LDL-C", "levels", "reduces", "the", "risk", "of", "future", "cardiovascular", "events", "and", "provides", "continued", "patient", "benefit.", "<tag2>", "The", "Company", "believes", "that", "the", "DSMB's", "decision", "was", "based", "on", "the", "belief", "that", "the", "risk", "profile", "of", "the", "drug", "would", "not", "outweigh", "any", "benefit.", "<tag3>"], "wordsA": ["Results", "from", "large", "clinical", "outcome", "studies", "demonstrate", "achieving", "incrementally", "lower", "LDL-C", "levels", "reduces", "the", "risk", "of", "future", "cardiovascular", "events", "and", "provides", "continued", "patient", "benefit."], "wordsB": ["The", "Company", "believes", "that", "the", "DSMB's", "decision", "was", "based", "on", "the", "belief", "that", "the", "risk", "profile", "of", "the", "drug", "would", "not", "outweigh", "any", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p79_s1", "idA": "1316175_11_item1_p65_s1", "sentA": "Results from large clinical outcome studies demonstrate achieving incrementally lower LDL-C levels reduces the risk of future cardiovascular events and provides continued patient benefit.", "sentB": "The Company believes that the DSMB's decision was based on the belief that the risk profile of the drug would not outweigh any benefit.", "type": 1, "words": ["<tag1>", "Results", "from", "large", "clinical", "outcome", "studies", "demonstrate", "achieving", "incrementally", "lower", "LDL-C", "levels", "reduces", "the", "risk", "of", "future", "cardiovascular", "events", "and", "provides", "continued", "patient", "benefit.", "<tag2>", "The", "Company", "believes", "that", "the", "DSMB's", "decision", "was", "based", "on", "the", "belief", "that", "the", "risk", "profile", "of", "the", "drug", "would", "not", "outweigh", "any", "benefit.", "<tag3>"], "wordsA": ["Results", "from", "large", "clinical", "outcome", "studies", "demonstrate", "achieving", "incrementally", "lower", "LDL-C", "levels", "reduces", "the", "risk", "of", "future", "cardiovascular", "events", "and", "provides", "continued", "patient", "benefit."], "wordsB": ["The", "Company", "believes", "that", "the", "DSMB's", "decision", "was", "based", "on", "the", "belief", "that", "the", "risk", "profile", "of", "the", "drug", "would", "not", "outweigh", "any", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p15_s2", "idA": "1316175_11_item1_p71_s0", "sentA": "In 2008, based on the results from Phase 2 stable CAD studies, as discussed below, we met with the FDA to discuss the next steps of clinical development of varespladib during our end of Phase 2 meeting.", "sentB": "In March 2012, we closed enrollment in our IMPACTS-2 study for varespladib sodium and informed all investigators to remove patients from therapy based on the recommendation from an independent data safety monitoring board.", "type": 1, "words": ["<tag1>", "In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting.", "<tag2>", "In", "March", "2012,", "we", "closed", "enrollment", "in", "our", "IMPACTS-2", "study", "for", "varespladib", "sodium", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "based", "on", "the", "recommendation", "from", "an", "independent", "data", "safety", "monitoring", "board.", "<tag3>"], "wordsA": ["In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting."], "wordsB": ["In", "March", "2012,", "we", "closed", "enrollment", "in", "our", "IMPACTS-2", "study", "for", "varespladib", "sodium", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "based", "on", "the", "recommendation", "from", "an", "independent", "data", "safety", "monitoring", "board."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p81_s0", "idA": "1316175_12_item1_p104_s3", "sentA": "In addition, statistically significant reductions from baseline to week eight were seen in total cholesterol and non-HDL cholesterol in the overall clinical study population treated with varespladib.", "sentB": "No obvious clinical or scientific reason has been found for the increased hazard for non-fatal myocardial infarction amongst subjects treated with varespladib despite positive treatment-related changes in LDL-C and CRP.", "type": 1, "words": ["<tag1>", "In", "addition,", "statistically", "significant", "reductions", "from", "baseline", "to", "week", "eight", "were", "seen", "in", "total", "cholesterol", "and", "non-HDL", "cholesterol", "in", "the", "overall", "clinical", "study", "population", "treated", "with", "varespladib.", "<tag2>", "No", "obvious", "clinical", "or", "scientific", "reason", "has", "been", "found", "for", "the", "increased", "hazard", "for", "non-fatal", "myocardial", "infarction", "amongst", "subjects", "treated", "with", "varespladib", "despite", "positive", "treatment-related", "changes", "in", "LDL-C", "and", "CRP.", "<tag3>"], "wordsA": ["In", "addition,", "statistically", "significant", "reductions", "from", "baseline", "to", "week", "eight", "were", "seen", "in", "total", "cholesterol", "and", "non-HDL", "cholesterol", "in", "the", "overall", "clinical", "study", "population", "treated", "with", "varespladib."], "wordsB": ["No", "obvious", "clinical", "or", "scientific", "reason", "has", "been", "found", "for", "the", "increased", "hazard", "for", "non-fatal", "myocardial", "infarction", "amongst", "subjects", "treated", "with", "varespladib", "despite", "positive", "treatment-related", "changes", "in", "LDL-C", "and", "CRP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p25_s0", "idA": "1316175_12_item1_p105_s1", "sentA": "In general, adverse effects were mild or moderate with no imbalance of adverse events in the varespladib groups as compared to placebo.", "sentB": "In subjects with baseline urinary protein excretion equivalent to 1-6 g/24hrs, treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "type": 1, "words": ["<tag1>", "In", "general,", "adverse", "effects", "were", "mild", "or", "moderate", "with", "no", "imbalance", "of", "adverse", "events", "in", "the", "varespladib", "groups", "as", "compared", "to", "placebo.", "<tag2>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag3>"], "wordsA": ["In", "general,", "adverse", "effects", "were", "mild", "or", "moderate", "with", "no", "imbalance", "of", "adverse", "events", "in", "the", "varespladib", "groups", "as", "compared", "to", "placebo."], "wordsB": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p48_s1", "idA": "1316175_12_item1_p105_s3", "sentA": "There were mild and transient elevations of liver function tests, defined as elevations three times the upper limit of normal, in patients taking varespladib.", "sentB": "Men are affected three times as often as women.", "type": 1, "words": ["<tag1>", "There", "were", "mild", "and", "transient", "elevations", "of", "liver", "function", "tests,", "defined", "as", "elevations", "three", "times", "the", "upper", "limit", "of", "normal,", "in", "patients", "taking", "varespladib.", "<tag2>", "Men", "are", "affected", "three", "times", "as", "often", "as", "women.", "<tag3>"], "wordsA": ["There", "were", "mild", "and", "transient", "elevations", "of", "liver", "function", "tests,", "defined", "as", "elevations", "three", "times", "the", "upper", "limit", "of", "normal,", "in", "patients", "taking", "varespladib."], "wordsB": ["Men", "are", "affected", "three", "times", "as", "often", "as", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p18_s0", "idA": "1316175_12_item1_p109_s1", "sentA": "Patients on varespladib demonstrated a 77.8% reduction in sPLA 2 concentration as compared to an increase of 8.3% in placebo treated patients (p 0.0001).", "sentB": "Using a higher treatment threshold of an eight point reduction in the SELENA-SLEDAI, or an SRI-8 endpoint, in this enhanced subgroup population, the 200mg blisibimod treatment group demonstrated a 15.6% treatment difference compared to pooled placebo (41.7% versus 26.1%, p 0.05) and 31.1% treatment difference compare to treatment matched placebo (41.7% versus 10.6%, p 0.001) at 24 weeks.", "type": 1, "words": ["<tag1>", "Patients", "on", "varespladib", "demonstrated", "a", "77.8%", "reduction", "in", "sPLA", "2", "concentration", "as", "compared", "to", "an", "increase", "of", "8.3%", "in", "placebo", "treated", "patients", "(p", "0.0001).", "<tag2>", "Using", "a", "higher", "treatment", "threshold", "of", "an", "eight", "point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "treatment", "matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks.", "<tag3>"], "wordsA": ["Patients", "on", "varespladib", "demonstrated", "a", "77.8%", "reduction", "in", "sPLA", "2", "concentration", "as", "compared", "to", "an", "increase", "of", "8.3%", "in", "placebo", "treated", "patients", "(p", "0.0001)."], "wordsB": ["Using", "a", "higher", "treatment", "threshold", "of", "an", "eight", "point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "treatment", "matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p54_s0", "idA": "1316175_12_item1_p109_s1", "sentA": "Patients on varespladib demonstrated a 77.8% reduction in sPLA 2 concentration as compared to an increase of 8.3% in placebo treated patients (p 0.0001).", "sentB": "Using a higher treatment threshold of an eight point reduction in the SELENA-SLEDAI, or an SRI-8 endpoint, in this enhanced subgroup population, the 200mg blisibimod treatment group demonstrated a 15.6% treatment difference compared to pooled placebo (41.7% versus 26.1%, p 0.05) and 31.1% treatment difference compare to treatment matched placebo (41.7% versus 10.6%, p 0.001) at 24 weeks.", "type": 1, "words": ["<tag1>", "Patients", "on", "varespladib", "demonstrated", "a", "77.8%", "reduction", "in", "sPLA", "2", "concentration", "as", "compared", "to", "an", "increase", "of", "8.3%", "in", "placebo", "treated", "patients", "(p", "0.0001).", "<tag2>", "Using", "a", "higher", "treatment", "threshold", "of", "an", "eight", "point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "treatment", "matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks.", "<tag3>"], "wordsA": ["Patients", "on", "varespladib", "demonstrated", "a", "77.8%", "reduction", "in", "sPLA", "2", "concentration", "as", "compared", "to", "an", "increase", "of", "8.3%", "in", "placebo", "treated", "patients", "(p", "0.0001)."], "wordsB": ["Using", "a", "higher", "treatment", "threshold", "of", "an", "eight", "point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "treatment", "matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p41_s1", "idA": "1316175_12_item1_p110_s1", "sentA": "Due to the small size of this clinical study and the low baseline inflammation present in these patients, no meaningful changes with CRP could be detected between the active and control groups.", "sentB": "The journal of Arthritis and Rheumatism estimates similar prevalence rates for Europe and Asia.", "type": 1, "words": ["<tag1>", "Due", "to", "the", "small", "size", "of", "this", "clinical", "study", "and", "the", "low", "baseline", "inflammation", "present", "in", "these", "patients,", "no", "meaningful", "changes", "with", "CRP", "could", "be", "detected", "between", "the", "active", "and", "control", "groups.", "<tag2>", "The", "journal", "of", "Arthritis", "and", "Rheumatism", "estimates", "similar", "prevalence", "rates", "for", "Europe", "and", "Asia.", "<tag3>"], "wordsA": ["Due", "to", "the", "small", "size", "of", "this", "clinical", "study", "and", "the", "low", "baseline", "inflammation", "present", "in", "these", "patients,", "no", "meaningful", "changes", "with", "CRP", "could", "be", "detected", "between", "the", "active", "and", "control", "groups."], "wordsB": ["The", "journal", "of", "Arthritis", "and", "Rheumatism", "estimates", "similar", "prevalence", "rates", "for", "Europe", "and", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p5_s0", "idA": "1316175_12_item1_p128_s0", "sentA": "convenient, at-home, patient-administered subcutaneous dosing with a range of dosing frequencies including monthly and weekly; ability to inhibit the activity of both membrane-bound and soluble BAFF, which may confer differentiating pharmacodynamic characteristics; non-glycosylated peptibody that is produced in a bacterial fermentation manufacturing process, which may reduce the potential to be immunogenic and may provide manufacturing benefits and lower cost of goods; and multiple binding domains achieve highest reported affinity for inhibition of BAFF.", "sentB": "Blisibimod inhibits both soluble and membrane bound BAFF.", "type": 1, "words": ["<tag1>", "convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF,", "which", "may", "confer", "differentiating", "pharmacodynamic", "characteristics;", "non-glycosylated", "peptibody", "that", "is", "produced", "in", "a", "bacterial", "fermentation", "manufacturing", "process,", "which", "may", "reduce", "the", "potential", "to", "be", "immunogenic", "and", "may", "provide", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF.", "<tag2>", "Blisibimod", "inhibits", "both", "soluble", "and", "membrane", "bound", "BAFF.", "<tag3>"], "wordsA": ["convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF,", "which", "may", "confer", "differentiating", "pharmacodynamic", "characteristics;", "non-glycosylated", "peptibody", "that", "is", "produced", "in", "a", "bacterial", "fermentation", "manufacturing", "process,", "which", "may", "reduce", "the", "potential", "to", "be", "immunogenic", "and", "may", "provide", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF."], "wordsB": ["Blisibimod", "inhibits", "both", "soluble", "and", "membrane", "bound", "BAFF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p13_s3", "idA": "1316175_12_item1_p132_s0", "sentA": "Although the cause of lupus is still not completely understood, B-cell activation and autoantibody production are known to be central to the process.", "sentB": "In preclinical studies in mice that develop lupus-like disease, BAFF is known to be elevated, and treatment with blisibimod improves outcomes and survival.", "type": 1, "words": ["<tag1>", "Although", "the", "cause", "of", "lupus", "is", "still", "not", "completely", "understood,", "B-cell", "activation", "and", "autoantibody", "production", "are", "known", "to", "be", "central", "to", "the", "process.", "<tag2>", "In", "preclinical", "studies", "in", "mice", "that", "develop", "lupus-like", "disease,", "BAFF", "is", "known", "to", "be", "elevated,", "and", "treatment", "with", "blisibimod", "improves", "outcomes", "and", "survival.", "<tag3>"], "wordsA": ["Although", "the", "cause", "of", "lupus", "is", "still", "not", "completely", "understood,", "B-cell", "activation", "and", "autoantibody", "production", "are", "known", "to", "be", "central", "to", "the", "process."], "wordsB": ["In", "preclinical", "studies", "in", "mice", "that", "develop", "lupus-like", "disease,", "BAFF", "is", "known", "to", "be", "elevated,", "and", "treatment", "with", "blisibimod", "improves", "outcomes", "and", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s5", "idA": "1316175_12_item1_p141_s1", "sentA": "Subsequent to this clearance, the FDA requested additional information regarding characterization and qualification of the manufactured vials of blisibimod.", "sentB": "We plan to conduct an interim analysis of the BRIGHT-SC clinical results after the eight-week induction phase to determine effects of blisibimod as an induction therapy on proteinuria.", "type": 1, "words": ["<tag1>", "Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "blisibimod.", "<tag2>", "We", "plan", "to", "conduct", "an", "interim", "analysis", "of", "the", "BRIGHT-SC", "clinical", "results", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "as", "an", "induction", "therapy", "on", "proteinuria.", "<tag3>"], "wordsA": ["Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "blisibimod."], "wordsB": ["We", "plan", "to", "conduct", "an", "interim", "analysis", "of", "the", "BRIGHT-SC", "clinical", "results", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "as", "an", "induction", "therapy", "on", "proteinuria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p12_s1", "idA": "1316175_12_item1_p141_s5", "sentA": "We submitted a response to the FDA in October 2010.", "sentB": "B-cells represent a critical component of a human immune response to infection and other pathogens.", "type": 1, "words": ["<tag1>", "We", "submitted", "a", "response", "to", "the", "FDA", "in", "October", "2010.", "<tag2>", "B-cells", "represent", "a", "critical", "component", "of", "a", "human", "immune", "response", "to", "infection", "and", "other", "pathogens.", "<tag3>"], "wordsA": ["We", "submitted", "a", "response", "to", "the", "FDA", "in", "October", "2010."], "wordsB": ["B-cells", "represent", "a", "critical", "component", "of", "a", "human", "immune", "response", "to", "infection", "and", "other", "pathogens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p34_s1", "idA": "1316175_12_item1_p156_s1", "sentA": "According to the Sickle Cell Information Center, in the United States, over 70,000 people currently suffer from the disease and approximately 1,000 children are born with the disease annually.", "sentB": "In Asia, a similar prevalence to the U.S. would be estimated to affect over 500,000 people annually.", "type": 1, "words": ["<tag1>", "According", "to", "the", "Sickle", "Cell", "Information", "Center,", "in", "the", "United", "States,", "over", "70,000", "people", "currently", "suffer", "from", "the", "disease", "and", "approximately", "1,000", "children", "are", "born", "with", "the", "disease", "annually.", "<tag2>", "In", "Asia,", "a", "similar", "prevalence", "to", "the", "U.S.", "would", "be", "estimated", "to", "affect", "over", "500,000", "people", "annually.", "<tag3>"], "wordsA": ["According", "to", "the", "Sickle", "Cell", "Information", "Center,", "in", "the", "United", "States,", "over", "70,000", "people", "currently", "suffer", "from", "the", "disease", "and", "approximately", "1,000", "children", "are", "born", "with", "the", "disease", "annually."], "wordsB": ["In", "Asia,", "a", "similar", "prevalence", "to", "the", "U.S.", "would", "be", "estimated", "to", "affect", "over", "500,000", "people", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p38_s2", "idA": "1316175_12_item1_p15_s0", "sentA": "Acute chest syndrome is a form of inflammation-induced lung failure and is the most common cause of death in patients with sickle cell disease.", "sentB": "In IgAN, increased plasma B-cells express immunogenic IgA that forms immune complexes that deposit in renal tissue and lead to renal inflammation and damage that can progress to renal failure and end-stage renal disease.", "type": 1, "words": ["<tag1>", "Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease.", "<tag2>", "In", "IgAN,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease.", "<tag3>"], "wordsA": ["Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease."], "wordsB": ["In", "IgAN,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p60_s2", "idA": "1316175_12_item1_p15_s0", "sentA": "Acute chest syndrome is a form of inflammation-induced lung failure and is the most common cause of death in patients with sickle cell disease.", "sentB": "In IgAN, increased plasma B-cells express immunogenic IgA that forms immune complexes that deposit in renal tissue and lead to renal inflammation and damage that can progress to renal failure and end-stage renal disease.", "type": 1, "words": ["<tag1>", "Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease.", "<tag2>", "In", "IgAN,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease.", "<tag3>"], "wordsA": ["Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease."], "wordsB": ["In", "IgAN,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p13_s4", "idA": "1316175_12_item1_p162_s0", "sentA": "There are no marketed therapies targeting acute chest syndrome associated with sickle cell disease.", "sentB": "Similarly, in IgAN, mice that over-express BAFF develop a fatal nephropathy associated with IgA.", "type": 1, "words": ["<tag1>", "There", "are", "no", "marketed", "therapies", "targeting", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "Similarly,", "in", "IgAN,", "mice", "that", "over-express", "BAFF", "develop", "a", "fatal", "nephropathy", "associated", "with", "IgA.", "<tag3>"], "wordsA": ["There", "are", "no", "marketed", "therapies", "targeting", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["Similarly,", "in", "IgAN,", "mice", "that", "over-express", "BAFF", "develop", "a", "fatal", "nephropathy", "associated", "with", "IgA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p80_s1", "idA": "1316175_12_item1_p165_s0", "sentA": "The primary endpoint of this study will be freedom from acute chest syndrome as determined by physician assessment and independent review of chest X-rays.", "sentB": "In addition to reviewing the primary endpoint data, this review included an unblinded review of demographics, baseline characteristics, laboratory results, concomitant medications, treatment emergent adverse events (AEs), and serious adverse events (SAEs).", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays.", "<tag2>", "In", "addition", "to", "reviewing", "the", "primary", "endpoint", "data,", "this", "review", "included", "an", "unblinded", "review", "of", "demographics,", "baseline", "characteristics,", "laboratory", "results,", "concomitant", "medications,", "treatment", "emergent", "adverse", "events", "(AEs),", "and", "serious", "adverse", "events", "(SAEs).", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays."], "wordsB": ["In", "addition", "to", "reviewing", "the", "primary", "endpoint", "data,", "this", "review", "included", "an", "unblinded", "review", "of", "demographics,", "baseline", "characteristics,", "laboratory", "results,", "concomitant", "medications,", "treatment", "emergent", "adverse", "events", "(AEs),", "and", "serious", "adverse", "events", "(SAEs)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p85_s2", "idA": "1316175_12_item1_p174_s1", "sentA": "We have completed enrollment in the Phase 2b clinical study known as PEARL-SC in lupus patients.", "sentB": "The data will help us select an appropriate orphan path to supplement our approach in lupus.", "type": 1, "words": ["<tag1>", "We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag2>", "The", "data", "will", "help", "us", "select", "an", "appropriate", "orphan", "path", "to", "supplement", "our", "approach", "in", "lupus.", "<tag3>"], "wordsA": ["We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "wordsB": ["The", "data", "will", "help", "us", "select", "an", "appropriate", "orphan", "path", "to", "supplement", "our", "approach", "in", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p30_s3", "idA": "1316175_12_item1_p176_s0", "sentA": "Our primary product candidate is focused on highly-specialized physician segments, such as rheumatologists.", "sentB": "Safety and efficacy will be evaluated using key disease biomarkers such as double-stranded DNA, C3, C4 and proteinuria.", "type": 1, "words": ["<tag1>", "Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists.", "<tag2>", "Safety", "and", "efficacy", "will", "be", "evaluated", "using", "key", "disease", "biomarkers", "such", "as", "double-stranded", "DNA,", "C3,", "C4", "and", "proteinuria.", "<tag3>"], "wordsA": ["Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists."], "wordsB": ["Safety", "and", "efficacy", "will", "be", "evaluated", "using", "key", "disease", "biomarkers", "such", "as", "double-stranded", "DNA,", "C3,", "C4", "and", "proteinuria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s6", "idA": "1316175_12_item1_p183_s0", "sentA": "Several new biological agents under development have targeted BAFF (or BLyS) and other B-cell related pathways for the treatment of lupus.", "sentB": "This revised study design could allow for the incremental inclusion of patients with more significant kidney manifestations of lupus including proteinuria and evidence of renal damage.", "type": 1, "words": ["<tag1>", "Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(or", "BLyS)", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus.", "<tag2>", "This", "revised", "study", "design", "could", "allow", "for", "the", "incremental", "inclusion", "of", "patients", "with", "more", "significant", "kidney", "manifestations", "of", "lupus", "including", "proteinuria", "and", "evidence", "of", "renal", "damage.", "<tag3>"], "wordsA": ["Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(or", "BLyS)", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus."], "wordsB": ["This", "revised", "study", "design", "could", "allow", "for", "the", "incremental", "inclusion", "of", "patients", "with", "more", "significant", "kidney", "manifestations", "of", "lupus", "including", "proteinuria", "and", "evidence", "of", "renal", "damage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p86_s1", "idA": "1316175_12_item1_p1_s1", "sentA": "We currently have one Phase 2 clinical program, blisibimod.", "sentB": "We believe improvement in patient outcomes will allow for premium orphan pricing for blisibimod.", "type": 1, "words": ["<tag1>", "We", "currently", "have", "one", "Phase", "2", "clinical", "program,", "blisibimod.", "<tag2>", "We", "believe", "improvement", "in", "patient", "outcomes", "will", "allow", "for", "premium", "orphan", "pricing", "for", "blisibimod.", "<tag3>"], "wordsA": ["We", "currently", "have", "one", "Phase", "2", "clinical", "program,", "blisibimod."], "wordsB": ["We", "believe", "improvement", "in", "patient", "outcomes", "will", "allow", "for", "premium", "orphan", "pricing", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s1", "idA": "1316175_12_item1_p228_s1", "sentA": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon initiation of the first Phase 3 clinical study for any blisibimod formulation.", "sentB": "BRIGHT-SC will serve as our initial proof of concept study for an eventual Phase 3 path in renal diseases with blisibimod.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation.", "<tag2>", "BRIGHT-SC", "will", "serve", "as", "our", "initial", "proof", "of", "concept", "study", "for", "an", "eventual", "Phase", "3", "path", "in", "renal", "diseases", "with", "blisibimod.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation."], "wordsB": ["BRIGHT-SC", "will", "serve", "as", "our", "initial", "proof", "of", "concept", "study", "for", "an", "eventual", "Phase", "3", "path", "in", "renal", "diseases", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p115_s4", "idA": "1316175_12_item1_p229_s0", "sentA": "The license agreement will remain in effect until we elect to terminate, or until termination for material breach by either party or insolvency on our part.", "sentB": "The license agreement was effectively terminated in November 2012 and U.S. Investigational New Drug application, or IND was withdrawn in January 2013.", "type": 1, "words": ["<tag1>", "The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part.", "<tag2>", "The", "license", "agreement", "was", "effectively", "terminated", "in", "November", "2012", "and", "U.S.", "Investigational", "New", "Drug", "application,", "or", "IND", "was", "withdrawn", "in", "January", "2013.", "<tag3>"], "wordsA": ["The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part."], "wordsB": ["The", "license", "agreement", "was", "effectively", "terminated", "in", "November", "2012", "and", "U.S.", "Investigational", "New", "Drug", "application,", "or", "IND", "was", "withdrawn", "in", "January", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p66_s1", "idA": "1316175_12_item1_p249_s1", "sentA": "Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all.", "sentB": "The Phase 3 CHABLIS-SC program incorporates feedback and advice obtained from both regulatory agencies.", "type": 1, "words": ["<tag1>", "Phase", "1,", "Phase", "2", "and", "Phase", "3", "testing", "may", "not", "be", "completed", "successfully", "within", "any", "specified", "period,", "if", "at", "all.", "<tag2>", "The", "Phase", "3", "CHABLIS-SC", "program", "incorporates", "feedback", "and", "advice", "obtained", "from", "both", "regulatory", "agencies.", "<tag3>"], "wordsA": ["Phase", "1,", "Phase", "2", "and", "Phase", "3", "testing", "may", "not", "be", "completed", "successfully", "within", "any", "specified", "period,", "if", "at", "all."], "wordsB": ["The", "Phase", "3", "CHABLIS-SC", "program", "incorporates", "feedback", "and", "advice", "obtained", "from", "both", "regulatory", "agencies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p85_s0", "idA": "1316175_12_item1_p251_s1", "sentA": "The submission of an NDA or BLA is subject to the payment of a substantial user fee; a waiver of such fee may be obtained under certain limited circumstances.", "sentB": "Orphan indications in renal diseases represent a substantial untapped opportunity.", "type": 1, "words": ["<tag1>", "The", "submission", "of", "an", "NDA", "or", "BLA", "is", "subject", "to", "the", "payment", "of", "a", "substantial", "user", "fee;", "a", "waiver", "of", "such", "fee", "may", "be", "obtained", "under", "certain", "limited", "circumstances.", "<tag2>", "Orphan", "indications", "in", "renal", "diseases", "represent", "a", "substantial", "untapped", "opportunity.", "<tag3>"], "wordsA": ["The", "submission", "of", "an", "NDA", "or", "BLA", "is", "subject", "to", "the", "payment", "of", "a", "substantial", "user", "fee;", "a", "waiver", "of", "such", "fee", "may", "be", "obtained", "under", "certain", "limited", "circumstances."], "wordsB": ["Orphan", "indications", "in", "renal", "diseases", "represent", "a", "substantial", "untapped", "opportunity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p101_s1", "idA": "1316175_12_item1_p259_s0", "sentA": "Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments.", "sentB": "See Regulatory Matters Patent Term Restoration and Marketing Exclusivity.", "type": 1, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Amendments.", "<tag2>", "See", "Regulatory", "Matters", "Patent", "Term", "Restoration", "and", "Marketing", "Exclusivity.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Amendments."], "wordsB": ["See", "Regulatory", "Matters", "Patent", "Term", "Restoration", "and", "Marketing", "Exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p8_s1", "idA": "1316175_12_item1_p261_s7", "sentA": "However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical studies necessary to demonstrate safety and effectiveness.", "sentB": "Our current plan includes commencing the CHABLIS-SC and BRIGHT-SC clinical studies, continuing the ongoing blisibimod open label extension safety and efficacy study, or OLE study, and investigating the structure of future clinical studies and research and development activities.", "type": 1, "words": ["<tag1>", "However,", "an", "applicant", "submitting", "a", "full", "NDA", "would", "be", "required", "to", "conduct", "or", "obtain", "a", "right", "of", "reference", "to", "all", "of", "the", "preclinical", "studies", "and", "adequate", "and", "well-controlled", "clinical", "studies", "necessary", "to", "demonstrate", "safety", "and", "effectiveness.", "<tag2>", "Our", "current", "plan", "includes", "commencing", "the", "CHABLIS-SC", "and", "BRIGHT-SC", "clinical", "studies,", "continuing", "the", "ongoing", "blisibimod", "open", "label", "extension", "safety", "and", "efficacy", "study,", "or", "OLE", "study,", "and", "investigating", "the", "structure", "of", "future", "clinical", "studies", "and", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["However,", "an", "applicant", "submitting", "a", "full", "NDA", "would", "be", "required", "to", "conduct", "or", "obtain", "a", "right", "of", "reference", "to", "all", "of", "the", "preclinical", "studies", "and", "adequate", "and", "well-controlled", "clinical", "studies", "necessary", "to", "demonstrate", "safety", "and", "effectiveness."], "wordsB": ["Our", "current", "plan", "includes", "commencing", "the", "CHABLIS-SC", "and", "BRIGHT-SC", "clinical", "studies,", "continuing", "the", "ongoing", "blisibimod", "open", "label", "extension", "safety", "and", "efficacy", "study,", "or", "OLE", "study,", "and", "investigating", "the", "structure", "of", "future", "clinical", "studies", "and", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p36_s2", "idA": "1316175_12_item1_p30_s1", "sentA": "Patients with sickle cell disease experience periods of intense pain known as vaso-occlusive crisis, or VOC, as structurally altered red blood cells bind together and occlude small blood vessels that supply blood and nutrients to vital tissue and bone.", "sentB": "These IgA deposits build up inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged leading to leakage of blood and protein into urine.", "type": 1, "words": ["<tag1>", "Patients", "with", "sickle", "cell", "disease", "experience", "periods", "of", "intense", "pain", "known", "as", "vaso-occlusive", "crisis,", "or", "VOC,", "as", "structurally", "altered", "red", "blood", "cells", "bind", "together", "and", "occlude", "small", "blood", "vessels", "that", "supply", "blood", "and", "nutrients", "to", "vital", "tissue", "and", "bone.", "<tag2>", "These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag3>"], "wordsA": ["Patients", "with", "sickle", "cell", "disease", "experience", "periods", "of", "intense", "pain", "known", "as", "vaso-occlusive", "crisis,", "or", "VOC,", "as", "structurally", "altered", "red", "blood", "cells", "bind", "together", "and", "occlude", "small", "blood", "vessels", "that", "supply", "blood", "and", "nutrients", "to", "vital", "tissue", "and", "bone."], "wordsB": ["These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p46_s1", "idA": "1316175_12_item1_p30_s1", "sentA": "Patients with sickle cell disease experience periods of intense pain known as vaso-occlusive crisis, or VOC, as structurally altered red blood cells bind together and occlude small blood vessels that supply blood and nutrients to vital tissue and bone.", "sentB": "These immunogenic IgA immune complexes deposit inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged leading to leakage of blood and protein into urine.", "type": 1, "words": ["<tag1>", "Patients", "with", "sickle", "cell", "disease", "experience", "periods", "of", "intense", "pain", "known", "as", "vaso-occlusive", "crisis,", "or", "VOC,", "as", "structurally", "altered", "red", "blood", "cells", "bind", "together", "and", "occlude", "small", "blood", "vessels", "that", "supply", "blood", "and", "nutrients", "to", "vital", "tissue", "and", "bone.", "<tag2>", "These", "immunogenic", "IgA", "immune", "complexes", "deposit", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag3>"], "wordsA": ["Patients", "with", "sickle", "cell", "disease", "experience", "periods", "of", "intense", "pain", "known", "as", "vaso-occlusive", "crisis,", "or", "VOC,", "as", "structurally", "altered", "red", "blood", "cells", "bind", "together", "and", "occlude", "small", "blood", "vessels", "that", "supply", "blood", "and", "nutrients", "to", "vital", "tissue", "and", "bone."], "wordsB": ["These", "immunogenic", "IgA", "immune", "complexes", "deposit", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p36_s0", "idA": "1316175_12_item1_p34_s0", "sentA": "A peptibody is a novel fusion protein that is distinct from an antibody.", "sentB": "Immunoglobulin A, or IgA, is a human antibody that helps the body fight infections.", "type": 1, "words": ["<tag1>", "A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody.", "<tag2>", "Immunoglobulin", "A,", "or", "IgA,", "is", "a", "human", "antibody", "that", "helps", "the", "body", "fight", "infections.", "<tag3>"], "wordsA": ["A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody."], "wordsB": ["Immunoglobulin", "A,", "or", "IgA,", "is", "a", "human", "antibody", "that", "helps", "the", "body", "fight", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p45_s0", "idA": "1316175_12_item1_p34_s0", "sentA": "A peptibody is a novel fusion protein that is distinct from an antibody.", "sentB": "Immunoglobulin A (IgA) is an antibody that plays a critical role in mucosal immunity.", "type": 1, "words": ["<tag1>", "A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody.", "<tag2>", "Immunoglobulin", "A", "(IgA)", "is", "an", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity.", "<tag3>"], "wordsA": ["A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody."], "wordsB": ["Immunoglobulin", "A", "(IgA)", "is", "an", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p45_s2", "idA": "1316175_12_item1_p34_s0", "sentA": "A peptibody is a novel fusion protein that is distinct from an antibody.", "sentB": "IgA is a human antibody that helps the body fight infections.", "type": 1, "words": ["<tag1>", "A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody.", "<tag2>", "IgA", "is", "a", "human", "antibody", "that", "helps", "the", "body", "fight", "infections.", "<tag3>"], "wordsA": ["A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody."], "wordsB": ["IgA", "is", "a", "human", "antibody", "that", "helps", "the", "body", "fight", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p155_s1", "idA": "1316175_12_item1_p43_s0", "sentA": "A SPA provides an opportunity for the clinical study sponsor to receive feedback from the FDA regarding the potential adequacy of a clinical study to meet certain regulatory and scientific requirements if conducted in accordance with the SPA agreement.", "sentB": "The FDA actions to expedite the development of a Breakthrough Therapy include (a) holding meetings with the sponsor and the review team throughout the development of the drug, (b) providing timely advice to and interactive communication with the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable (c) involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review, (d) assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor and (e) taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment.", "type": 1, "words": ["<tag1>", "A", "SPA", "provides", "an", "opportunity", "for", "the", "clinical", "study", "sponsor", "to", "receive", "feedback", "from", "the", "FDA", "regarding", "the", "potential", "adequacy", "of", "a", "clinical", "study", "to", "meet", "certain", "regulatory", "and", "scientific", "requirements", "if", "conducted", "in", "accordance", "with", "the", "SPA", "agreement.", "<tag2>", "The", "FDA", "actions", "to", "expedite", "the", "development", "of", "a", "Breakthrough", "Therapy", "include", "(a)", "holding", "meetings", "with", "the", "sponsor", "and", "the", "review", "team", "throughout", "the", "development", "of", "the", "drug,", "(b)", "providing", "timely", "advice", "to", "and", "interactive", "communication", "with", "the", "sponsor", "regarding", "the", "development", "of", "the", "drug", "to", "ensure", "that", "the", "development", "program", "to", "gather", "the", "nonclinical", "and", "clinical", "data", "necessary", "for", "approval", "is", "as", "efficient", "as", "practicable", "(c)", "involving", "senior", "managers", "and", "experienced", "review", "staff,", "as", "appropriate,", "in", "a", "collaborative,", "cross-disciplinary", "review,", "(d)", "assigning", "a", "cross-disciplinary", "project", "lead", "for", "the", "FDA", "review", "team", "to", "facilitate", "an", "efficient", "review", "of", "the", "development", "program", "and", "to", "serve", "as", "a", "scientific", "liaison", "between", "the", "review", "team", "and", "the", "sponsor", "and", "(e)", "taking", "steps", "to", "ensure", "that", "the", "design", "of", "the", "clinical", "trials", "is", "as", "efficient", "as", "practicable,", "when", "scientifically", "appropriate,", "such", "as", "by", "minimizing", "the", "number", "of", "patients", "exposed", "to", "a", "potentially", "less", "efficacious", "treatment.", "<tag3>"], "wordsA": ["A", "SPA", "provides", "an", "opportunity", "for", "the", "clinical", "study", "sponsor", "to", "receive", "feedback", "from", "the", "FDA", "regarding", "the", "potential", "adequacy", "of", "a", "clinical", "study", "to", "meet", "certain", "regulatory", "and", "scientific", "requirements", "if", "conducted", "in", "accordance", "with", "the", "SPA", "agreement."], "wordsB": ["The", "FDA", "actions", "to", "expedite", "the", "development", "of", "a", "Breakthrough", "Therapy", "include", "(a)", "holding", "meetings", "with", "the", "sponsor", "and", "the", "review", "team", "throughout", "the", "development", "of", "the", "drug,", "(b)", "providing", "timely", "advice", "to", "and", "interactive", "communication", "with", "the", "sponsor", "regarding", "the", "development", "of", "the", "drug", "to", "ensure", "that", "the", "development", "program", "to", "gather", "the", "nonclinical", "and", "clinical", "data", "necessary", "for", "approval", "is", "as", "efficient", "as", "practicable", "(c)", "involving", "senior", "managers", "and", "experienced", "review", "staff,", "as", "appropriate,", "in", "a", "collaborative,", "cross-disciplinary", "review,", "(d)", "assigning", "a", "cross-disciplinary", "project", "lead", "for", "the", "FDA", "review", "team", "to", "facilitate", "an", "efficient", "review", "of", "the", "development", "program", "and", "to", "serve", "as", "a", "scientific", "liaison", "between", "the", "review", "team", "and", "the", "sponsor", "and", "(e)", "taking", "steps", "to", "ensure", "that", "the", "design", "of", "the", "clinical", "trials", "is", "as", "efficient", "as", "practicable,", "when", "scientifically", "appropriate,", "such", "as", "by", "minimizing", "the", "number", "of", "patients", "exposed", "to", "a", "potentially", "less", "efficacious", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p35_s0", "idA": "1316175_12_item1_p51_s0", "sentA": "According to the World Health Organization, or the WHO, cardiovascular disease is the most common cause of death in the western world and a major cause of hospital admissions.", "sentB": "According to the National Kidney and Urologic Diseases Information Clearinghouse, 25% of adults with IgA nephropathy eventually develop total kidney failure.", "type": 1, "words": ["<tag1>", "According", "to", "the", "World", "Health", "Organization,", "or", "the", "WHO,", "cardiovascular", "disease", "is", "the", "most", "common", "cause", "of", "death", "in", "the", "western", "world", "and", "a", "major", "cause", "of", "hospital", "admissions.", "<tag2>", "According", "to", "the", "National", "Kidney", "and", "Urologic", "Diseases", "Information", "Clearinghouse,", "25%", "of", "adults", "with", "IgA", "nephropathy", "eventually", "develop", "total", "kidney", "failure.", "<tag3>"], "wordsA": ["According", "to", "the", "World", "Health", "Organization,", "or", "the", "WHO,", "cardiovascular", "disease", "is", "the", "most", "common", "cause", "of", "death", "in", "the", "western", "world", "and", "a", "major", "cause", "of", "hospital", "admissions."], "wordsB": ["According", "to", "the", "National", "Kidney", "and", "Urologic", "Diseases", "Information", "Clearinghouse,", "25%", "of", "adults", "with", "IgA", "nephropathy", "eventually", "develop", "total", "kidney", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p50_s0", "idA": "1316175_12_item1_p51_s0", "sentA": "According to the World Health Organization, or the WHO, cardiovascular disease is the most common cause of death in the western world and a major cause of hospital admissions.", "sentB": "According to the National Kidney and Urologic Diseases Information Clearinghouse, 25% of adults with IgA nephropathy eventually develop total kidney failure.", "type": 1, "words": ["<tag1>", "According", "to", "the", "World", "Health", "Organization,", "or", "the", "WHO,", "cardiovascular", "disease", "is", "the", "most", "common", "cause", "of", "death", "in", "the", "western", "world", "and", "a", "major", "cause", "of", "hospital", "admissions.", "<tag2>", "According", "to", "the", "National", "Kidney", "and", "Urologic", "Diseases", "Information", "Clearinghouse,", "25%", "of", "adults", "with", "IgA", "nephropathy", "eventually", "develop", "total", "kidney", "failure.", "<tag3>"], "wordsA": ["According", "to", "the", "World", "Health", "Organization,", "or", "the", "WHO,", "cardiovascular", "disease", "is", "the", "most", "common", "cause", "of", "death", "in", "the", "western", "world", "and", "a", "major", "cause", "of", "hospital", "admissions."], "wordsB": ["According", "to", "the", "National", "Kidney", "and", "Urologic", "Diseases", "Information", "Clearinghouse,", "25%", "of", "adults", "with", "IgA", "nephropathy", "eventually", "develop", "total", "kidney", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p86_s0", "idA": "1316175_12_item1_p61_s0", "sentA": "Statins reduce the level of CRP and other markers of inflammation in patients with stable CAD.", "sentB": "The progression of patients with IgA nephropathy and lupus nephritis to end stage renal disease poses a considerable cost and societal burden.", "type": 1, "words": ["<tag1>", "Statins", "reduce", "the", "level", "of", "CRP", "and", "other", "markers", "of", "inflammation", "in", "patients", "with", "stable", "CAD.", "<tag2>", "The", "progression", "of", "patients", "with", "IgA", "nephropathy", "and", "lupus", "nephritis", "to", "end", "stage", "renal", "disease", "poses", "a", "considerable", "cost", "and", "societal", "burden.", "<tag3>"], "wordsA": ["Statins", "reduce", "the", "level", "of", "CRP", "and", "other", "markers", "of", "inflammation", "in", "patients", "with", "stable", "CAD."], "wordsB": ["The", "progression", "of", "patients", "with", "IgA", "nephropathy", "and", "lupus", "nephritis", "to", "end", "stage", "renal", "disease", "poses", "a", "considerable", "cost", "and", "societal", "burden."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p14_s1", "idA": "1316175_12_item1_p65_s0", "sentA": "In 2005, the New England Journal of Medicine published data from the PROVE-IT study.", "sentB": "The Journal of Arthritis and Rheumatism estimates similar prevalence rates for Europe and Asia.", "type": 1, "words": ["<tag1>", "In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study.", "<tag2>", "The", "Journal", "of", "Arthritis", "and", "Rheumatism", "estimates", "similar", "prevalence", "rates", "for", "Europe", "and", "Asia.", "<tag3>"], "wordsA": ["In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study."], "wordsB": ["The", "Journal", "of", "Arthritis", "and", "Rheumatism", "estimates", "similar", "prevalence", "rates", "for", "Europe", "and", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p82_s1", "idA": "1316175_12_item1_p7_s1", "sentA": "As a result, it is tightly regulated by the body to ensure appropriate activation and prompt resolution.", "sentB": "We modified work orders with key vendors to ensure efficient wind-down activities, while still maintaining patient safety as a top priority.", "type": 1, "words": ["<tag1>", "As", "a", "result,", "it", "is", "tightly", "regulated", "by", "the", "body", "to", "ensure", "appropriate", "activation", "and", "prompt", "resolution.", "<tag2>", "We", "modified", "work", "orders", "with", "key", "vendors", "to", "ensure", "efficient", "wind-down", "activities,", "while", "still", "maintaining", "patient", "safety", "as", "a", "top", "priority.", "<tag3>"], "wordsA": ["As", "a", "result,", "it", "is", "tightly", "regulated", "by", "the", "body", "to", "ensure", "appropriate", "activation", "and", "prompt", "resolution."], "wordsB": ["We", "modified", "work", "orders", "with", "key", "vendors", "to", "ensure", "efficient", "wind-down", "activities,", "while", "still", "maintaining", "patient", "safety", "as", "a", "top", "priority."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p7_s1", "idA": "1316175_12_item1_p7_s3", "sentA": "All of these circumstances can cause significant damage to cells and tissues, leading to a range of inflammatory disorders, such as cardiovascular and autoimmune diseases.", "sentB": "Inhibition of BAFF is believed to reduce survival and subsequent elevations in B-cells leading to a reduction in severity of disease and resolution of Lupus symptoms.", "type": 1, "words": ["<tag1>", "All", "of", "these", "circumstances", "can", "cause", "significant", "damage", "to", "cells", "and", "tissues,", "leading", "to", "a", "range", "of", "inflammatory", "disorders,", "such", "as", "cardiovascular", "and", "autoimmune", "diseases.", "<tag2>", "Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "and", "subsequent", "elevations", "in", "B-cells", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "Lupus", "symptoms.", "<tag3>"], "wordsA": ["All", "of", "these", "circumstances", "can", "cause", "significant", "damage", "to", "cells", "and", "tissues,", "leading", "to", "a", "range", "of", "inflammatory", "disorders,", "such", "as", "cardiovascular", "and", "autoimmune", "diseases."], "wordsB": ["Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "and", "subsequent", "elevations", "in", "B-cells", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "Lupus", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p14_s3", "idA": "1316175_12_item1_p81_s2", "sentA": "The clinical study was designed to evaluate the safety and efficacy of varespladib when co-administered with the highest dose (80 mg) of Lipitor (atorvastatin).", "sentB": "The prevalence of IgAN varies throughout the world, with the highest prevalence in Asia (Singapore, Japan, and Hong Kong), Australia, Finland, and southern Europe (20 to 40% of all glomerulnephritis).", "type": 1, "words": ["<tag1>", "The", "clinical", "study", "was", "designed", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "varespladib", "when", "co-administered", "with", "the", "highest", "dose", "(80", "mg)", "of", "Lipitor", "(atorvastatin).", "<tag2>", "The", "prevalence", "of", "IgAN", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan,", "and", "Hong", "Kong),", "Australia,", "Finland,", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulnephritis).", "<tag3>"], "wordsA": ["The", "clinical", "study", "was", "designed", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "varespladib", "when", "co-administered", "with", "the", "highest", "dose", "(80", "mg)", "of", "Lipitor", "(atorvastatin)."], "wordsB": ["The", "prevalence", "of", "IgAN", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan,", "and", "Hong", "Kong),", "Australia,", "Finland,", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulnephritis)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p86_s3", "idA": "1316175_12_item1_p89_s1", "sentA": "While the FRANCIS study was not designed to demonstrate statistically significant changes in CRP and IL-6, the results were consistent with previous studies, which demonstrated improvement across these biomarkers and achieved statistical significance at some time points.", "sentB": "Furthermore, disease-specific dosing regimens may enable product commercialization at substantially different price points.", "type": 1, "words": ["<tag1>", "While", "the", "FRANCIS", "study", "was", "not", "designed", "to", "demonstrate", "statistically", "significant", "changes", "in", "CRP", "and", "IL-6,", "the", "results", "were", "consistent", "with", "previous", "studies,", "which", "demonstrated", "improvement", "across", "these", "biomarkers", "and", "achieved", "statistical", "significance", "at", "some", "time", "points.", "<tag2>", "Furthermore,", "disease-specific", "dosing", "regimens", "may", "enable", "product", "commercialization", "at", "substantially", "different", "price", "points.", "<tag3>"], "wordsA": ["While", "the", "FRANCIS", "study", "was", "not", "designed", "to", "demonstrate", "statistically", "significant", "changes", "in", "CRP", "and", "IL-6,", "the", "results", "were", "consistent", "with", "previous", "studies,", "which", "demonstrated", "improvement", "across", "these", "biomarkers", "and", "achieved", "statistical", "significance", "at", "some", "time", "points."], "wordsB": ["Furthermore,", "disease-specific", "dosing", "regimens", "may", "enable", "product", "commercialization", "at", "substantially", "different", "price", "points."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p17_s0", "idA": "1316175_12_item1_p91_s0", "sentA": "In addition, treatment-related reductions in CRP and IL-6 levels were also greater in varespladib treated patients compared to those treated with placebo at all time points in the clinical study.", "sentB": "In addition, in a subgroup population of severely ill, seropositive lupus patients, defined as those patients having a SELENA-SLEDAI score of greater or equal to ten who were also receiving background corticosteroid medication at the time of randomization, a more pronounced treatment benefit was seen with the blisibimod 200mg weekly dose compared to other doses.", "type": 1, "words": ["<tag1>", "In", "addition,", "treatment-related", "reductions", "in", "CRP", "and", "IL-6", "levels", "were", "also", "greater", "in", "varespladib", "treated", "patients", "compared", "to", "those", "treated", "with", "placebo", "at", "all", "time", "points", "in", "the", "clinical", "study.", "<tag2>", "In", "addition,", "in", "a", "subgroup", "population", "of", "severely", "ill,", "seropositive", "lupus", "patients,", "defined", "as", "those", "patients", "having", "a", "SELENA-SLEDAI", "score", "of", "greater", "or", "equal", "to", "ten", "who", "were", "also", "receiving", "background", "corticosteroid", "medication", "at", "the", "time", "of", "randomization,", "a", "more", "pronounced", "treatment", "benefit", "was", "seen", "with", "the", "blisibimod", "200mg", "weekly", "dose", "compared", "to", "other", "doses.", "<tag3>"], "wordsA": ["In", "addition,", "treatment-related", "reductions", "in", "CRP", "and", "IL-6", "levels", "were", "also", "greater", "in", "varespladib", "treated", "patients", "compared", "to", "those", "treated", "with", "placebo", "at", "all", "time", "points", "in", "the", "clinical", "study."], "wordsB": ["In", "addition,", "in", "a", "subgroup", "population", "of", "severely", "ill,", "seropositive", "lupus", "patients,", "defined", "as", "those", "patients", "having", "a", "SELENA-SLEDAI", "score", "of", "greater", "or", "equal", "to", "ten", "who", "were", "also", "receiving", "background", "corticosteroid", "medication", "at", "the", "time", "of", "randomization,", "a", "more", "pronounced", "treatment", "benefit", "was", "seen", "with", "the", "blisibimod", "200mg", "weekly", "dose", "compared", "to", "other", "doses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p53_s2", "idA": "1316175_12_item1_p91_s0", "sentA": "In addition, treatment-related reductions in CRP and IL-6 levels were also greater in varespladib treated patients compared to those treated with placebo at all time points in the clinical study.", "sentB": "In addition, in a subgroup population of severely ill, seropositive lupus patients, defined as those patients having a SELENA-SLEDAI score of 10 who were also receiving background corticosteroid medication at the time of randomization, a more pronounced treatment benefit was seen with the blisibimod 200mg weekly dose compared to other doses.", "type": 1, "words": ["<tag1>", "In", "addition,", "treatment-related", "reductions", "in", "CRP", "and", "IL-6", "levels", "were", "also", "greater", "in", "varespladib", "treated", "patients", "compared", "to", "those", "treated", "with", "placebo", "at", "all", "time", "points", "in", "the", "clinical", "study.", "<tag2>", "In", "addition,", "in", "a", "subgroup", "population", "of", "severely", "ill,", "seropositive", "lupus", "patients,", "defined", "as", "those", "patients", "having", "a", "SELENA-SLEDAI", "score", "of", "10", "who", "were", "also", "receiving", "background", "corticosteroid", "medication", "at", "the", "time", "of", "randomization,", "a", "more", "pronounced", "treatment", "benefit", "was", "seen", "with", "the", "blisibimod", "200mg", "weekly", "dose", "compared", "to", "other", "doses.", "<tag3>"], "wordsA": ["In", "addition,", "treatment-related", "reductions", "in", "CRP", "and", "IL-6", "levels", "were", "also", "greater", "in", "varespladib", "treated", "patients", "compared", "to", "those", "treated", "with", "placebo", "at", "all", "time", "points", "in", "the", "clinical", "study."], "wordsB": ["In", "addition,", "in", "a", "subgroup", "population", "of", "severely", "ill,", "seropositive", "lupus", "patients,", "defined", "as", "those", "patients", "having", "a", "SELENA-SLEDAI", "score", "of", "10", "who", "were", "also", "receiving", "background", "corticosteroid", "medication", "at", "the", "time", "of", "randomization,", "a", "more", "pronounced", "treatment", "benefit", "was", "seen", "with", "the", "blisibimod", "200mg", "weekly", "dose", "compared", "to", "other", "doses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p20_s2", "idA": "1316175_12_item1_p91_s2", "sentA": "At weeks two, four, eight and 16, varespladib treated patients had numerically reduced levels of CRP versus patients treated with placebo.", "sentB": "SRI improvements compared with placebo were generally higher in subjects who attained SELENA SLEDAI improvements of 6, 7, 8 (SRI-6, SRI-7, and SRI-8, respectively).", "type": 1, "words": ["<tag1>", "At", "weeks", "two,", "four,", "eight", "and", "16,", "varespladib", "treated", "patients", "had", "numerically", "reduced", "levels", "of", "CRP", "versus", "patients", "treated", "with", "placebo.", "<tag2>", "SRI", "improvements", "compared", "with", "placebo", "were", "generally", "higher", "in", "subjects", "who", "attained", "SELENA", "SLEDAI", "improvements", "of", "6,", "7,", "8", "(SRI-6,", "SRI-7,", "and", "SRI-8,", "respectively).", "<tag3>"], "wordsA": ["At", "weeks", "two,", "four,", "eight", "and", "16,", "varespladib", "treated", "patients", "had", "numerically", "reduced", "levels", "of", "CRP", "versus", "patients", "treated", "with", "placebo."], "wordsB": ["SRI", "improvements", "compared", "with", "placebo", "were", "generally", "higher", "in", "subjects", "who", "attained", "SELENA", "SLEDAI", "improvements", "of", "6,", "7,", "8", "(SRI-6,", "SRI-7,", "and", "SRI-8,", "respectively)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p21_s2", "idA": "1316175_12_item1_p91_s2", "sentA": "At weeks two, four, eight and 16, varespladib treated patients had numerically reduced levels of CRP versus patients treated with placebo.", "sentB": "SRI improvements compared with placebo were higher still in subjects who attained SELENA SLEDAI improvements of 6, 7, 8 (SRI-6, SRI-7, and SRI-8, respectively).", "type": 1, "words": ["<tag1>", "At", "weeks", "two,", "four,", "eight", "and", "16,", "varespladib", "treated", "patients", "had", "numerically", "reduced", "levels", "of", "CRP", "versus", "patients", "treated", "with", "placebo.", "<tag2>", "SRI", "improvements", "compared", "with", "placebo", "were", "higher", "still", "in", "subjects", "who", "attained", "SELENA", "SLEDAI", "improvements", "of", "6,", "7,", "8", "(SRI-6,", "SRI-7,", "and", "SRI-8,", "respectively).", "<tag3>"], "wordsA": ["At", "weeks", "two,", "four,", "eight", "and", "16,", "varespladib", "treated", "patients", "had", "numerically", "reduced", "levels", "of", "CRP", "versus", "patients", "treated", "with", "placebo."], "wordsB": ["SRI", "improvements", "compared", "with", "placebo", "were", "higher", "still", "in", "subjects", "who", "attained", "SELENA", "SLEDAI", "improvements", "of", "6,", "7,", "8", "(SRI-6,", "SRI-7,", "and", "SRI-8,", "respectively)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p195_s0", "idA": "1316175_13_item1_p0_s0", "sentA": "Unless the context otherwise requires, we use the terms Anthera Pharmaceuticals, Anthera, we, us, the Company and our in this report to refer to Anthera Pharmaceuticals, Inc. and its subsidiaries.", "sentB": "On July 15, 2013, the Company effectuated a 1-for-8 reverse split of its outstanding common stock.", "type": 1, "words": ["<tag1>", "Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "Anthera", "Pharmaceuticals,", "Anthera,", "we,", "us,", "the", "Company", "and", "our", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries.", "<tag2>", "On", "July", "15,", "2013,", "the", "Company", "effectuated", "a", "1-for-8", "reverse", "split", "of", "its", "outstanding", "common", "stock.", "<tag3>"], "wordsA": ["Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "Anthera", "Pharmaceuticals,", "Anthera,", "we,", "us,", "the", "Company", "and", "our", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries."], "wordsB": ["On", "July", "15,", "2013,", "the", "Company", "effectuated", "a", "1-for-8", "reverse", "split", "of", "its", "outstanding", "common", "stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p195_s1", "idA": "1316175_13_item1_p115_s0", "sentA": "Upon entering into the license agreement, we made one-time payments of cash in the amount of $250,000 and issued shares of convertible preferred stock with a total aggregate value of $2.3 million to Eli Lilly and Shionogi Co., Ltd.", "sentB": "All references to shares of common stock outstanding and per share data for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted to reflect such reverse split.", "type": 1, "words": ["<tag1>", "Upon", "entering", "into", "the", "license", "agreement,", "we", "made", "one-time", "payments", "of", "cash", "in", "the", "amount", "of", "$250,000", "and", "issued", "shares", "of", "convertible", "preferred", "stock", "with", "a", "total", "aggregate", "value", "of", "$2.3", "million", "to", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag2>", "All", "references", "to", "shares", "of", "common", "stock", "outstanding", "and", "per", "share", "data", "for", "all", "periods", "presented", "in", "the", "accompanying", "consolidated", "financial", "statements", "and", "notes", "thereto", "have", "been", "adjusted", "to", "reflect", "such", "reverse", "split.", "<tag3>"], "wordsA": ["Upon", "entering", "into", "the", "license", "agreement,", "we", "made", "one-time", "payments", "of", "cash", "in", "the", "amount", "of", "$250,000", "and", "issued", "shares", "of", "convertible", "preferred", "stock", "with", "a", "total", "aggregate", "value", "of", "$2.3", "million", "to", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "wordsB": ["All", "references", "to", "shares", "of", "common", "stock", "outstanding", "and", "per", "share", "data", "for", "all", "periods", "presented", "in", "the", "accompanying", "consolidated", "financial", "statements", "and", "notes", "thereto", "have", "been", "adjusted", "to", "reflect", "such", "reverse", "split."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p75_s0", "idA": "1316175_13_item1_p11_s0", "sentA": "Blisibimod (also referred to as A-623) is a peptibody antagonist of the BAFF cytokine that we are developing as a treatment for systemic lupus erythematosus, or lupus and IgAN.", "sentB": "Lupus Europe estimates that one in 750 women in Europe suffer from lupus and that lupus is a worldwide disease more common in some races than others.", "type": 1, "words": ["<tag1>", "Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "we", "are", "developing", "as", "a", "treatment", "for", "systemic", "lupus", "erythematosus,", "or", "lupus", "and", "IgAN.", "<tag2>", "Lupus", "Europe", "estimates", "that", "one", "in", "750", "women", "in", "Europe", "suffer", "from", "lupus", "and", "that", "lupus", "is", "a", "worldwide", "disease", "more", "common", "in", "some", "races", "than", "others.", "<tag3>"], "wordsA": ["Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "we", "are", "developing", "as", "a", "treatment", "for", "systemic", "lupus", "erythematosus,", "or", "lupus", "and", "IgAN."], "wordsB": ["Lupus", "Europe", "estimates", "that", "one", "in", "750", "women", "in", "Europe", "suffer", "from", "lupus", "and", "that", "lupus", "is", "a", "worldwide", "disease", "more", "common", "in", "some", "races", "than", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p90_s5", "idA": "1316175_13_item1_p130_s0", "sentA": "Involves studies in a limited patient population to identify possible adverse effects and safety risks to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.", "sentB": "Further discussion of the proteinuria endpoint, as well as the inclusion of Japan in a global harmonized program of studies in IgA nephropathy will take place at the PMDA in April 2014.", "type": 1, "words": ["<tag1>", "Involves", "studies", "in", "a", "limited", "patient", "population", "to", "identify", "possible", "adverse", "effects", "and", "safety", "risks", "to", "preliminarily", "evaluate", "the", "efficacy", "of", "the", "product", "for", "specific", "targeted", "diseases", "and", "to", "determine", "dosage", "tolerance", "and", "optimal", "dosage", "and", "schedule.", "<tag2>", "Further", "discussion", "of", "the", "proteinuria", "endpoint,", "as", "well", "as", "the", "inclusion", "of", "Japan", "in", "a", "global", "harmonized", "program", "of", "studies", "in", "IgA", "nephropathy", "will", "take", "place", "at", "the", "PMDA", "in", "April", "2014.", "<tag3>"], "wordsA": ["Involves", "studies", "in", "a", "limited", "patient", "population", "to", "identify", "possible", "adverse", "effects", "and", "safety", "risks", "to", "preliminarily", "evaluate", "the", "efficacy", "of", "the", "product", "for", "specific", "targeted", "diseases", "and", "to", "determine", "dosage", "tolerance", "and", "optimal", "dosage", "and", "schedule."], "wordsB": ["Further", "discussion", "of", "the", "proteinuria", "endpoint,", "as", "well", "as", "the", "inclusion", "of", "Japan", "in", "a", "global", "harmonized", "program", "of", "studies", "in", "IgA", "nephropathy", "will", "take", "place", "at", "the", "PMDA", "in", "April", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p48_s1", "idA": "1316175_13_item1_p131_s1", "sentA": "These studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.", "sentB": "This futility analysis is not intended to provide any rules for stopping for overwhelming efficacy, change in study sample size, or alteration of the study design.", "type": 1, "words": ["<tag1>", "These", "studies", "are", "intended", "to", "establish", "the", "overall", "risk/benefit", "ratio", "of", "the", "product", "and", "provide", "an", "adequate", "basis", "for", "product", "labeling.", "<tag2>", "This", "futility", "analysis", "is", "not", "intended", "to", "provide", "any", "rules", "for", "stopping", "for", "overwhelming", "efficacy,", "change", "in", "study", "sample", "size,", "or", "alteration", "of", "the", "study", "design.", "<tag3>"], "wordsA": ["These", "studies", "are", "intended", "to", "establish", "the", "overall", "risk/benefit", "ratio", "of", "the", "product", "and", "provide", "an", "adequate", "basis", "for", "product", "labeling."], "wordsB": ["This", "futility", "analysis", "is", "not", "intended", "to", "provide", "any", "rules", "for", "stopping", "for", "overwhelming", "efficacy,", "change", "in", "study", "sample", "size,", "or", "alteration", "of", "the", "study", "design."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p49_s1", "idA": "1316175_13_item1_p145_s2", "sentA": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued Written Request for such a study.", "sentB": "An independent DSMB will convene to review the study at the end of March 2014 and mid-July 2014.", "type": 1, "words": ["<tag1>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study.", "<tag2>", "An", "independent", "DSMB", "will", "convene", "to", "review", "the", "study", "at", "the", "end", "of", "March", "2014", "and", "mid-July", "2014.", "<tag3>"], "wordsA": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study."], "wordsB": ["An", "independent", "DSMB", "will", "convene", "to", "review", "the", "study", "at", "the", "end", "of", "March", "2014", "and", "mid-July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p36_s1", "idA": "1316175_13_item1_p147_s2", "sentA": "Orphan product exclusivity could also block the approval of one of our products for seven years if a competitor obtains approval of the same drug or biological product as defined by the FDA or if our product candidate is determined to be contained within the competitor s product for the same indication or disease.", "sentB": "Separately, data are shown for the subgroup of subjects with high inflammatory biomarker status at enrollment, defined by low C3 and high anti-dsDNA autoantibodies at baseline.", "type": 1, "words": ["<tag1>", "Orphan", "product", "exclusivity", "could", "also", "block", "the", "approval", "of", "one", "of", "our", "products", "for", "seven", "years", "if", "a", "competitor", "obtains", "approval", "of", "the", "same", "drug", "or", "biological", "product", "as", "defined", "by", "the", "FDA", "or", "if", "our", "product", "candidate", "is", "determined", "to", "be", "contained", "within", "the", "competitor", "s", "product", "for", "the", "same", "indication", "or", "disease.", "<tag2>", "Separately,", "data", "are", "shown", "for", "the", "subgroup", "of", "subjects", "with", "high", "inflammatory", "biomarker", "status", "at", "enrollment,", "defined", "by", "low", "C3", "and", "high", "anti-dsDNA", "autoantibodies", "at", "baseline.", "<tag3>"], "wordsA": ["Orphan", "product", "exclusivity", "could", "also", "block", "the", "approval", "of", "one", "of", "our", "products", "for", "seven", "years", "if", "a", "competitor", "obtains", "approval", "of", "the", "same", "drug", "or", "biological", "product", "as", "defined", "by", "the", "FDA", "or", "if", "our", "product", "candidate", "is", "determined", "to", "be", "contained", "within", "the", "competitor", "s", "product", "for", "the", "same", "indication", "or", "disease."], "wordsB": ["Separately,", "data", "are", "shown", "for", "the", "subgroup", "of", "subjects", "with", "high", "inflammatory", "biomarker", "status", "at", "enrollment,", "defined", "by", "low", "C3", "and", "high", "anti-dsDNA", "autoantibodies", "at", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p3_s1", "idA": "1316175_13_item1_p1_s0", "sentA": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.", "sentB": "In January 2012, Anthera Pharmaceuticals, Limited, a wholly-owned subsidiary, was incorporated in Ireland.", "type": 1, "words": ["<tag1>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "autoimmune", "diseases.", "<tag2>", "In", "January", "2012,", "Anthera", "Pharmaceuticals,", "Limited,", "a", "wholly-owned", "subsidiary,", "was", "incorporated", "in", "Ireland.", "<tag3>"], "wordsA": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "autoimmune", "diseases."], "wordsB": ["In", "January", "2012,", "Anthera", "Pharmaceuticals,", "Limited,", "a", "wholly-owned", "subsidiary,", "was", "incorporated", "in", "Ireland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p33_s0", "idA": "1316175_13_item1_p20_s1", "sentA": "Across all subjects enrolled in the PEARL-SC study, the percent of subjects achieving the SRI-5 at 24 weeks was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "sentB": "Analyses were conducted in the subgroup of subjects with more severe lupus (SELENA-SLEDAI score 10) at enrollment.", "type": 1, "words": ["<tag1>", "Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag2>", "Analyses", "were", "conducted", "in", "the", "subgroup", "of", "subjects", "with", "more", "severe", "lupus", "(SELENA-SLEDAI", "score", "10)", "at", "enrollment.", "<tag3>"], "wordsA": ["Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "wordsB": ["Analyses", "were", "conducted", "in", "the", "subgroup", "of", "subjects", "with", "more", "severe", "lupus", "(SELENA-SLEDAI", "score", "10)", "at", "enrollment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s5", "idA": "1316175_13_item1_p21_s2", "sentA": "SRI improvements compared with placebo were higher still in subjects who attained SELENA SLEDAI improvements of 6, 7, 8 (SRI-6, SRI-7, and SRI-8, respectively).", "sentB": "In pre-specified secondary analyses, benefit was observed at Week 24 with the 200mg QW group compared with matched placebo using modified SRI analyses in which responders attained SELENA-SLEDAI improvements of 7 or 8 ( SRI 5 = 8.7% p=0.23; SRI-7 =16.3% p=0.003; SRI-8 =17.4% p=0.001, Figure 1).", "type": 1, "words": ["<tag1>", "SRI", "improvements", "compared", "with", "placebo", "were", "higher", "still", "in", "subjects", "who", "attained", "SELENA", "SLEDAI", "improvements", "of", "6,", "7,", "8", "(SRI-6,", "SRI-7,", "and", "SRI-8,", "respectively).", "<tag2>", "In", "pre-specified", "secondary", "analyses,", "benefit", "was", "observed", "at", "Week", "24", "with", "the", "200mg", "QW", "group", "compared", "with", "matched", "placebo", "using", "modified", "SRI", "analyses", "in", "which", "responders", "attained", "SELENA-SLEDAI", "improvements", "of", "7", "or", "8", "(", "SRI", "5", "=", "8.7%", "p=0.23;", "SRI-7", "=16.3%", "p=0.003;", "SRI-8", "=17.4%", "p=0.001,", "Figure", "1).", "<tag3>"], "wordsA": ["SRI", "improvements", "compared", "with", "placebo", "were", "higher", "still", "in", "subjects", "who", "attained", "SELENA", "SLEDAI", "improvements", "of", "6,", "7,", "8", "(SRI-6,", "SRI-7,", "and", "SRI-8,", "respectively)."], "wordsB": ["In", "pre-specified", "secondary", "analyses,", "benefit", "was", "observed", "at", "Week", "24", "with", "the", "200mg", "QW", "group", "compared", "with", "matched", "placebo", "using", "modified", "SRI", "analyses", "in", "which", "responders", "attained", "SELENA-SLEDAI", "improvements", "of", "7", "or", "8", "(", "SRI", "5", "=", "8.7%", "p=0.23;", "SRI-7", "=16.3%", "p=0.003;", "SRI-8", "=17.4%", "p=0.001,", "Figure", "1)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p36_s3", "idA": "1316175_13_item1_p22_s0", "sentA": "The following table shows the N values at the different time points in the graph above.", "sentB": "See data presented by Dr. Richard Furie at the European League Against Rheumatology Annual Conference, Madrid, Spain 2013 in Figure 3.", "type": 1, "words": ["<tag1>", "The", "following", "table", "shows", "the", "N", "values", "at", "the", "different", "time", "points", "in", "the", "graph", "above.", "<tag2>", "See", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "European", "League", "Against", "Rheumatology", "Annual", "Conference,", "Madrid,", "Spain", "2013", "in", "Figure", "3.", "<tag3>"], "wordsA": ["The", "following", "table", "shows", "the", "N", "values", "at", "the", "different", "time", "points", "in", "the", "graph", "above."], "wordsB": ["See", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "European", "League", "Against", "Rheumatology", "Annual", "Conference,", "Madrid,", "Spain", "2013", "in", "Figure", "3."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p72_s0", "idA": "1316175_13_item1_p24_s0", "sentA": "To date, three (3) randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two (2) Phase 1 dose-ranging studies in which a total of 104 patients were randomized, and a Phase 2b dose-ranging clinical outcomes study in which 547 subjects were enrolled.", "sentB": "In a recently completed, open-label, Phase 1 trial the BAFF inhibitor tabalumab was associated with a 55% increase in overall response rate in patients with multiple myeloma with a concomitant decrease in immunoglobulins secreted form multiple myeloma cells (called M proteins).", "type": 1, "words": ["<tag1>", "To", "date,", "three", "(3)", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "(2)", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "randomized,", "and", "a", "Phase", "2b", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled.", "<tag2>", "In", "a", "recently", "completed,", "open-label,", "Phase", "1", "trial", "the", "BAFF", "inhibitor", "tabalumab", "was", "associated", "with", "a", "55%", "increase", "in", "overall", "response", "rate", "in", "patients", "with", "multiple", "myeloma", "with", "a", "concomitant", "decrease", "in", "immunoglobulins", "secreted", "form", "multiple", "myeloma", "cells", "(called", "M", "proteins).", "<tag3>"], "wordsA": ["To", "date,", "three", "(3)", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "(2)", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "randomized,", "and", "a", "Phase", "2b", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled."], "wordsB": ["In", "a", "recently", "completed,", "open-label,", "Phase", "1", "trial", "the", "BAFF", "inhibitor", "tabalumab", "was", "associated", "with", "a", "55%", "increase", "in", "overall", "response", "rate", "in", "patients", "with", "multiple", "myeloma", "with", "a", "concomitant", "decrease", "in", "immunoglobulins", "secreted", "form", "multiple", "myeloma", "cells", "(called", "M", "proteins)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p70_s0", "idA": "1316175_13_item1_p24_s3", "sentA": "Details of the findings of these trials are provided in the Historical Clinical Studies section.", "sentB": "The disease presentation often includes bone pain, elevated calcium in the blood, anemia, clotting disorders and a loss of function of the immune system with a resulting increase in infection risk.", "type": 1, "words": ["<tag1>", "Details", "of", "the", "findings", "of", "these", "trials", "are", "provided", "in", "the", "Historical", "Clinical", "Studies", "section.", "<tag2>", "The", "disease", "presentation", "often", "includes", "bone", "pain,", "elevated", "calcium", "in", "the", "blood,", "anemia,", "clotting", "disorders", "and", "a", "loss", "of", "function", "of", "the", "immune", "system", "with", "a", "resulting", "increase", "in", "infection", "risk.", "<tag3>"], "wordsA": ["Details", "of", "the", "findings", "of", "these", "trials", "are", "provided", "in", "the", "Historical", "Clinical", "Studies", "section."], "wordsB": ["The", "disease", "presentation", "often", "includes", "bone", "pain,", "elevated", "calcium", "in", "the", "blood,", "anemia,", "clotting", "disorders", "and", "a", "loss", "of", "function", "of", "the", "immune", "system", "with", "a", "resulting", "increase", "in", "infection", "risk."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p86_s0", "idA": "1316175_13_item1_p24_s3", "sentA": "Details of the findings of these trials are provided in the Historical Clinical Studies section.", "sentB": "The disease presentation often includes bone pain, elevated calcium in the blood, anemia, clotting disorders, and a loss of function of the immune system with a resulting increase in infection risk.", "type": 1, "words": ["<tag1>", "Details", "of", "the", "findings", "of", "these", "trials", "are", "provided", "in", "the", "Historical", "Clinical", "Studies", "section.", "<tag2>", "The", "disease", "presentation", "often", "includes", "bone", "pain,", "elevated", "calcium", "in", "the", "blood,", "anemia,", "clotting", "disorders,", "and", "a", "loss", "of", "function", "of", "the", "immune", "system", "with", "a", "resulting", "increase", "in", "infection", "risk.", "<tag3>"], "wordsA": ["Details", "of", "the", "findings", "of", "these", "trials", "are", "provided", "in", "the", "Historical", "Clinical", "Studies", "section."], "wordsB": ["The", "disease", "presentation", "often", "includes", "bone", "pain,", "elevated", "calcium", "in", "the", "blood,", "anemia,", "clotting", "disorders,", "and", "a", "loss", "of", "function", "of", "the", "immune", "system", "with", "a", "resulting", "increase", "in", "infection", "risk."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p104_s2", "idA": "1316175_13_item1_p38_s4", "sentA": "In our PEARL-SC Phase 2b study, significant reductions in total B-cells as well as significant improvements in proteinuria and increases in complement C3 were observed with blisibimod in lupus patients.", "sentB": "This proposal is supported by the observed increase in BAFF levels in patients, as well as data with BAFF inhibitors showing decreased survival of multiple myeloma cells and improvements in survival and bone lesions in animals transformed with human multiple myeloma.", "type": 1, "words": ["<tag1>", "In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients.", "<tag2>", "This", "proposal", "is", "supported", "by", "the", "observed", "increase", "in", "BAFF", "levels", "in", "patients,", "as", "well", "as", "data", "with", "BAFF", "inhibitors", "showing", "decreased", "survival", "of", "multiple", "myeloma", "cells", "and", "improvements", "in", "survival", "and", "bone", "lesions", "in", "animals", "transformed", "with", "human", "multiple", "myeloma.", "<tag3>"], "wordsA": ["In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients."], "wordsB": ["This", "proposal", "is", "supported", "by", "the", "observed", "increase", "in", "BAFF", "levels", "in", "patients,", "as", "well", "as", "data", "with", "BAFF", "inhibitors", "showing", "decreased", "survival", "of", "multiple", "myeloma", "cells", "and", "improvements", "in", "survival", "and", "bone", "lesions", "in", "animals", "transformed", "with", "human", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p20_s1", "idA": "1316175_13_item1_p45_s2", "sentA": "IgA is a human antibody that helps the body fight infections.", "sentB": "Lupus Europe estimates that one in 750 women suffer from lupus in Europe and that lupus is a worldwide disease more common in some races than others.", "type": 1, "words": ["<tag1>", "IgA", "is", "a", "human", "antibody", "that", "helps", "the", "body", "fight", "infections.", "<tag2>", "Lupus", "Europe", "estimates", "that", "one", "in", "750", "women", "suffer", "from", "lupus", "in", "Europe", "and", "that", "lupus", "is", "a", "worldwide", "disease", "more", "common", "in", "some", "races", "than", "others.", "<tag3>"], "wordsA": ["IgA", "is", "a", "human", "antibody", "that", "helps", "the", "body", "fight", "infections."], "wordsB": ["Lupus", "Europe", "estimates", "that", "one", "in", "750", "women", "suffer", "from", "lupus", "in", "Europe", "and", "that", "lupus", "is", "a", "worldwide", "disease", "more", "common", "in", "some", "races", "than", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p74_s6", "idA": "1316175_13_item1_p51_s2", "sentA": "Subjects were randomized into three active subcutaneous treatment arms and one placebo treatment arm for a minimum of 24 weeks and a maximum of 52 weeks.", "sentB": "These patients are further categorized into three disease categories ranging from mild, moderate, to severe.", "type": 1, "words": ["<tag1>", "Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks.", "<tag2>", "These", "patients", "are", "further", "categorized", "into", "three", "disease", "categories", "ranging", "from", "mild,", "moderate,", "to", "severe.", "<tag3>"], "wordsA": ["Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks."], "wordsB": ["These", "patients", "are", "further", "categorized", "into", "three", "disease", "categories", "ranging", "from", "mild,", "moderate,", "to", "severe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p64_s4", "idA": "1316175_13_item1_p53_s1", "sentA": "While the pre-specified primary efficacy endpoint in the PEARL-SC clinical study was not met due to a lack of clinical efficacy in the two lower dose groups, additional prospective data from the PEARL-SC study suggest consistent treatment benefits in the 200mg weekly dose group when utilizing higher thresholds of disease improvement, as measured by larger point reductions in the SELENA-SLEDAI scoring index.", "sentB": "In addition, the FDA indicated a requirement for us to provide confirmatory data from a post-marketing study which would include measurement of clinical endpoints, such as changes in kidney function, progression to dialysis and death in patients previously enrolled in the two registration studies and a third outcomes study.", "type": 1, "words": ["<tag1>", "While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "a", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lower", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "the", "SELENA-SLEDAI", "scoring", "index.", "<tag2>", "In", "addition,", "the", "FDA", "indicated", "a", "requirement", "for", "us", "to", "provide", "confirmatory", "data", "from", "a", "post-marketing", "study", "which", "would", "include", "measurement", "of", "clinical", "endpoints,", "such", "as", "changes", "in", "kidney", "function,", "progression", "to", "dialysis", "and", "death", "in", "patients", "previously", "enrolled", "in", "the", "two", "registration", "studies", "and", "a", "third", "outcomes", "study.", "<tag3>"], "wordsA": ["While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "a", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lower", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "the", "SELENA-SLEDAI", "scoring", "index."], "wordsB": ["In", "addition,", "the", "FDA", "indicated", "a", "requirement", "for", "us", "to", "provide", "confirmatory", "data", "from", "a", "post-marketing", "study", "which", "would", "include", "measurement", "of", "clinical", "endpoints,", "such", "as", "changes", "in", "kidney", "function,", "progression", "to", "dialysis", "and", "death", "in", "patients", "previously", "enrolled", "in", "the", "two", "registration", "studies", "and", "a", "third", "outcomes", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p6_s0", "idA": "1316175_13_item1_p60_s5", "sentA": "We believe inhibition of BAFF may reduce proliferative B-cells and plasma B-cells, reduce serum levels of IgA and therefore reduce progressive renal damage in patients with IgAN.", "sentB": "BAFF is primarily expressed by macrophages, monocytes and dendritic cells and interacts with three different receptors on B-cells and plasma cells including BAFF receptor, or BAFF-R, B-cell maturation antigen, or BCMA, and transmembrane activator and cyclophilin ligand interactor, or TACI.", "type": 1, "words": ["<tag1>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN.", "<tag2>", "BAFF", "is", "primarily", "expressed", "by", "macrophages,", "monocytes", "and", "dendritic", "cells", "and", "interacts", "with", "three", "different", "receptors", "on", "B-cells", "and", "plasma", "cells", "including", "BAFF", "receptor,", "or", "BAFF-R,", "B-cell", "maturation", "antigen,", "or", "BCMA,", "and", "transmembrane", "activator", "and", "cyclophilin", "ligand", "interactor,", "or", "TACI.", "<tag3>"], "wordsA": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN."], "wordsB": ["BAFF", "is", "primarily", "expressed", "by", "macrophages,", "monocytes", "and", "dendritic", "cells", "and", "interacts", "with", "three", "different", "receptors", "on", "B-cells", "and", "plasma", "cells", "including", "BAFF", "receptor,", "or", "BAFF-R,", "B-cell", "maturation", "antigen,", "or", "BCMA,", "and", "transmembrane", "activator", "and", "cyclophilin", "ligand", "interactor,", "or", "TACI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p71_s2", "idA": "1316175_13_item1_p7_s1", "sentA": "Inhibition of BAFF is believed to reduce survival and subsequent elevations in B-cells leading to a reduction in severity of disease and resolution of Lupus symptoms.", "sentB": "Furthermore, in an animal model of disease induced by human multiple myeloma cells, BAFF inhibition was found to increase survival and decrease disease-associated bone lesions.", "type": 1, "words": ["<tag1>", "Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "and", "subsequent", "elevations", "in", "B-cells", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "Lupus", "symptoms.", "<tag2>", "Furthermore,", "in", "an", "animal", "model", "of", "disease", "induced", "by", "human", "multiple", "myeloma", "cells,", "BAFF", "inhibition", "was", "found", "to", "increase", "survival", "and", "decrease", "disease-associated", "bone", "lesions.", "<tag3>"], "wordsA": ["Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "and", "subsequent", "elevations", "in", "B-cells", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "Lupus", "symptoms."], "wordsB": ["Furthermore,", "in", "an", "animal", "model", "of", "disease", "induced", "by", "human", "multiple", "myeloma", "cells,", "BAFF", "inhibition", "was", "found", "to", "increase", "survival", "and", "decrease", "disease-associated", "bone", "lesions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p26_s0", "idA": "1316175_13_item1_p82_s3", "sentA": "Based on the recommendation of the DSMB, we do not expect to engage in any further development activities of varespladib and varespladib sodium.", "sentB": "Based on SELENA SLEDAI definitions, 76 subjects (13.9%) had renal involvement at baseline and 54 subjects had proteinuria equivalent 1g/24hr.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "recommendation", "of", "the", "DSMB,", "we", "do", "not", "expect", "to", "engage", "in", "any", "further", "development", "activities", "of", "varespladib", "and", "varespladib", "sodium.", "<tag2>", "Based", "on", "SELENA", "SLEDAI", "definitions,", "76", "subjects", "(13.9%)", "had", "renal", "involvement", "at", "baseline", "and", "54", "subjects", "had", "proteinuria", "equivalent", "1g/24hr.", "<tag3>"], "wordsA": ["Based", "on", "the", "recommendation", "of", "the", "DSMB,", "we", "do", "not", "expect", "to", "engage", "in", "any", "further", "development", "activities", "of", "varespladib", "and", "varespladib", "sodium."], "wordsB": ["Based", "on", "SELENA", "SLEDAI", "definitions,", "76", "subjects", "(13.9%)", "had", "renal", "involvement", "at", "baseline", "and", "54", "subjects", "had", "proteinuria", "equivalent", "1g/24hr."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p111_s2", "idA": "1316175_13_item1_p93_s1", "sentA": "These product candidates include Benlysta (belimumab) from Human Genome Sciences, Inc., tabalumab (LY2127399) from Eli Lilly and Company, atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc., as well as others acting via non B-cell mechanisms, such as Lupuzor from Cephalon.", "sentB": "Other pathways targeting both B-cell and non-B-cell mechanisms are in earlier-phase clinical trials, such as Lupuzor from ImmuPharma plc; anti-inhibitors of interferon (IFN) alpha, MEDI-545 and MEDI-546 and rontalizumab; the anti-IFN gamma antibody AMG 811; toll-like receptor inhibitors; the anti-interleukin 6 antibody sirukumab; the phosphodiesterase 4 inhibitor CC-10004; the anti-CD74 monocloncal antibody milatuzumab; and inhibition of B7 related protein (B7RP-1) pathway with AMG 557.", "type": 1, "words": ["<tag1>", "These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon.", "<tag2>", "Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "MEDI-545", "and", "MEDI-546", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibody", "sirukumab;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557.", "<tag3>"], "wordsA": ["These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon."], "wordsB": ["Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "MEDI-545", "and", "MEDI-546", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibody", "sirukumab;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p13_s2", "idA": "1316175_14_item1_p104_s2", "sentA": "This proposal is supported by the observed increase in BAFF levels in patients, as well as data with BAFF inhibitors showing decreased survival of multiple myeloma cells and improvements in survival and bone lesions in animals transformed with human multiple myeloma.", "sentB": "This finding is further supported by the similar efficacy observed between liprotamase and Creon in pigs with surgically-induced pancreatic insufficiency.", "type": 1, "words": ["<tag1>", "This", "proposal", "is", "supported", "by", "the", "observed", "increase", "in", "BAFF", "levels", "in", "patients,", "as", "well", "as", "data", "with", "BAFF", "inhibitors", "showing", "decreased", "survival", "of", "multiple", "myeloma", "cells", "and", "improvements", "in", "survival", "and", "bone", "lesions", "in", "animals", "transformed", "with", "human", "multiple", "myeloma.", "<tag2>", "This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "liprotamase", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency.", "<tag3>"], "wordsA": ["This", "proposal", "is", "supported", "by", "the", "observed", "increase", "in", "BAFF", "levels", "in", "patients,", "as", "well", "as", "data", "with", "BAFF", "inhibitors", "showing", "decreased", "survival", "of", "multiple", "myeloma", "cells", "and", "improvements", "in", "survival", "and", "bone", "lesions", "in", "animals", "transformed", "with", "human", "multiple", "myeloma."], "wordsB": ["This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "liprotamase", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p99_s1", "idA": "1316175_14_item1_p109_s1", "sentA": "Benlysta , the first novel therapy approved in the last 50 years, was acquired by GSK in July 2012.", "sentB": "The two latter product candidates were terminated in March 2012.", "type": 1, "words": ["<tag1>", "Benlysta", ",", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years,", "was", "acquired", "by", "GSK", "in", "July", "2012.", "<tag2>", "The", "two", "latter", "product", "candidates", "were", "terminated", "in", "March", "2012.", "<tag3>"], "wordsA": ["Benlysta", ",", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years,", "was", "acquired", "by", "GSK", "in", "July", "2012."], "wordsB": ["The", "two", "latter", "product", "candidates", "were", "terminated", "in", "March", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p204_s1", "idA": "1316175_14_item1_p115_s0", "sentA": "As of the date of this report, our blisibimod patent portfolio includes:", "sentB": "Information contained on, or that can be accessed through, our website does not constitute part of this Annual Report on Form 10-K.", "type": 1, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:", "<tag2>", "Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "does", "not", "constitute", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:"], "wordsB": ["Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "does", "not", "constitute", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p109_s0", "idA": "1316175_14_item1_p119_s4", "sentA": "The EP patents are currently scheduled to expire in May 2022.", "sentB": "There are currently several marketed products for EPI caused by cystic fibrosis, including Creon marketed by AbbVie, Inc., Pancreaze by Janssen Pharmaceuticals, Inc., Pertzye by Cornestone Therapeutics, Inc., and Ultresa and Zenpep by Aptalis Pharma US.", "type": 1, "words": ["<tag1>", "The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag2>", "There", "are", "currently", "several", "marketed", "products", "for", "EPI", "caused", "by", "cystic", "fibrosis,", "including", "Creon", "marketed", "by", "AbbVie,", "Inc.,", "Pancreaze", "by", "Janssen", "Pharmaceuticals,", "Inc.,", "Pertzye", "by", "Cornestone", "Therapeutics,", "Inc.,", "and", "Ultresa", "and", "Zenpep", "by", "Aptalis", "Pharma", "US.", "<tag3>"], "wordsA": ["The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "wordsB": ["There", "are", "currently", "several", "marketed", "products", "for", "EPI", "caused", "by", "cystic", "fibrosis,", "including", "Creon", "marketed", "by", "AbbVie,", "Inc.,", "Pancreaze", "by", "Janssen", "Pharmaceuticals,", "Inc.,", "Pertzye", "by", "Cornestone", "Therapeutics,", "Inc.,", "and", "Ultresa", "and", "Zenpep", "by", "Aptalis", "Pharma", "US."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p133_s2", "idA": "1316175_14_item1_p124_s0", "sentA": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "The licensed patent rights include all patents controlled by us or our affiliates relating to blisibimod, including those licensed to us under the Amgen Agreement.", "type": 1, "words": ["<tag1>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "The", "licensed", "patent", "rights", "include", "all", "patents", "controlled", "by", "us", "or", "our", "affiliates", "relating", "to", "blisibimod,", "including", "those", "licensed", "to", "us", "under", "the", "Amgen", "Agreement.", "<tag3>"], "wordsA": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["The", "licensed", "patent", "rights", "include", "all", "patents", "controlled", "by", "us", "or", "our", "affiliates", "relating", "to", "blisibimod,", "including", "those", "licensed", "to", "us", "under", "the", "Amgen", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p37_s0", "idA": "1316175_14_item1_p125_s2", "sentA": "During the period of the agreement, we are responsible for the filing, prosecution, defense and maintenance of all exclusively licensed blisibimod patents and applications.", "sentB": "The exocrine pancreas is responsible for synthesis and secretion of digestive enzymes, including lipase, protease, and amylase.", "type": 1, "words": ["<tag1>", "During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "blisibimod", "patents", "and", "applications.", "<tag2>", "The", "exocrine", "pancreas", "is", "responsible", "for", "synthesis", "and", "secretion", "of", "digestive", "enzymes,", "including", "lipase,", "protease,", "and", "amylase.", "<tag3>"], "wordsA": ["During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "blisibimod", "patents", "and", "applications."], "wordsB": ["The", "exocrine", "pancreas", "is", "responsible", "for", "synthesis", "and", "secretion", "of", "digestive", "enzymes,", "including", "lipase,", "protease,", "and", "amylase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p133_s1", "idA": "1316175_14_item1_p127_s0", "sentA": "Pursuant to the terms of the license agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "sentB": "Zenyaku also obtained certain rights to grant sublicenses and an option to expand the territory of the license to include China (including Hong Kong), Singapore, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia and South Korea.", "type": 1, "words": ["<tag1>", "Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag2>", "Zenyaku", "also", "obtained", "certain", "rights", "to", "grant", "sublicenses", "and", "an", "option", "to", "expand", "the", "territory", "of", "the", "license", "to", "include", "China", "(including", "Hong", "Kong),", "Singapore,", "Taiwan,", "Philippines,", "Thailand,", "Malaysia,", "Vietnam,", "Indonesia", "and", "South", "Korea.", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "wordsB": ["Zenyaku", "also", "obtained", "certain", "rights", "to", "grant", "sublicenses", "and", "an", "option", "to", "expand", "the", "territory", "of", "the", "license", "to", "include", "China", "(including", "Hong", "Kong),", "Singapore,", "Taiwan,", "Philippines,", "Thailand,", "Malaysia,", "Vietnam,", "Indonesia", "and", "South", "Korea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p137_s3", "idA": "1316175_14_item1_p127_s0", "sentA": "Pursuant to the terms of the license agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "sentB": "Pursuant to the Zenyaku Agreement, we may also require Zenyaku to purchase up to an additional $8.0 million of shares of our common stock at the Premium Purchase Price in quarterly installments of no more than $2.0 million during the period from June 1, 2015 to March 31, 2016.", "type": 1, "words": ["<tag1>", "Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag2>", "Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "may", "also", "require", "Zenyaku", "to", "purchase", "up", "to", "an", "additional", "$8.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "the", "Premium", "Purchase", "Price", "in", "quarterly", "installments", "of", "no", "more", "than", "$2.0", "million", "during", "the", "period", "from", "June", "1,", "2015", "to", "March", "31,", "2016.", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "wordsB": ["Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "may", "also", "require", "Zenyaku", "to", "purchase", "up", "to", "an", "additional", "$8.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "the", "Premium", "Purchase", "Price", "in", "quarterly", "installments", "of", "no", "more", "than", "$2.0", "million", "during", "the", "period", "from", "June", "1,", "2015", "to", "March", "31,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s5", "idA": "1316175_14_item1_p128_s0", "sentA": "The license agreement will remain in effect until we elect to terminate, or until termination for material breach by either party or insolvency on our part.", "sentB": "Upon termination due to material breach by Anthera, Zenyaku is entitled to retain all license rights; however, is still obligated to pay the milestone payments to us, royalty payment to Amgen and any third party payments.", "type": 1, "words": ["<tag1>", "The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part.", "<tag2>", "Upon", "termination", "due", "to", "material", "breach", "by", "Anthera,", "Zenyaku", "is", "entitled", "to", "retain", "all", "license", "rights;", "however,", "is", "still", "obligated", "to", "pay", "the", "milestone", "payments", "to", "us,", "royalty", "payment", "to", "Amgen", "and", "any", "third", "party", "payments.", "<tag3>"], "wordsA": ["The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part."], "wordsB": ["Upon", "termination", "due", "to", "material", "breach", "by", "Anthera,", "Zenyaku", "is", "entitled", "to", "retain", "all", "license", "rights;", "however,", "is", "still", "obligated", "to", "pay", "the", "milestone", "payments", "to", "us,", "royalty", "payment", "to", "Amgen", "and", "any", "third", "party", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p130_s1", "idA": "1316175_14_item1_p129_s1", "sentA": "We plan to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our product candidate if and when approved for marketing by the FDA.", "sentB": "Under this amendment, we also agreed to grant Amgen that number of shares of our common stock equal $1,000,000 divided by the volume weighted average price of our common stock for 20 trading days prior to issuance.", "type": 1, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidate", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA.", "<tag2>", "Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1,000,000", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance.", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidate", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA."], "wordsB": ["Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1,000,000", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p40_s0", "idA": "1316175_14_item1_p130_s1", "sentA": "We believe that this will provide a sufficient supply of these raw materials and drug product to meet our needs for the foreseeable future.", "sentB": "We believe liprotamase is potentially the first soluble, stable and non-porcine derived enzyme product to offer a novel solution to patients who are unable to maintain appropriate nutritional health with existing enzyme therapies.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "this", "will", "provide", "a", "sufficient", "supply", "of", "these", "raw", "materials", "and", "drug", "product", "to", "meet", "our", "needs", "for", "the", "foreseeable", "future.", "<tag2>", "We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health", "with", "existing", "enzyme", "therapies.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "will", "provide", "a", "sufficient", "supply", "of", "these", "raw", "materials", "and", "drug", "product", "to", "meet", "our", "needs", "for", "the", "foreseeable", "future."], "wordsB": ["We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health", "with", "existing", "enzyme", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p99_s3", "idA": "1316175_14_item1_p131_s0", "sentA": "Our research and development activities involve the controlled use of potentially hazardous substances, including toxic chemical and biological materials.", "sentB": "In the years ended December 31, 2014, 2013 and 2012, we incurred $21.8 million, $21.7 million and $49.2 million, respectively, of research and development expense.", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "the", "controlled", "use", "of", "potentially", "hazardous", "substances,", "including", "toxic", "chemical", "and", "biological", "materials.", "<tag2>", "In", "the", "years", "ended", "December", "31,", "2014,", "2013", "and", "2012,", "we", "incurred", "$21.8", "million,", "$21.7", "million", "and", "$49.2", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "the", "controlled", "use", "of", "potentially", "hazardous", "substances,", "including", "toxic", "chemical", "and", "biological", "materials."], "wordsB": ["In", "the", "years", "ended", "December", "31,", "2014,", "2013", "and", "2012,", "we", "incurred", "$21.8", "million,", "$21.7", "million", "and", "$49.2", "million,", "respectively,", "of", "research", "and", "development", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p24_s2", "idA": "1316175_14_item1_p137_s0", "sentA": "FDA review and approval of the NDA or BLA.", "sentB": "The available data suggests an improved consistency of the SRI-6 endpoint across multiple trials.", "type": 1, "words": ["<tag1>", "FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA.", "<tag2>", "The", "available", "data", "suggests", "an", "improved", "consistency", "of", "the", "SRI-6", "endpoint", "across", "multiple", "trials.", "<tag3>"], "wordsA": ["FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA."], "wordsB": ["The", "available", "data", "suggests", "an", "improved", "consistency", "of", "the", "SRI-6", "endpoint", "across", "multiple", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s1", "idA": "1316175_14_item1_p140_s0", "sentA": "Some preclinical testing may continue even after the IND is submitted.", "sentB": "If the agreement is not terminated early, Zenyaku may continue to obtain clinical/commercial drug supplies from Anthera after such expiration for three (3) years from providing a written notice to discontinue such supplies.", "type": 1, "words": ["<tag1>", "Some", "preclinical", "testing", "may", "continue", "even", "after", "the", "IND", "is", "submitted.", "<tag2>", "If", "the", "agreement", "is", "not", "terminated", "early,", "Zenyaku", "may", "continue", "to", "obtain", "clinical/commercial", "drug", "supplies", "from", "Anthera", "after", "such", "expiration", "for", "three", "(3)", "years", "from", "providing", "a", "written", "notice", "to", "discontinue", "such", "supplies.", "<tag3>"], "wordsA": ["Some", "preclinical", "testing", "may", "continue", "even", "after", "the", "IND", "is", "submitted."], "wordsB": ["If", "the", "agreement", "is", "not", "terminated", "early,", "Zenyaku", "may", "continue", "to", "obtain", "clinical/commercial", "drug", "supplies", "from", "Anthera", "after", "such", "expiration", "for", "three", "(3)", "years", "from", "providing", "a", "written", "notice", "to", "discontinue", "such", "supplies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p16_s0", "idA": "1316175_14_item1_p146_s0", "sentA": "Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites.", "sentB": "Since protease and lipase can become irreversibly inactivated in an acid environment, most products are provided as enteric-coated microbeads.", "type": 1, "words": ["<tag1>", "Clinical", "studies", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "study", "sites.", "<tag2>", "Since", "protease", "and", "lipase", "can", "become", "irreversibly", "inactivated", "in", "an", "acid", "environment,", "most", "products", "are", "provided", "as", "enteric-coated", "microbeads.", "<tag3>"], "wordsA": ["Clinical", "studies", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "study", "sites."], "wordsB": ["Since", "protease", "and", "lipase", "can", "become", "irreversibly", "inactivated", "in", "an", "acid", "environment,", "most", "products", "are", "provided", "as", "enteric-coated", "microbeads."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p13_s0", "idA": "1316175_14_item1_p146_s1", "sentA": "These studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.", "sentB": "The individual enzyme components of liprotamase are formulated at a fixed ratio of lipase, protease, and amylase.", "type": 1, "words": ["<tag1>", "These", "studies", "are", "intended", "to", "establish", "the", "overall", "risk/benefit", "ratio", "of", "the", "product", "and", "provide", "an", "adequate", "basis", "for", "product", "labeling.", "<tag2>", "The", "individual", "enzyme", "components", "of", "liprotamase", "are", "formulated", "at", "a", "fixed", "ratio", "of", "lipase,", "protease,", "and", "amylase.", "<tag3>"], "wordsA": ["These", "studies", "are", "intended", "to", "establish", "the", "overall", "risk/benefit", "ratio", "of", "the", "product", "and", "provide", "an", "adequate", "basis", "for", "product", "labeling."], "wordsB": ["The", "individual", "enzyme", "components", "of", "liprotamase", "are", "formulated", "at", "a", "fixed", "ratio", "of", "lipase,", "protease,", "and", "amylase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p41_s0", "idA": "1316175_14_item1_p15_s2", "sentA": "We believe that certain of these markets and product opportunities for blisibimod can be commercialized through utilization of a limited specialty sales force targeting a small set of clinical specialists.", "sentB": "Liprotamase s chemical characteristics, unlike currently available PERTs, make it ideal for powder formulation as either a capsule or sachet product, which can be conveniently co-administered with a small volume of water.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "certain", "of", "these", "markets", "and", "product", "opportunities", "for", "blisibimod", "can", "be", "commercialized", "through", "utilization", "of", "a", "limited", "specialty", "sales", "force", "targeting", "a", "small", "set", "of", "clinical", "specialists.", "<tag2>", "Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule", "or", "sachet", "product,", "which", "can", "be", "conveniently", "co-administered", "with", "a", "small", "volume", "of", "water.", "<tag3>"], "wordsA": ["We", "believe", "that", "certain", "of", "these", "markets", "and", "product", "opportunities", "for", "blisibimod", "can", "be", "commercialized", "through", "utilization", "of", "a", "limited", "specialty", "sales", "force", "targeting", "a", "small", "set", "of", "clinical", "specialists."], "wordsB": ["Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule", "or", "sachet", "product,", "which", "can", "be", "conveniently", "co-administered", "with", "a", "small", "volume", "of", "water."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p13_s1", "idA": "1316175_14_item1_p166_s1", "sentA": "For a fast track product, the FDA may consider for review on a rolling basis sections of the NDA or BLA before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.", "sentB": "The liprotamase enzyme dose ratio was selected from preclinical efficacy studies conducted using a canine model of pancreatic insufficiency which demonstrated that the lipase enzyme in liprotamase was efficacious when administered at 500 units/kg per meal, and the protease doses 1000 units/kg per meal (Borowitz et al . 2006).", "type": 1, "words": ["<tag1>", "For", "a", "fast", "track", "product,", "the", "FDA", "may", "consider", "for", "review", "on", "a", "rolling", "basis", "sections", "of", "the", "NDA", "or", "BLA", "before", "the", "complete", "application", "is", "submitted,", "if", "the", "sponsor", "provides", "a", "schedule", "for", "the", "submission", "of", "the", "sections", "of", "the", "NDA", "or", "BLA,", "the", "FDA", "agrees", "to", "accept", "sections", "of", "the", "NDA", "or", "BLA", "and", "determines", "that", "the", "schedule", "is", "acceptable,", "and", "the", "sponsor", "pays", "any", "required", "user", "fees", "upon", "submission", "of", "the", "first", "section", "of", "the", "NDA", "or", "BLA.", "<tag2>", "The", "liprotamase", "enzyme", "dose", "ratio", "was", "selected", "from", "preclinical", "efficacy", "studies", "conducted", "using", "a", "canine", "model", "of", "pancreatic", "insufficiency", "which", "demonstrated", "that", "the", "lipase", "enzyme", "in", "liprotamase", "was", "efficacious", "when", "administered", "at", "500", "units/kg", "per", "meal,", "and", "the", "protease", "doses", "1000", "units/kg", "per", "meal", "(Borowitz", "et", "al", ".", "2006).", "<tag3>"], "wordsA": ["For", "a", "fast", "track", "product,", "the", "FDA", "may", "consider", "for", "review", "on", "a", "rolling", "basis", "sections", "of", "the", "NDA", "or", "BLA", "before", "the", "complete", "application", "is", "submitted,", "if", "the", "sponsor", "provides", "a", "schedule", "for", "the", "submission", "of", "the", "sections", "of", "the", "NDA", "or", "BLA,", "the", "FDA", "agrees", "to", "accept", "sections", "of", "the", "NDA", "or", "BLA", "and", "determines", "that", "the", "schedule", "is", "acceptable,", "and", "the", "sponsor", "pays", "any", "required", "user", "fees", "upon", "submission", "of", "the", "first", "section", "of", "the", "NDA", "or", "BLA."], "wordsB": ["The", "liprotamase", "enzyme", "dose", "ratio", "was", "selected", "from", "preclinical", "efficacy", "studies", "conducted", "using", "a", "canine", "model", "of", "pancreatic", "insufficiency", "which", "demonstrated", "that", "the", "lipase", "enzyme", "in", "liprotamase", "was", "efficacious", "when", "administered", "at", "500", "units/kg", "per", "meal,", "and", "the", "protease", "doses", "1000", "units/kg", "per", "meal", "(Borowitz", "et", "al", ".", "2006)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p104_s2", "idA": "1316175_14_item1_p172_s1", "sentA": "Drugs and biological products may be promoted only for the approved indications and in accordance with the provisions of the approved label.", "sentB": "Our primary competitors are described in further detail below, under Approved Categories of Drugs and B-Cell Targeting Drugs Under Late-Stage Clinical Development .", "type": 1, "words": ["<tag1>", "Drugs", "and", "biological", "products", "may", "be", "promoted", "only", "for", "the", "approved", "indications", "and", "in", "accordance", "with", "the", "provisions", "of", "the", "approved", "label.", "<tag2>", "Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", "and", "B-Cell", "Targeting", "Drugs", "Under", "Late-Stage", "Clinical", "Development", ".", "<tag3>"], "wordsA": ["Drugs", "and", "biological", "products", "may", "be", "promoted", "only", "for", "the", "approved", "indications", "and", "in", "accordance", "with", "the", "provisions", "of", "the", "approved", "label."], "wordsB": ["Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", "and", "B-Cell", "Targeting", "Drugs", "Under", "Late-Stage", "Clinical", "Development", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p130_s0", "idA": "1316175_14_item1_p172_s1", "sentA": "Drugs and biological products may be promoted only for the approved indications and in accordance with the provisions of the approved label.", "sentB": "In connection with the collaborative arrangement with Zenyaku, we amended the Amgen Agreement in November 2014 to (i) adjust certain royalty and milestone payment obligations payable to Amgen in light of our collaboration with Zenyaku and (ii) provide that the sublicense granted by us to Zenyaku shall survive the termination of the Amgen Agreement.", "type": 1, "words": ["<tag1>", "Drugs", "and", "biological", "products", "may", "be", "promoted", "only", "for", "the", "approved", "indications", "and", "in", "accordance", "with", "the", "provisions", "of", "the", "approved", "label.", "<tag2>", "In", "connection", "with", "the", "collaborative", "arrangement", "with", "Zenyaku,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement.", "<tag3>"], "wordsA": ["Drugs", "and", "biological", "products", "may", "be", "promoted", "only", "for", "the", "approved", "indications", "and", "in", "accordance", "with", "the", "provisions", "of", "the", "approved", "label."], "wordsB": ["In", "connection", "with", "the", "collaborative", "arrangement", "with", "Zenyaku,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p137_s4", "idA": "1316175_14_item1_p175_s0", "sentA": "We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products.", "sentB": "Additionally, prior to May 31, 2016, we may sell $4.0 million of shares of our common stock to Zenyaku should Zenyaku elects to exercise their option for the Additional Asian Countries.", "type": 1, "words": ["<tag1>", "We", "rely,", "and", "expect", "to", "continue", "to", "rely,", "on", "third", "parties", "for", "the", "production", "of", "clinical", "and", "commercial", "quantities", "of", "our", "products.", "<tag2>", "Additionally,", "prior", "to", "May", "31,", "2016,", "we", "may", "sell", "$4.0", "million", "of", "shares", "of", "our", "common", "stock", "to", "Zenyaku", "should", "Zenyaku", "elects", "to", "exercise", "their", "option", "for", "the", "Additional", "Asian", "Countries.", "<tag3>"], "wordsA": ["We", "rely,", "and", "expect", "to", "continue", "to", "rely,", "on", "third", "parties", "for", "the", "production", "of", "clinical", "and", "commercial", "quantities", "of", "our", "products."], "wordsB": ["Additionally,", "prior", "to", "May", "31,", "2016,", "we", "may", "sell", "$4.0", "million", "of", "shares", "of", "our", "common", "stock", "to", "Zenyaku", "should", "Zenyaku", "elects", "to", "exercise", "their", "option", "for", "the", "Additional", "Asian", "Countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p138_s1", "idA": "1316175_14_item1_p182_s2", "sentA": "The centralized procedure is compulsory for medicines produced by certain biotechnological processes, products with a new active substance indicated for the treatment of certain diseases such as neurodegenerative disorder or diabetes and products designated as orphan medicinal products, and optional for those products which are highly innovative or for which a centralized process is in the interest of patients.", "sentB": "In exchange, we intend to issue a Secured Promissory Note to Zenyaku, to be secured by certain information and material necessary for the manufacture of blisibimod, with a maturity date of December 11, 2021 and an accrued interest of 1% per annum.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure", "is", "compulsory", "for", "medicines", "produced", "by", "certain", "biotechnological", "processes,", "products", "with", "a", "new", "active", "substance", "indicated", "for", "the", "treatment", "of", "certain", "diseases", "such", "as", "neurodegenerative", "disorder", "or", "diabetes", "and", "products", "designated", "as", "orphan", "medicinal", "products,", "and", "optional", "for", "those", "products", "which", "are", "highly", "innovative", "or", "for", "which", "a", "centralized", "process", "is", "in", "the", "interest", "of", "patients.", "<tag2>", "In", "exchange,", "we", "intend", "to", "issue", "a", "Secured", "Promissory", "Note", "to", "Zenyaku,", "to", "be", "secured", "by", "certain", "information", "and", "material", "necessary", "for", "the", "manufacture", "of", "blisibimod,", "with", "a", "maturity", "date", "of", "December", "11,", "2021", "and", "an", "accrued", "interest", "of", "1%", "per", "annum.", "<tag3>"], "wordsA": ["The", "centralized", "procedure", "is", "compulsory", "for", "medicines", "produced", "by", "certain", "biotechnological", "processes,", "products", "with", "a", "new", "active", "substance", "indicated", "for", "the", "treatment", "of", "certain", "diseases", "such", "as", "neurodegenerative", "disorder", "or", "diabetes", "and", "products", "designated", "as", "orphan", "medicinal", "products,", "and", "optional", "for", "those", "products", "which", "are", "highly", "innovative", "or", "for", "which", "a", "centralized", "process", "is", "in", "the", "interest", "of", "patients."], "wordsB": ["In", "exchange,", "we", "intend", "to", "issue", "a", "Secured", "Promissory", "Note", "to", "Zenyaku,", "to", "be", "secured", "by", "certain", "information", "and", "material", "necessary", "for", "the", "manufacture", "of", "blisibimod,", "with", "a", "maturity", "date", "of", "December", "11,", "2021", "and", "an", "accrued", "interest", "of", "1%", "per", "annum."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p99_s0", "idA": "1316175_14_item1_p184_s2", "sentA": "We anticipate third-party payors will provide reimbursement for our product.", "sentB": "Since our inception in 2004, we have focused primarily on developing our product candidates, blisibimod, liprotamase, varespladib and varespladib sodium.", "type": 1, "words": ["<tag1>", "We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product.", "<tag2>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "blisibimod,", "liprotamase,", "varespladib", "and", "varespladib", "sodium.", "<tag3>"], "wordsA": ["We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product."], "wordsB": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "blisibimod,", "liprotamase,", "varespladib", "and", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p43_s0", "idA": "1316175_14_item1_p184_s5", "sentA": "We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products.", "sentB": "lower pill burden given a larger concentration of lipase per capsule: adult patients who may prefer liprotamase capsules will be able to take fewer capsules and smaller capsules in order to attain the same enzyme dosage.", "type": 1, "words": ["<tag1>", "We", "may", "need", "to", "conduct", "expensive", "pharmacoeconomic", "studies", "in", "order", "to", "demonstrate", "the", "cost-effectiveness", "of", "our", "products.", "<tag2>", "lower", "pill", "burden", "given", "a", "larger", "concentration", "of", "lipase", "per", "capsule:", "adult", "patients", "who", "may", "prefer", "liprotamase", "capsules", "will", "be", "able", "to", "take", "fewer", "capsules", "and", "smaller", "capsules", "in", "order", "to", "attain", "the", "same", "enzyme", "dosage.", "<tag3>"], "wordsA": ["We", "may", "need", "to", "conduct", "expensive", "pharmacoeconomic", "studies", "in", "order", "to", "demonstrate", "the", "cost-effectiveness", "of", "our", "products."], "wordsB": ["lower", "pill", "burden", "given", "a", "larger", "concentration", "of", "lipase", "per", "capsule:", "adult", "patients", "who", "may", "prefer", "liprotamase", "capsules", "will", "be", "able", "to", "take", "fewer", "capsules", "and", "smaller", "capsules", "in", "order", "to", "attain", "the", "same", "enzyme", "dosage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s4", "idA": "1316175_14_item1_p184_s8", "sentA": "Reimbursement may not be available or sufficient to allow us to sell our product on a competitive and profitable basis.", "sentB": "Upon expiration (but not earlier termination), Zenyaku may retain the licensed patent on a fully-paid and royalty free (subject to the Amgen royalty and any third party payments), irrevocable and perpetual basis.", "type": 1, "words": ["<tag1>", "Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "product", "on", "a", "competitive", "and", "profitable", "basis.", "<tag2>", "Upon", "expiration", "(but", "not", "earlier", "termination),", "Zenyaku", "may", "retain", "the", "licensed", "patent", "on", "a", "fully-paid", "and", "royalty", "free", "(subject", "to", "the", "Amgen", "royalty", "and", "any", "third", "party", "payments),", "irrevocable", "and", "perpetual", "basis.", "<tag3>"], "wordsA": ["Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "product", "on", "a", "competitive", "and", "profitable", "basis."], "wordsB": ["Upon", "expiration", "(but", "not", "earlier", "termination),", "Zenyaku", "may", "retain", "the", "licensed", "patent", "on", "a", "fully-paid", "and", "royalty", "free", "(subject", "to", "the", "Amgen", "royalty", "and", "any", "third", "party", "payments),", "irrevocable", "and", "perpetual", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p21_s0", "idA": "1316175_14_item1_p196_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "1 picomolar affinity for BAFF , compared to the 120-350 picomolar reported for anti-BAFF monoclonal antibodies.", "type": 1, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "1", "picomolar", "affinity", "for", "BAFF", ",", "compared", "to", "the", "120-350", "picomolar", "reported", "for", "anti-BAFF", "monoclonal", "antibodies.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["1", "picomolar", "affinity", "for", "BAFF", ",", "compared", "to", "the", "120-350", "picomolar", "reported", "for", "anti-BAFF", "monoclonal", "antibodies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s1", "idA": "1316175_14_item1_p23_s1", "sentA": "The study enrolled 547 patients in 11 countries at 72 clinical sites.", "sentB": "The study is currently enrolling in 12 countries across Asia, Eastern Europe and Latin America.", "type": 1, "words": ["<tag1>", "The", "study", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites.", "<tag2>", "The", "study", "is", "currently", "enrolling", "in", "12", "countries", "across", "Asia,", "Eastern", "Europe", "and", "Latin", "America.", "<tag3>"], "wordsA": ["The", "study", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites."], "wordsB": ["The", "study", "is", "currently", "enrolling", "in", "12", "countries", "across", "Asia,", "Eastern", "Europe", "and", "Latin", "America."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s6", "idA": "1316175_14_item1_p25_s2", "sentA": "The primary endpoint of this study was not met due to the lack of efficacy in the two lowest dose groups.", "sentB": "Upon termination due to material breach or at will by Zenyaku, all license rights granted to Zenyaku automatically terminate.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups.", "<tag2>", "Upon", "termination", "due", "to", "material", "breach", "or", "at", "will", "by", "Zenyaku,", "all", "license", "rights", "granted", "to", "Zenyaku", "automatically", "terminate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups."], "wordsB": ["Upon", "termination", "due", "to", "material", "breach", "or", "at", "will", "by", "Zenyaku,", "all", "license", "rights", "granted", "to", "Zenyaku", "automatically", "terminate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p96_s1", "idA": "1316175_14_item1_p25_s2", "sentA": "The primary endpoint of this study was not met due to the lack of efficacy in the two lowest dose groups.", "sentB": "There was a protocol-specified dose increase to two capsules per meal and one capsule per snack allowed in cases of involuntary weight loss, steatorrhea, or lack of weight gain.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups.", "<tag2>", "There", "was", "a", "protocol-specified", "dose", "increase", "to", "two", "capsules", "per", "meal", "and", "one", "capsule", "per", "snack", "allowed", "in", "cases", "of", "involuntary", "weight", "loss,", "steatorrhea,", "or", "lack", "of", "weight", "gain.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups."], "wordsB": ["There", "was", "a", "protocol-specified", "dose", "increase", "to", "two", "capsules", "per", "meal", "and", "one", "capsule", "per", "snack", "allowed", "in", "cases", "of", "involuntary", "weight", "loss,", "steatorrhea,", "or", "lack", "of", "weight", "gain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p23_s2", "idA": "1316175_14_item1_p25_s4", "sentA": "Treatment benefit was greater still when compared with the regimen-matched (QW) placebo.", "sentB": "Rather, the analysis suggests that the observed data conforms with the assumptions upon which the trial was designed.", "type": 1, "words": ["<tag1>", "Treatment", "benefit", "was", "greater", "still", "when", "compared", "with", "the", "regimen-matched", "(QW)", "placebo.", "<tag2>", "Rather,", "the", "analysis", "suggests", "that", "the", "observed", "data", "conforms", "with", "the", "assumptions", "upon", "which", "the", "trial", "was", "designed.", "<tag3>"], "wordsA": ["Treatment", "benefit", "was", "greater", "still", "when", "compared", "with", "the", "regimen-matched", "(QW)", "placebo."], "wordsB": ["Rather,", "the", "analysis", "suggests", "that", "the", "observed", "data", "conforms", "with", "the", "assumptions", "upon", "which", "the", "trial", "was", "designed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p22_s1", "idA": "1316175_14_item1_p29_s5", "sentA": "Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.", "sentB": "During these regular meetings, the DSMB reviews un-blinded safety data which include adverse events, suspected unexpected serious adverse reactions or SUSARs, deaths, laboratory data, and withdrawal data and compares trends between treatments.", "type": 1, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events.", "<tag2>", "During", "these", "regular", "meetings,", "the", "DSMB", "reviews", "un-blinded", "safety", "data", "which", "include", "adverse", "events,", "suspected", "unexpected", "serious", "adverse", "reactions", "or", "SUSARs,", "deaths,", "laboratory", "data,", "and", "withdrawal", "data", "and", "compares", "trends", "between", "treatments.", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events."], "wordsB": ["During", "these", "regular", "meetings,", "the", "DSMB", "reviews", "un-blinded", "safety", "data", "which", "include", "adverse", "events,", "suspected", "unexpected", "serious", "adverse", "reactions", "or", "SUSARs,", "deaths,", "laboratory", "data,", "and", "withdrawal", "data", "and", "compares", "trends", "between", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p94_s0", "idA": "1316175_14_item1_p29_s5", "sentA": "Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.", "sentB": "The dose-ranging Phase 1 study TC-1B evaluated five dose levels across a 50-fold range, from 100-to-5000 units (U) per kg per meal in CF-EPI subjects.", "type": 1, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events.", "<tag2>", "The", "dose-ranging", "Phase", "1", "study", "TC-1B", "evaluated", "five", "dose", "levels", "across", "a", "50-fold", "range,", "from", "100-to-5000", "units", "(U)", "per", "kg", "per", "meal", "in", "CF-EPI", "subjects.", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events."], "wordsB": ["The", "dose-ranging", "Phase", "1", "study", "TC-1B", "evaluated", "five", "dose", "levels", "across", "a", "50-fold", "range,", "from", "100-to-5000", "units", "(U)", "per", "kg", "per", "meal", "in", "CF-EPI", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p95_s0", "idA": "1316175_14_item1_p33_s0", "sentA": "Analyses were conducted in the subgroup of subjects with more severe lupus (SELENA-SLEDAI score 10) at enrollment.", "sentB": "Study TC-2A, a Phase 2, randomized, double-blind, parallel group, dose-finding trial, was conducted in 125 pediatric and adult subjects with CF-related EPI who were treated with liprotamase in one of three dosing regimens containing 6,500 U, 32,500 U, and 130,000 U lipase administered per meal or snack.", "type": 1, "words": ["<tag1>", "Analyses", "were", "conducted", "in", "the", "subgroup", "of", "subjects", "with", "more", "severe", "lupus", "(SELENA-SLEDAI", "score", "10)", "at", "enrollment.", "<tag2>", "Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "liprotamase", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack.", "<tag3>"], "wordsA": ["Analyses", "were", "conducted", "in", "the", "subgroup", "of", "subjects", "with", "more", "severe", "lupus", "(SELENA-SLEDAI", "score", "10)", "at", "enrollment."], "wordsB": ["Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "liprotamase", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p97_s1", "idA": "1316175_14_item1_p33_s0", "sentA": "Analyses were conducted in the subgroup of subjects with more severe lupus (SELENA-SLEDAI score 10) at enrollment.", "sentB": "Study 810 evaluated adult subjects with EPI due to CP or after pancreatectomy.", "type": 1, "words": ["<tag1>", "Analyses", "were", "conducted", "in", "the", "subgroup", "of", "subjects", "with", "more", "severe", "lupus", "(SELENA-SLEDAI", "score", "10)", "at", "enrollment.", "<tag2>", "Study", "810", "evaluated", "adult", "subjects", "with", "EPI", "due", "to", "CP", "or", "after", "pancreatectomy.", "<tag3>"], "wordsA": ["Analyses", "were", "conducted", "in", "the", "subgroup", "of", "subjects", "with", "more", "severe", "lupus", "(SELENA-SLEDAI", "score", "10)", "at", "enrollment."], "wordsB": ["Study", "810", "evaluated", "adult", "subjects", "with", "EPI", "due", "to", "CP", "or", "after", "pancreatectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p98_s1", "idA": "1316175_14_item1_p39_s1", "sentA": "Specifically, the improvements in proteinuria observed in the subgroup of patients with abnormal proteinuria at enrollment (Figure 4), were maintained over 52 weeks of continuous blisibimod therapy.", "sentB": "Mean BMI z-scores for subjects in Study 767 were maintained over time on study (mean BMI z-score at baseline, Months 3, 6, and 12 were -0.503,-0.637, -0.688, and -0.655, respectively).", "type": 1, "words": ["<tag1>", "Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "(Figure", "4),", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy.", "<tag2>", "Mean", "BMI", "z-scores", "for", "subjects", "in", "Study", "767", "were", "maintained", "over", "time", "on", "study", "(mean", "BMI", "z-score", "at", "baseline,", "Months", "3,", "6,", "and", "12", "were", "-0.503,-0.637,", "-0.688,", "and", "-0.655,", "respectively).", "<tag3>"], "wordsA": ["Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "(Figure", "4),", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy."], "wordsB": ["Mean", "BMI", "z-scores", "for", "subjects", "in", "Study", "767", "were", "maintained", "over", "time", "on", "study", "(mean", "BMI", "z-score", "at", "baseline,", "Months", "3,", "6,", "and", "12", "were", "-0.503,-0.637,", "-0.688,", "and", "-0.655,", "respectively)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p98_s0", "idA": "1316175_14_item1_p43_s1", "sentA": "These effects were found to be durable in subjects who continued to receive blisibimod through the OLE study.", "sentB": "Amongst the 214 subjects who were treated, an average dose of 5.5 capsules (containing 32,500 U lipase, with protease and amylase in fixed ratios) of liprotamase per day maintained nutritional status as assessed by serial measurement of height and weight, including age-appropriate growth and weight gain in children.", "type": 1, "words": ["<tag1>", "These", "effects", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study.", "<tag2>", "Amongst", "the", "214", "subjects", "who", "were", "treated,", "an", "average", "dose", "of", "5.5", "capsules", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "of", "liprotamase", "per", "day", "maintained", "nutritional", "status", "as", "assessed", "by", "serial", "measurement", "of", "height", "and", "weight,", "including", "age-appropriate", "growth", "and", "weight", "gain", "in", "children.", "<tag3>"], "wordsA": ["These", "effects", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study."], "wordsB": ["Amongst", "the", "214", "subjects", "who", "were", "treated,", "an", "average", "dose", "of", "5.5", "capsules", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "of", "liprotamase", "per", "day", "maintained", "nutritional", "status", "as", "assessed", "by", "serial", "measurement", "of", "height", "and", "weight,", "including", "age-appropriate", "growth", "and", "weight", "gain", "in", "children."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p38_s0", "idA": "1316175_14_item1_p56_s1", "sentA": "These IgA deposits build up inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "sentB": "A reduction in, or absence of the normally secreted pancreatic digestive enzymes, causes lipids, proteins, and carbohydrates to enter the distal gastrointestinal ( GI ) tract in unabsorbable forms, leading to GI pain and distention, maldigestion, and steatorrhea.", "type": 1, "words": ["<tag1>", "These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag2>", "A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "unabsorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "maldigestion,", "and", "steatorrhea.", "<tag3>"], "wordsA": ["These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "wordsB": ["A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "unabsorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "maldigestion,", "and", "steatorrhea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p56_s0", "idA": "1316175_14_item1_p56_s1", "sentA": "These IgA deposits build up inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "sentB": "The most common causes of EPI are chronic pancreatitis and cystic fibrosis, the former a longstanding inflammation of the pancreas altering the organ's normal structure and function that can arise as a result of malnutrition, heredity, or (in the western world especially), behavior (alcohol use and smoking), and the latter a recessive hereditary disease most common in Europeans and Ashkenazi Jews where the molecular culprit is an altered, CFTR-encoded chloride channel.", "type": 1, "words": ["<tag1>", "These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag2>", "The", "most", "common", "causes", "of", "EPI", "are", "chronic", "pancreatitis", "and", "cystic", "fibrosis,", "the", "former", "a", "longstanding", "inflammation", "of", "the", "pancreas", "altering", "the", "organ's", "normal", "structure", "and", "function", "that", "can", "arise", "as", "a", "result", "of", "malnutrition,", "heredity,", "or", "(in", "the", "western", "world", "especially),", "behavior", "(alcohol", "use", "and", "smoking),", "and", "the", "latter", "a", "recessive", "hereditary", "disease", "most", "common", "in", "Europeans", "and", "Ashkenazi", "Jews", "where", "the", "molecular", "culprit", "is", "an", "altered,", "CFTR-encoded", "chloride", "channel.", "<tag3>"], "wordsA": ["These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "wordsB": ["The", "most", "common", "causes", "of", "EPI", "are", "chronic", "pancreatitis", "and", "cystic", "fibrosis,", "the", "former", "a", "longstanding", "inflammation", "of", "the", "pancreas", "altering", "the", "organ's", "normal", "structure", "and", "function", "that", "can", "arise", "as", "a", "result", "of", "malnutrition,", "heredity,", "or", "(in", "the", "western", "world", "especially),", "behavior", "(alcohol", "use", "and", "smoking),", "and", "the", "latter", "a", "recessive", "hereditary", "disease", "most", "common", "in", "Europeans", "and", "Ashkenazi", "Jews", "where", "the", "molecular", "culprit", "is", "an", "altered,", "CFTR-encoded", "chloride", "channel."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p42_s2", "idA": "1316175_14_item1_p61_s0", "sentA": "The BRIGHT-SC1 study (Figure 10) is a Phase 2/3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "sentB": "This pivotal study is intended to evaluate the non-inferiority of liprotamase compared with other commercially available PERT in a population enriched for PERT responders.", "type": 1, "words": ["<tag1>", "The", "BRIGHT-SC1", "study", "(Figure", "10)", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag2>", "This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "other", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC1", "study", "(Figure", "10)", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "wordsB": ["This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "other", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p12_s1", "idA": "1316175_14_item1_p70_s0", "sentA": "The disease presentation often includes bone pain, elevated calcium in the blood, anemia, clotting disorders and a loss of function of the immune system with a resulting increase in infection risk.", "sentB": "The lipase in liprotamase is more stable than the porcine derived lipase in the low pH environment of the stomach and therefore liprotamase does not have an enteric polymer coating, nor does it contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "type": 1, "words": ["<tag1>", "The", "disease", "presentation", "often", "includes", "bone", "pain,", "elevated", "calcium", "in", "the", "blood,", "anemia,", "clotting", "disorders", "and", "a", "loss", "of", "function", "of", "the", "immune", "system", "with", "a", "resulting", "increase", "in", "infection", "risk.", "<tag2>", "The", "lipase", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating,", "nor", "does", "it", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag3>"], "wordsA": ["The", "disease", "presentation", "often", "includes", "bone", "pain,", "elevated", "calcium", "in", "the", "blood,", "anemia,", "clotting", "disorders", "and", "a", "loss", "of", "function", "of", "the", "immune", "system", "with", "a", "resulting", "increase", "in", "infection", "risk."], "wordsB": ["The", "lipase", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating,", "nor", "does", "it", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s0", "idA": "1316175_14_item1_p76_s1", "sentA": "Inflammation of the brain may cause seizures and other neurologic abnormalities.", "sentB": "Zenyaku may terminate the agreement at will or in the event annual sales of generic drug containing blisibimod reach 50% of annual sales of the drug resulting from this collaboration in Japan and other potential Asian countries.", "type": 1, "words": ["<tag1>", "Inflammation", "of", "the", "brain", "may", "cause", "seizures", "and", "other", "neurologic", "abnormalities.", "<tag2>", "Zenyaku", "may", "terminate", "the", "agreement", "at", "will", "or", "in", "the", "event", "annual", "sales", "of", "generic", "drug", "containing", "blisibimod", "reach", "50%", "of", "annual", "sales", "of", "the", "drug", "resulting", "from", "this", "collaboration", "in", "Japan", "and", "other", "potential", "Asian", "countries.", "<tag3>"], "wordsA": ["Inflammation", "of", "the", "brain", "may", "cause", "seizures", "and", "other", "neurologic", "abnormalities."], "wordsB": ["Zenyaku", "may", "terminate", "the", "agreement", "at", "will", "or", "in", "the", "event", "annual", "sales", "of", "generic", "drug", "containing", "blisibimod", "reach", "50%", "of", "annual", "sales", "of", "the", "drug", "resulting", "from", "this", "collaboration", "in", "Japan", "and", "other", "potential", "Asian", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p39_s0", "idA": "1316175_14_item1_p76_s2", "sentA": "Inflammation of the heart may cause heart failure or sudden death.", "sentB": "Without appropriate therapy, patients with EPI may experience malnutrition, poor growth or weight loss, reduced quality of life, and, in severe cases, increased morbidity and early death.", "type": 1, "words": ["<tag1>", "Inflammation", "of", "the", "heart", "may", "cause", "heart", "failure", "or", "sudden", "death.", "<tag2>", "Without", "appropriate", "therapy,", "patients", "with", "EPI", "may", "experience", "malnutrition,", "poor", "growth", "or", "weight", "loss,", "reduced", "quality", "of", "life,", "and,", "in", "severe", "cases,", "increased", "morbidity", "and", "early", "death.", "<tag3>"], "wordsA": ["Inflammation", "of", "the", "heart", "may", "cause", "heart", "failure", "or", "sudden", "death."], "wordsB": ["Without", "appropriate", "therapy,", "patients", "with", "EPI", "may", "experience", "malnutrition,", "poor", "growth", "or", "weight", "loss,", "reduced", "quality", "of", "life,", "and,", "in", "severe", "cases,", "increased", "morbidity", "and", "early", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p12_s0", "idA": "1316175_14_item1_p7_s0", "sentA": "A peptibody is a novel fusion protein that is distinct from an antibody with several potential advantages, including ease of manufacture, potency and relatively small molecular weight.", "sentB": "Liprotamase is a novel non-porcine PERT that contains three biotechnology-derived digestive enzymes: a lipase, a protease and an amylase.", "type": 1, "words": ["<tag1>", "A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody", "with", "several", "potential", "advantages,", "including", "ease", "of", "manufacture,", "potency", "and", "relatively", "small", "molecular", "weight.", "<tag2>", "Liprotamase", "is", "a", "novel", "non-porcine", "PERT", "that", "contains", "three", "biotechnology-derived", "digestive", "enzymes:", "a", "lipase,", "a", "protease", "and", "an", "amylase.", "<tag3>"], "wordsA": ["A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody", "with", "several", "potential", "advantages,", "including", "ease", "of", "manufacture,", "potency", "and", "relatively", "small", "molecular", "weight."], "wordsB": ["Liprotamase", "is", "a", "novel", "non-porcine", "PERT", "that", "contains", "three", "biotechnology-derived", "digestive", "enzymes:", "a", "lipase,", "a", "protease", "and", "an", "amylase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p108_s1", "idA": "1316175_14_item1_p88_s3", "sentA": "Furthermore, we plan to develop an auto injector strategy for the product presentation at launch in 2014.", "sentB": "These data demonstrate that targeting BAFF remains an effective strategy for improving chronic disease activity in SLE.", "type": 1, "words": ["<tag1>", "Furthermore,", "we", "plan", "to", "develop", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation", "at", "launch", "in", "2014.", "<tag2>", "These", "data", "demonstrate", "that", "targeting", "BAFF", "remains", "an", "effective", "strategy", "for", "improving", "chronic", "disease", "activity", "in", "SLE.", "<tag3>"], "wordsA": ["Furthermore,", "we", "plan", "to", "develop", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation", "at", "launch", "in", "2014."], "wordsB": ["These", "data", "demonstrate", "that", "targeting", "BAFF", "remains", "an", "effective", "strategy", "for", "improving", "chronic", "disease", "activity", "in", "SLE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p17_s1", "idA": "1316175_14_item1_p89_s4", "sentA": "Each study plans to randomize approximately 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "sentB": "Poor stability and variability in terms of potency and pharmaceutical properties have also been identified as important factors contributing to a poor response of some patients to PERTs.", "type": 1, "words": ["<tag1>", "Each", "study", "plans", "to", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag2>", "Poor", "stability", "and", "variability", "in", "terms", "of", "potency", "and", "pharmaceutical", "properties", "have", "also", "been", "identified", "as", "important", "factors", "contributing", "to", "a", "poor", "response", "of", "some", "patients", "to", "PERTs.", "<tag3>"], "wordsA": ["Each", "study", "plans", "to", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "wordsB": ["Poor", "stability", "and", "variability", "in", "terms", "of", "potency", "and", "pharmaceutical", "properties", "have", "also", "been", "identified", "as", "important", "factors", "contributing", "to", "a", "poor", "response", "of", "some", "patients", "to", "PERTs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s4", "idA": "1316175_14_item1_p90_s5", "sentA": "Further discussion of the proteinuria endpoint, as well as the inclusion of Japan in a global harmonized program of studies in IgA nephropathy will take place at the PMDA in April 2014.", "sentB": "We reached an agreement with the EMA on the acceptability of proteinuria as the primary efficacy variable as well as the requirement for a single study to support a Conditional Marketing Authorization Application ( CMAA ) provided that confirmatory evidence from a second study, would be available post approval.", "type": 1, "words": ["<tag1>", "Further", "discussion", "of", "the", "proteinuria", "endpoint,", "as", "well", "as", "the", "inclusion", "of", "Japan", "in", "a", "global", "harmonized", "program", "of", "studies", "in", "IgA", "nephropathy", "will", "take", "place", "at", "the", "PMDA", "in", "April", "2014.", "<tag2>", "We", "reached", "an", "agreement", "with", "the", "EMA", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "variable", "as", "well", "as", "the", "requirement", "for", "a", "single", "study", "to", "support", "a", "Conditional", "Marketing", "Authorization", "Application", "(", "CMAA", ")", "provided", "that", "confirmatory", "evidence", "from", "a", "second", "study,", "would", "be", "available", "post", "approval.", "<tag3>"], "wordsA": ["Further", "discussion", "of", "the", "proteinuria", "endpoint,", "as", "well", "as", "the", "inclusion", "of", "Japan", "in", "a", "global", "harmonized", "program", "of", "studies", "in", "IgA", "nephropathy", "will", "take", "place", "at", "the", "PMDA", "in", "April", "2014."], "wordsB": ["We", "reached", "an", "agreement", "with", "the", "EMA", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "variable", "as", "well", "as", "the", "requirement", "for", "a", "single", "study", "to", "support", "a", "Conditional", "Marketing", "Authorization", "Application", "(", "CMAA", ")", "provided", "that", "confirmatory", "evidence", "from", "a", "second", "study,", "would", "be", "available", "post", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p15_s2", "idA": "1316175_14_item1_p91_s0", "sentA": "We anticipate submitting an application to designate blisibimod as a breakthrough therapy in the treatment of IgA nephropathy.", "sentB": "For example, as the porcine-derived proteins contained in the PERTs pass through the low pH environment of the stomach, enzyme activity rapidly diminishes and, as a consequence, large doses of porcine enzymes are often required.", "type": 1, "words": ["<tag1>", "We", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgA", "nephropathy.", "<tag2>", "For", "example,", "as", "the", "porcine-derived", "proteins", "contained", "in", "the", "PERTs", "pass", "through", "the", "low", "pH", "environment", "of", "the", "stomach,", "enzyme", "activity", "rapidly", "diminishes", "and,", "as", "a", "consequence,", "large", "doses", "of", "porcine", "enzymes", "are", "often", "required.", "<tag3>"], "wordsA": ["We", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgA", "nephropathy."], "wordsB": ["For", "example,", "as", "the", "porcine-derived", "proteins", "contained", "in", "the", "PERTs", "pass", "through", "the", "low", "pH", "environment", "of", "the", "stomach,", "enzyme", "activity", "rapidly", "diminishes", "and,", "as", "a", "consequence,", "large", "doses", "of", "porcine", "enzymes", "are", "often", "required."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p136_s0", "idA": "1316175_14_item1_p9_s0", "sentA": "We have worldwide rights to blisibimod for all potential indications.", "sentB": "Zenyaku is also responsible for all development, marketing and commercialization costs and will reimburse us for i) 100% of blisibimod development cost in Japan; ii) a percentage of global blisibimod development cost outside of Japan; and iii) exclusive purchase of blisibimod clinical drug supplies at cost and blisibimod commercial drug products at a premium from us.", "type": 1, "words": ["<tag1>", "We", "have", "worldwide", "rights", "to", "blisibimod", "for", "all", "potential", "indications.", "<tag2>", "Zenyaku", "is", "also", "responsible", "for", "all", "development,", "marketing", "and", "commercialization", "costs", "and", "will", "reimburse", "us", "for", "i)", "100%", "of", "blisibimod", "development", "cost", "in", "Japan;", "ii)", "a", "percentage", "of", "global", "blisibimod", "development", "cost", "outside", "of", "Japan;", "and", "iii)", "exclusive", "purchase", "of", "blisibimod", "clinical", "drug", "supplies", "at", "cost", "and", "blisibimod", "commercial", "drug", "products", "at", "a", "premium", "from", "us.", "<tag3>"], "wordsA": ["We", "have", "worldwide", "rights", "to", "blisibimod", "for", "all", "potential", "indications."], "wordsB": ["Zenyaku", "is", "also", "responsible", "for", "all", "development,", "marketing", "and", "commercialization", "costs", "and", "will", "reimburse", "us", "for", "i)", "100%", "of", "blisibimod", "development", "cost", "in", "Japan;", "ii)", "a", "percentage", "of", "global", "blisibimod", "development", "cost", "outside", "of", "Japan;", "and", "iii)", "exclusive", "purchase", "of", "blisibimod", "clinical", "drug", "supplies", "at", "cost", "and", "blisibimod", "commercial", "drug", "products", "at", "a", "premium", "from", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p68_s1", "idA": "1316175_15_item1_p100_s1", "sentA": "We retain full development and commercialization rights of blisibimod for all other global territories including North America and the European Union and we are actively pursuing partnerships with pharmaceutical and biotech companies to develop and commercialize blisibimod in these territories.", "sentB": "The large scale fermentation and the associated down-stream processing for all three enzyme APIs are anticipated to be complete through process validation in 2016.", "type": 1, "words": ["<tag1>", "We", "retain", "full", "development", "and", "commercialization", "rights", "of", "blisibimod", "for", "all", "other", "global", "territories", "including", "North", "America", "and", "the", "European", "Union", "and", "we", "are", "actively", "pursuing", "partnerships", "with", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "in", "these", "territories.", "<tag2>", "The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "processing", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "through", "process", "validation", "in", "2016.", "<tag3>"], "wordsA": ["We", "retain", "full", "development", "and", "commercialization", "rights", "of", "blisibimod", "for", "all", "other", "global", "territories", "including", "North", "America", "and", "the", "European", "Union", "and", "we", "are", "actively", "pursuing", "partnerships", "with", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "in", "these", "territories."], "wordsB": ["The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "processing", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "through", "process", "validation", "in", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p2_s0", "idA": "1316175_15_item1_p126_s2", "sentA": "During the period of the agreement, we are responsible for the filing, prosecution, defense and maintenance of all exclusively licensed blisibimod patents and applications.", "sentB": "We licensed blisibimod from Amgen, Inc. ( Amgen ) in December 2007.", "type": 1, "words": ["<tag1>", "During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "blisibimod", "patents", "and", "applications.", "<tag2>", "We", "licensed", "blisibimod", "from", "Amgen,", "Inc.", "(", "Amgen", ")", "in", "December", "2007.", "<tag3>"], "wordsA": ["During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "blisibimod", "patents", "and", "applications."], "wordsB": ["We", "licensed", "blisibimod", "from", "Amgen,", "Inc.", "(", "Amgen", ")", "in", "December", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p149_s2", "idA": "1316175_15_item1_p132_s0", "sentA": "On December 11, 2014, we entered into the Zenyaku Agreement with Zenyaku, pursuant to which we granted Zenyaku an exclusive license to certain patent rights, know-how and other intellectual property relating to blisibimod.", "sentB": "The termination was at will and Zenyaku alleged no breach of the Zenyaku Agreement by us.", "type": 1, "words": ["<tag1>", "On", "December", "11,", "2014,", "we", "entered", "into", "the", "Zenyaku", "Agreement", "with", "Zenyaku,", "pursuant", "to", "which", "we", "granted", "Zenyaku", "an", "exclusive", "license", "to", "certain", "patent", "rights,", "know-how", "and", "other", "intellectual", "property", "relating", "to", "blisibimod.", "<tag2>", "The", "termination", "was", "at", "will", "and", "Zenyaku", "alleged", "no", "breach", "of", "the", "Zenyaku", "Agreement", "by", "us.", "<tag3>"], "wordsA": ["On", "December", "11,", "2014,", "we", "entered", "into", "the", "Zenyaku", "Agreement", "with", "Zenyaku,", "pursuant", "to", "which", "we", "granted", "Zenyaku", "an", "exclusive", "license", "to", "certain", "patent", "rights,", "know-how", "and", "other", "intellectual", "property", "relating", "to", "blisibimod."], "wordsB": ["The", "termination", "was", "at", "will", "and", "Zenyaku", "alleged", "no", "breach", "of", "the", "Zenyaku", "Agreement", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p149_s1", "idA": "1316175_15_item1_p137_s3", "sentA": "Pursuant to the Zenyaku Agreement, we may also require Zenyaku to purchase up to an additional $8.0 million of shares of our common stock at the Premium Purchase Price in quarterly installments of no more than $2.0 million during the period from June 1, 2015 to March 31, 2016.", "sentB": "In September 2015, Zenyaku provided us a notice of its intent to terminate the Zenyaku Agreement, effective January 7, 2016.", "type": 1, "words": ["<tag1>", "Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "may", "also", "require", "Zenyaku", "to", "purchase", "up", "to", "an", "additional", "$8.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "the", "Premium", "Purchase", "Price", "in", "quarterly", "installments", "of", "no", "more", "than", "$2.0", "million", "during", "the", "period", "from", "June", "1,", "2015", "to", "March", "31,", "2016.", "<tag2>", "In", "September", "2015,", "Zenyaku", "provided", "us", "a", "notice", "of", "its", "intent", "to", "terminate", "the", "Zenyaku", "Agreement,", "effective", "January", "7,", "2016.", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "may", "also", "require", "Zenyaku", "to", "purchase", "up", "to", "an", "additional", "$8.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "the", "Premium", "Purchase", "Price", "in", "quarterly", "installments", "of", "no", "more", "than", "$2.0", "million", "during", "the", "period", "from", "June", "1,", "2015", "to", "March", "31,", "2016."], "wordsB": ["In", "September", "2015,", "Zenyaku", "provided", "us", "a", "notice", "of", "its", "intent", "to", "terminate", "the", "Zenyaku", "Agreement,", "effective", "January", "7,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p68_s0", "idA": "1316175_15_item1_p141_s1", "sentA": "We believe that this will provide a sufficient supply of these raw materials and drug product to meet our needs for the foreseeable future.", "sentB": "Technology transfer to commercial scale active pharmaceutical ingredients, or API and drug product manufacturing CMOs was initiated in 2015 and is ongoing.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "this", "will", "provide", "a", "sufficient", "supply", "of", "these", "raw", "materials", "and", "drug", "product", "to", "meet", "our", "needs", "for", "the", "foreseeable", "future.", "<tag2>", "Technology", "transfer", "to", "commercial", "scale", "active", "pharmaceutical", "ingredients,", "or", "API", "and", "drug", "product", "manufacturing", "CMOs", "was", "initiated", "in", "2015", "and", "is", "ongoing.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "will", "provide", "a", "sufficient", "supply", "of", "these", "raw", "materials", "and", "drug", "product", "to", "meet", "our", "needs", "for", "the", "foreseeable", "future."], "wordsB": ["Technology", "transfer", "to", "commercial", "scale", "active", "pharmaceutical", "ingredients,", "or", "API", "and", "drug", "product", "manufacturing", "CMOs", "was", "initiated", "in", "2015", "and", "is", "ongoing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p32_s0", "idA": "1316175_15_item1_p144_s2", "sentA": "We may also choose to employ medical sales liaisons personnel to support the product.", "sentB": "fully human IgG1 Fc domain confers acceptable pharmacokinetic properties to support once-weekly dosing.", "type": 1, "words": ["<tag1>", "We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "the", "product.", "<tag2>", "fully", "human", "IgG1", "Fc", "domain", "confers", "acceptable", "pharmacokinetic", "properties", "to", "support", "once-weekly", "dosing.", "<tag3>"], "wordsA": ["We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "the", "product."], "wordsB": ["fully", "human", "IgG1", "Fc", "domain", "confers", "acceptable", "pharmacokinetic", "properties", "to", "support", "once-weekly", "dosing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p36_s1", "idA": "1316175_15_item1_p191_s5", "sentA": "We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products.", "sentB": "The CHABLIS 7.5 study s name emphasizes the intent to reduce background corticosteroid medication to 7.5mg prednisone in order to mitigate the risks associated with long-term steroid medication.", "type": 1, "words": ["<tag1>", "We", "may", "need", "to", "conduct", "expensive", "pharmacoeconomic", "studies", "in", "order", "to", "demonstrate", "the", "cost-effectiveness", "of", "our", "products.", "<tag2>", "The", "CHABLIS", "7.5", "study", "s", "name", "emphasizes", "the", "intent", "to", "reduce", "background", "corticosteroid", "medication", "to", "7.5mg", "prednisone", "in", "order", "to", "mitigate", "the", "risks", "associated", "with", "long-term", "steroid", "medication.", "<tag3>"], "wordsA": ["We", "may", "need", "to", "conduct", "expensive", "pharmacoeconomic", "studies", "in", "order", "to", "demonstrate", "the", "cost-effectiveness", "of", "our", "products."], "wordsB": ["The", "CHABLIS", "7.5", "study", "s", "name", "emphasizes", "the", "intent", "to", "reduce", "background", "corticosteroid", "medication", "to", "7.5mg", "prednisone", "in", "order", "to", "mitigate", "the", "risks", "associated", "with", "long-term", "steroid", "medication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p68_s2", "idA": "1316175_15_item1_p195_s0", "sentA": "There are also laws that govern a company s eligibility to participate in Medicare and Medicaid reimbursements.", "sentB": "In parallel, commercial scale capsule and sachet manufacturing are also being established at respective product CMOs.", "type": 1, "words": ["<tag1>", "There", "are", "also", "laws", "that", "govern", "a", "company", "s", "eligibility", "to", "participate", "in", "Medicare", "and", "Medicaid", "reimbursements.", "<tag2>", "In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "manufacturing", "are", "also", "being", "established", "at", "respective", "product", "CMOs.", "<tag3>"], "wordsA": ["There", "are", "also", "laws", "that", "govern", "a", "company", "s", "eligibility", "to", "participate", "in", "Medicare", "and", "Medicaid", "reimbursements."], "wordsB": ["In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "manufacturing", "are", "also", "being", "established", "at", "respective", "product", "CMOs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p36_s5", "idA": "1316175_15_item1_p26_s0", "sentA": "We are currently investigating blisibimod as a therapy for IgA nephropathy (also known as Berger s disease).", "sentB": "These two pivotal studies are anticipated to form the basis of submission for blisibimod as a treatment for active SLE that is not controlled by standard-of-care medication, including corticosteroids.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "investigating", "blisibimod", "as", "a", "therapy", "for", "IgA", "nephropathy", "(also", "known", "as", "Berger", "s", "disease).", "<tag2>", "These", "two", "pivotal", "studies", "are", "anticipated", "to", "form", "the", "basis", "of", "submission", "for", "blisibimod", "as", "a", "treatment", "for", "active", "SLE", "that", "is", "not", "controlled", "by", "standard-of-care", "medication,", "including", "corticosteroids.", "<tag3>"], "wordsA": ["We", "are", "currently", "investigating", "blisibimod", "as", "a", "therapy", "for", "IgA", "nephropathy", "(also", "known", "as", "Berger", "s", "disease)."], "wordsB": ["These", "two", "pivotal", "studies", "are", "anticipated", "to", "form", "the", "basis", "of", "submission", "for", "blisibimod", "as", "a", "treatment", "for", "active", "SLE", "that", "is", "not", "controlled", "by", "standard-of-care", "medication,", "including", "corticosteroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p15_s5", "idA": "1316175_15_item1_p32_s1", "sentA": "In patients with IgA nephropathy, levels of BAFF are significantly higher than in healthy patients.", "sentB": "The SIMPLICITY study will utilize sachets containing liprotamase powder for oral solution for ease of administration and will enroll approximately 60 patients.", "type": 1, "words": ["<tag1>", "In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients.", "<tag2>", "The", "SIMPLICITY", "study", "will", "utilize", "sachets", "containing", "liprotamase", "powder", "for", "oral", "solution", "for", "ease", "of", "administration", "and", "will", "enroll", "approximately", "60", "patients.", "<tag3>"], "wordsA": ["In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients."], "wordsB": ["The", "SIMPLICITY", "study", "will", "utilize", "sachets", "containing", "liprotamase", "powder", "for", "oral", "solution", "for", "ease", "of", "administration", "and", "will", "enroll", "approximately", "60", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p17_s0", "idA": "1316175_15_item1_p41_s0", "sentA": "Liprotamase s chemical characteristics, unlike currently available PERTs, make it ideal for powder formulation as either a capsule or sachet product, which can be conveniently co-administered with a small volume of water.", "sentB": "a sachet formulation containing liprotamase power for oral solution which can be easily dissolved into water, and finally provides patients, especially young pediatric patients, with an easy-to-swallow dosing option.", "type": 1, "words": ["<tag1>", "Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule", "or", "sachet", "product,", "which", "can", "be", "conveniently", "co-administered", "with", "a", "small", "volume", "of", "water.", "<tag2>", "a", "sachet", "formulation", "containing", "liprotamase", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option.", "<tag3>"], "wordsA": ["Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule", "or", "sachet", "product,", "which", "can", "be", "conveniently", "co-administered", "with", "a", "small", "volume", "of", "water."], "wordsB": ["a", "sachet", "formulation", "containing", "liprotamase", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p16_s0", "idA": "1316175_15_item1_p43_s0", "sentA": "lower pill burden given a larger concentration of lipase per capsule: adult patients who may prefer liprotamase capsules will be able to take fewer capsules and smaller capsules in order to attain the same enzyme dosage.", "sentB": "a capsule formulation using known, safe, excipients that provides lower pill burden and good delivery performance.", "type": 1, "words": ["<tag1>", "lower", "pill", "burden", "given", "a", "larger", "concentration", "of", "lipase", "per", "capsule:", "adult", "patients", "who", "may", "prefer", "liprotamase", "capsules", "will", "be", "able", "to", "take", "fewer", "capsules", "and", "smaller", "capsules", "in", "order", "to", "attain", "the", "same", "enzyme", "dosage.", "<tag2>", "a", "capsule", "formulation", "using", "known,", "safe,", "excipients", "that", "provides", "lower", "pill", "burden", "and", "good", "delivery", "performance.", "<tag3>"], "wordsA": ["lower", "pill", "burden", "given", "a", "larger", "concentration", "of", "lipase", "per", "capsule:", "adult", "patients", "who", "may", "prefer", "liprotamase", "capsules", "will", "be", "able", "to", "take", "fewer", "capsules", "and", "smaller", "capsules", "in", "order", "to", "attain", "the", "same", "enzyme", "dosage."], "wordsB": ["a", "capsule", "formulation", "using", "known,", "safe,", "excipients", "that", "provides", "lower", "pill", "burden", "and", "good", "delivery", "performance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p98_s1", "idA": "1316175_15_item1_p47_s3", "sentA": "In addition, treatment of lupus-prone mice with blisibimod ameliorates the disease.", "sentB": "Amongst the adverse events reported, only injection site reactions were more frequent with blisibimod than placebo; these were never serious or severe.", "type": 1, "words": ["<tag1>", "In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease.", "<tag2>", "Amongst", "the", "adverse", "events", "reported,", "only", "injection", "site", "reactions", "were", "more", "frequent", "with", "blisibimod", "than", "placebo;", "these", "were", "never", "serious", "or", "severe.", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease."], "wordsB": ["Amongst", "the", "adverse", "events", "reported,", "only", "injection", "site", "reactions", "were", "more", "frequent", "with", "blisibimod", "than", "placebo;", "these", "were", "never", "serious", "or", "severe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p57_s1", "idA": "1316175_15_item1_p75_s2", "sentA": "Blisibimod was safe and well-tolerated at all dose levels evaluated in this study, with no meaningful imbalances in serious adverse events or infections compared with placebo (see Table 2 in the next section).", "sentB": ", Stohl W . , Chatham W . , McCune W .", "type": 1, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section).", "<tag2>", ",", "Stohl", "W", ".", ",", "Chatham", "W", ".", ",", "McCune", "W", ".", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section)."], "wordsB": [",", "Stohl", "W", ".", ",", "Chatham", "W", ".", ",", "McCune", "W", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p57_s2", "idA": "1316175_15_item1_p75_s2", "sentA": "Blisibimod was safe and well-tolerated at all dose levels evaluated in this study, with no meaningful imbalances in serious adverse events or infections compared with placebo (see Table 2 in the next section).", "sentB": "J . , Chevrier M . , Ryel J . , Recta V .", "type": 1, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section).", "<tag2>", "J", ".", ",", "Chevrier", "M", ".", ",", "Ryel", "J", ".", ",", "Recta", "V", ".", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section)."], "wordsB": ["J", ".", ",", "Chevrier", "M", ".", ",", "Ryel", "J", ".", ",", "Recta", "V", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p57_s3", "idA": "1316175_15_item1_p77_s2", "sentA": "Interim data from the combined PEARL-SC and OLE studies were presented at the 2013 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP).", "sentB": ", Zhong J . , Freimuth W. , Association of P lasma B L ymphocyte S timulator L evels and D isease A ctivity in S ystemic L lupus E rythematosus .", "type": 1, "words": ["<tag1>", "Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP).", "<tag2>", ",", "Zhong", "J", ".", ",", "Freimuth", "W.", ",", "Association", "of", "P", "lasma", "B", "L", "ymphocyte", "S", "timulator", "L", "evels", "and", "D", "isease", "A", "ctivity", "in", "S", "ystemic", "L", "lupus", "E", "rythematosus", ".", "<tag3>"], "wordsA": ["Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP)."], "wordsB": [",", "Zhong", "J", ".", ",", "Freimuth", "W.", ",", "Association", "of", "P", "lasma", "B", "L", "ymphocyte", "S", "timulator", "L", "evels", "and", "D", "isease", "A", "ctivity", "in", "S", "ystemic", "L", "lupus", "E", "rythematosus", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p0_s1", "idA": "1316175_15_item1_p85_s1", "sentA": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of blisibimod.", "sentB": "We currently have two Phase 3 product candidates, liprotamase also known as Sollpura TM and blisibimod.", "type": 1, "words": ["<tag1>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod.", "<tag2>", "We", "currently", "have", "two", "Phase", "3", "product", "candidates,", "liprotamase", "also", "known", "as", "Sollpura", "TM", "and", "blisibimod.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod."], "wordsB": ["We", "currently", "have", "two", "Phase", "3", "product", "candidates,", "liprotamase", "also", "known", "as", "Sollpura", "TM", "and", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p111_s1", "idA": "1316175_15_item1_p85_s2", "sentA": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as a single intravenous or subcutaneous dose was comparable to placebo.", "sentB": "Observations from this trial were published in 2015 (Stohl and colleagues, Arthritis Research Therapy ).", "type": 1, "words": ["<tag1>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "was", "comparable", "to", "placebo.", "<tag2>", "Observations", "from", "this", "trial", "were", "published", "in", "2015", "(Stohl", "and", "colleagues,", "Arthritis", "Research", "Therapy", ").", "<tag3>"], "wordsA": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "was", "comparable", "to", "placebo."], "wordsB": ["Observations", "from", "this", "trial", "were", "published", "in", "2015", "(Stohl", "and", "colleagues,", "Arthritis", "Research", "Therapy", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p115_s1", "idA": "1316175_15_item1_p85_s2", "sentA": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as a single intravenous or subcutaneous dose was comparable to placebo.", "sentB": "Observations from this trial were published in 2015 (Stohl and colleagues, Arthritis Research Therapy ).", "type": 1, "words": ["<tag1>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "was", "comparable", "to", "placebo.", "<tag2>", "Observations", "from", "this", "trial", "were", "published", "in", "2015", "(Stohl", "and", "colleagues,", "Arthritis", "Research", "Therapy", ").", "<tag3>"], "wordsA": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "was", "comparable", "to", "placebo."], "wordsB": ["Observations", "from", "this", "trial", "were", "published", "in", "2015", "(Stohl", "and", "colleagues,", "Arthritis", "Research", "Therapy", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s2", "idA": "1316175_16_item1_p133_s0", "sentA": "As of the date of this report, our blisibimod patent portfolio includes:", "sentB": "Of the original 57 patients enrolled into the study, 44 had a Week 48 observation and 22 patients had a Week 96 observation at the time of this analysis.", "type": 1, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:", "<tag2>", "Of", "the", "original", "57", "patients", "enrolled", "into", "the", "study,", "44", "had", "a", "Week", "48", "observation", "and", "22", "patients", "had", "a", "Week", "96", "observation", "at", "the", "time", "of", "this", "analysis.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:"], "wordsB": ["Of", "the", "original", "57", "patients", "enrolled", "into", "the", "study,", "44", "had", "a", "Week", "48", "observation", "and", "22", "patients", "had", "a", "Week", "96", "observation", "at", "the", "time", "of", "this", "analysis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p4_s1", "idA": "1316175_16_item1_p150_s1", "sentA": "We plan to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our product candidates if and when approved for marketing by the FDA.", "sentB": "We plan to modifiy the study to allow patients completing future studies (e.g., RESULT or SIMPLICITY Part B) to have continued access and continue the EASY study until the Biologic License Application ( BLA ) for Sollpura is approved by the U.S. Food and Drug Administration ( FDA ).", "type": 1, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA.", "<tag2>", "We", "plan", "to", "modifiy", "the", "study", "to", "allow", "patients", "completing", "future", "studies", "(e.g.,", "RESULT", "or", "SIMPLICITY", "Part", "B)", "to", "have", "continued", "access", "and", "continue", "the", "EASY", "study", "until", "the", "Biologic", "License", "Application", "(", "BLA", ")", "for", "Sollpura", "is", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(", "FDA", ").", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA."], "wordsB": ["We", "plan", "to", "modifiy", "the", "study", "to", "allow", "patients", "completing", "future", "studies", "(e.g.,", "RESULT", "or", "SIMPLICITY", "Part", "B)", "to", "have", "continued", "access", "and", "continue", "the", "EASY", "study", "until", "the", "Biologic", "License", "Application", "(", "BLA", ")", "for", "Sollpura", "is", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(", "FDA", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p101_s2", "idA": "1316175_16_item1_p153_s1", "sentA": "We expect that we would develop these capabilities once we receive Phase 3 data in contemplation of FDA approval and the commercial launch of our product candidates.", "sentB": "Both of our drug candidates, Sollpura and blisibimod, are biologically manufactured and will go through the BLA process for approval if successful in Phase 3.", "type": 1, "words": ["<tag1>", "We", "expect", "that", "we", "would", "develop", "these", "capabilities", "once", "we", "receive", "Phase", "3", "data", "in", "contemplation", "of", "FDA", "approval", "and", "the", "commercial", "launch", "of", "our", "product", "candidates.", "<tag2>", "Both", "of", "our", "drug", "candidates,", "Sollpura", "and", "blisibimod,", "are", "biologically", "manufactured", "and", "will", "go", "through", "the", "BLA", "process", "for", "approval", "if", "successful", "in", "Phase", "3.", "<tag3>"], "wordsA": ["We", "expect", "that", "we", "would", "develop", "these", "capabilities", "once", "we", "receive", "Phase", "3", "data", "in", "contemplation", "of", "FDA", "approval", "and", "the", "commercial", "launch", "of", "our", "product", "candidates."], "wordsB": ["Both", "of", "our", "drug", "candidates,", "Sollpura", "and", "blisibimod,", "are", "biologically", "manufactured", "and", "will", "go", "through", "the", "BLA", "process", "for", "approval", "if", "successful", "in", "Phase", "3."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p18_s2", "idA": "1316175_16_item1_p179_s2", "sentA": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued Written Request for such a study.", "sentB": "We expect to fully enroll the SIMPLICITY study and to report topline data around the end of 2017 or the early 2018 depending upon study initiation timeline.", "type": 1, "words": ["<tag1>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study.", "<tag2>", "We", "expect", "to", "fully", "enroll", "the", "SIMPLICITY", "study", "and", "to", "report", "topline", "data", "around", "the", "end", "of", "2017", "or", "the", "early", "2018", "depending", "upon", "study", "initiation", "timeline.", "<tag3>"], "wordsA": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study."], "wordsB": ["We", "expect", "to", "fully", "enroll", "the", "SIMPLICITY", "study", "and", "to", "report", "topline", "data", "around", "the", "end", "of", "2017", "or", "the", "early", "2018", "depending", "upon", "study", "initiation", "timeline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p21_s0", "idA": "1316175_16_item1_p182_s1", "sentA": "A product does not have to be designated as an orphan product to be eligible for the grant program.", "sentB": "A product that is wholly non-porcine.", "type": 1, "words": ["<tag1>", "A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program.", "<tag2>", "A", "product", "that", "is", "wholly", "non-porcine.", "<tag3>"], "wordsA": ["A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program."], "wordsB": ["A", "product", "that", "is", "wholly", "non-porcine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p56_s4", "idA": "1316175_16_item1_p184_s1", "sentA": "Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition.", "sentB": "The FDA agreed that IgAN meets the regulatory definition of a serious condition.", "type": 1, "words": ["<tag1>", "Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition.", "<tag2>", "The", "FDA", "agreed", "that", "IgAN", "meets", "the", "regulatory", "definition", "of", "a", "serious", "condition.", "<tag3>"], "wordsA": ["Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition."], "wordsB": ["The", "FDA", "agreed", "that", "IgAN", "meets", "the", "regulatory", "definition", "of", "a", "serious", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s3", "idA": "1316175_16_item1_p35_s2", "sentA": "Response rates to the SRI-8 responder index will remain a key secondary endpoint of the study.", "sentB": "Topline data announced in December 2016 showed that the study narrowly missed the Coefficient of Fat Absorption ( CFA ) non-inferiority margin of the primary modified Intent to Treat population (mITT) analysis by 1%; however, by additional pre-specified analyses of CFA (mITT-Baseline Observation Carried Forward and Per Protocol), Sollpura met the non-inferiority criterion.", "type": 1, "words": ["<tag1>", "Response", "rates", "to", "the", "SRI-8", "responder", "index", "will", "remain", "a", "key", "secondary", "endpoint", "of", "the", "study.", "<tag2>", "Topline", "data", "announced", "in", "December", "2016", "showed", "that", "the", "study", "narrowly", "missed", "the", "Coefficient", "of", "Fat", "Absorption", "(", "CFA", ")", "non-inferiority", "margin", "of", "the", "primary", "modified", "Intent", "to", "Treat", "population", "(mITT)", "analysis", "by", "1%;", "however,", "by", "additional", "pre-specified", "analyses", "of", "CFA", "(mITT-Baseline", "Observation", "Carried", "Forward", "and", "Per", "Protocol),", "Sollpura", "met", "the", "non-inferiority", "criterion.", "<tag3>"], "wordsA": ["Response", "rates", "to", "the", "SRI-8", "responder", "index", "will", "remain", "a", "key", "secondary", "endpoint", "of", "the", "study."], "wordsB": ["Topline", "data", "announced", "in", "December", "2016", "showed", "that", "the", "study", "narrowly", "missed", "the", "Coefficient", "of", "Fat", "Absorption", "(", "CFA", ")", "non-inferiority", "margin", "of", "the", "primary", "modified", "Intent", "to", "Treat", "population", "(mITT)", "analysis", "by", "1%;", "however,", "by", "additional", "pre-specified", "analyses", "of", "CFA", "(mITT-Baseline", "Observation", "Carried", "Forward", "and", "Per", "Protocol),", "Sollpura", "met", "the", "non-inferiority", "criterion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p139_s3", "idA": "1316175_17_item1_p101_s2", "sentA": "Both of our drug candidates, Sollpura and blisibimod, are biologically manufactured and will go through the BLA process for approval if successful in Phase 3.", "sentB": "It is also possible that comparative effectiveness research demonstrating benefits in a competitor s drug could adversely affect the sales of our drug candidate.", "type": 1, "words": ["<tag1>", "Both", "of", "our", "drug", "candidates,", "Sollpura", "and", "blisibimod,", "are", "biologically", "manufactured", "and", "will", "go", "through", "the", "BLA", "process", "for", "approval", "if", "successful", "in", "Phase", "3.", "<tag2>", "It", "is", "also", "possible", "that", "comparative", "effectiveness", "research", "demonstrating", "benefits", "in", "a", "competitor", "s", "drug", "could", "adversely", "affect", "the", "sales", "of", "our", "drug", "candidate.", "<tag3>"], "wordsA": ["Both", "of", "our", "drug", "candidates,", "Sollpura", "and", "blisibimod,", "are", "biologically", "manufactured", "and", "will", "go", "through", "the", "BLA", "process", "for", "approval", "if", "successful", "in", "Phase", "3."], "wordsB": ["It", "is", "also", "possible", "that", "comparative", "effectiveness", "research", "demonstrating", "benefits", "in", "a", "competitor", "s", "drug", "could", "adversely", "affect", "the", "sales", "of", "our", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p161_s3", "idA": "1316175_17_item1_p102_s1", "sentA": "The process of obtaining regulatory approvals and compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.", "sentB": "State and foreign laws also govern the privacy and security of health information in certain circumstances.", "type": 1, "words": ["<tag1>", "The", "process", "of", "obtaining", "regulatory", "approvals", "and", "compliance", "with", "appropriate", "federal,", "state,", "local", "and", "foreign", "statutes", "and", "regulations", "require", "the", "expenditure", "of", "substantial", "time", "and", "financial", "resources.", "<tag2>", "State", "and", "foreign", "laws", "also", "govern", "the", "privacy", "and", "security", "of", "health", "information", "in", "certain", "circumstances.", "<tag3>"], "wordsA": ["The", "process", "of", "obtaining", "regulatory", "approvals", "and", "compliance", "with", "appropriate", "federal,", "state,", "local", "and", "foreign", "statutes", "and", "regulations", "require", "the", "expenditure", "of", "substantial", "time", "and", "financial", "resources."], "wordsB": ["State", "and", "foreign", "laws", "also", "govern", "the", "privacy", "and", "security", "of", "health", "information", "in", "certain", "circumstances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p161_s2", "idA": "1316175_17_item1_p102_s2", "sentA": "Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions.", "sentB": "Some state laws require pharmaceutical companies to comply with the pharmaceutical industry s voluntary compliance guidelines and the relevant federal government compliance guidance, require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures.", "type": 1, "words": ["<tag1>", "Failure", "to", "comply", "with", "the", "applicable", "U.S.", "requirements", "at", "any", "time", "during", "the", "product", "development", "process,", "approval", "process,", "or", "after", "approval,", "may", "subject", "an", "applicant", "to", "administrative", "or", "judicial", "sanctions.", "<tag2>", "Some", "state", "laws", "require", "pharmaceutical", "companies", "to", "comply", "with", "the", "pharmaceutical", "industry", "s", "voluntary", "compliance", "guidelines", "and", "the", "relevant", "federal", "government", "compliance", "guidance,", "require", "drug", "manufacturers", "to", "report", "information", "related", "to", "payments", "and", "other", "transfers", "of", "value", "to", "physicians", "and", "other", "healthcare", "providers,", "and", "restrict", "marketing", "practices", "or", "require", "disclosure", "of", "marketing", "expenditures.", "<tag3>"], "wordsA": ["Failure", "to", "comply", "with", "the", "applicable", "U.S.", "requirements", "at", "any", "time", "during", "the", "product", "development", "process,", "approval", "process,", "or", "after", "approval,", "may", "subject", "an", "applicant", "to", "administrative", "or", "judicial", "sanctions."], "wordsB": ["Some", "state", "laws", "require", "pharmaceutical", "companies", "to", "comply", "with", "the", "pharmaceutical", "industry", "s", "voluntary", "compliance", "guidelines", "and", "the", "relevant", "federal", "government", "compliance", "guidance,", "require", "drug", "manufacturers", "to", "report", "information", "related", "to", "payments", "and", "other", "transfers", "of", "value", "to", "physicians", "and", "other", "healthcare", "providers,", "and", "restrict", "marketing", "practices", "or", "require", "disclosure", "of", "marketing", "expenditures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p99_s1", "idA": "1316175_17_item1_p112_s2", "sentA": "A sponsor also must notify FDA of any unexpected fatal or life-threatening suspected adverse reaction within 7 days after the sponsor s receipt of the information.", "sentB": "The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information.", "type": 1, "words": ["<tag1>", "A", "sponsor", "also", "must", "notify", "FDA", "of", "any", "unexpected", "fatal", "or", "life-threatening", "suspected", "adverse", "reaction", "within", "7", "days", "after", "the", "sponsor", "s", "receipt", "of", "the", "information.", "<tag2>", "The", "initial", "PSP", "must", "include", "an", "outline", "of", "the", "pediatric", "study", "or", "studies", "that", "the", "sponsor", "plans", "to", "conduct,", "including", "study", "objectives", "and", "design,", "age", "groups,", "relevant", "endpoints", "and", "statistical", "approach,", "or", "a", "justification", "for", "not", "including", "such", "detailed", "information,", "and", "any", "request", "for", "a", "deferral", "of", "pediatric", "assessments", "or", "a", "full", "or", "partial", "waiver", "of", "the", "requirement", "to", "provide", "data", "from", "pediatric", "studies", "along", "with", "supporting", "information.", "<tag3>"], "wordsA": ["A", "sponsor", "also", "must", "notify", "FDA", "of", "any", "unexpected", "fatal", "or", "life-threatening", "suspected", "adverse", "reaction", "within", "7", "days", "after", "the", "sponsor", "s", "receipt", "of", "the", "information."], "wordsB": ["The", "initial", "PSP", "must", "include", "an", "outline", "of", "the", "pediatric", "study", "or", "studies", "that", "the", "sponsor", "plans", "to", "conduct,", "including", "study", "objectives", "and", "design,", "age", "groups,", "relevant", "endpoints", "and", "statistical", "approach,", "or", "a", "justification", "for", "not", "including", "such", "detailed", "information,", "and", "any", "request", "for", "a", "deferral", "of", "pediatric", "assessments", "or", "a", "full", "or", "partial", "waiver", "of", "the", "requirement", "to", "provide", "data", "from", "pediatric", "studies", "along", "with", "supporting", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p99_s3", "idA": "1316175_17_item1_p112_s4", "sentA": "The FDA, a data safety monitoring board, or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.", "sentB": "A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs.", "type": 1, "words": ["<tag1>", "The", "FDA,", "a", "data", "safety", "monitoring", "board,", "or", "the", "sponsor", "may", "suspend", "or", "terminate", "a", "clinical", "study", "at", "any", "time", "on", "various", "grounds,", "including", "a", "finding", "that", "the", "research", "subjects", "or", "patients", "are", "being", "exposed", "to", "an", "unacceptable", "health", "risk.", "<tag2>", "A", "sponsor", "can", "submit", "amendments", "to", "an", "agreed-upon", "initial", "PSP", "at", "any", "time", "if", "changes", "to", "the", "pediatric", "plan", "need", "to", "be", "considered", "based", "on", "data", "collected", "from", "nonclinical", "studies,", "early", "phase", "clinical", "trials,", "and/or", "other", "clinical", "development", "programs.", "<tag3>"], "wordsA": ["The", "FDA,", "a", "data", "safety", "monitoring", "board,", "or", "the", "sponsor", "may", "suspend", "or", "terminate", "a", "clinical", "study", "at", "any", "time", "on", "various", "grounds,", "including", "a", "finding", "that", "the", "research", "subjects", "or", "patients", "are", "being", "exposed", "to", "an", "unacceptable", "health", "risk."], "wordsB": ["A", "sponsor", "can", "submit", "amendments", "to", "an", "agreed-upon", "initial", "PSP", "at", "any", "time", "if", "changes", "to", "the", "pediatric", "plan", "need", "to", "be", "considered", "based", "on", "data", "collected", "from", "nonclinical", "studies,", "early", "phase", "clinical", "trials,", "and/or", "other", "clinical", "development", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p154_s0", "idA": "1316175_17_item1_p114_s1", "sentA": "The submission of an NDA or BLA is subject to the payment of a substantial user fee; a waiver of such fee may be obtained under certain limited circumstances.", "sentB": "The federal False Claims Act imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government.", "type": 1, "words": ["<tag1>", "The", "submission", "of", "an", "NDA", "or", "BLA", "is", "subject", "to", "the", "payment", "of", "a", "substantial", "user", "fee;", "a", "waiver", "of", "such", "fee", "may", "be", "obtained", "under", "certain", "limited", "circumstances.", "<tag2>", "The", "federal", "False", "Claims", "Act", "imposes", "civil", "penalties,", "including", "through", "civil", "whistleblower", "or", "qui", "tam", "actions,", "against", "individuals", "or", "entities", "(including", "manufacturers)", "for,", "among", "other", "things,", "knowingly", "presenting,", "or", "causing", "to", "be", "presented", "false", "or", "fraudulent", "claims", "for", "payment", "by", "a", "federal", "healthcare", "program", "or", "making", "a", "false", "statement", "or", "record", "material", "to", "payment", "of", "a", "false", "claim", "or", "avoiding,", "decreasing", "or", "concealing", "an", "obligation", "to", "pay", "money", "to", "the", "federal", "government.", "<tag3>"], "wordsA": ["The", "submission", "of", "an", "NDA", "or", "BLA", "is", "subject", "to", "the", "payment", "of", "a", "substantial", "user", "fee;", "a", "waiver", "of", "such", "fee", "may", "be", "obtained", "under", "certain", "limited", "circumstances."], "wordsB": ["The", "federal", "False", "Claims", "Act", "imposes", "civil", "penalties,", "including", "through", "civil", "whistleblower", "or", "qui", "tam", "actions,", "against", "individuals", "or", "entities", "(including", "manufacturers)", "for,", "among", "other", "things,", "knowingly", "presenting,", "or", "causing", "to", "be", "presented", "false", "or", "fraudulent", "claims", "for", "payment", "by", "a", "federal", "healthcare", "program", "or", "making", "a", "false", "statement", "or", "record", "material", "to", "payment", "of", "a", "false", "claim", "or", "avoiding,", "decreasing", "or", "concealing", "an", "obligation", "to", "pay", "money", "to", "the", "federal", "government."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p155_s0", "idA": "1316175_17_item1_p117_s0", "sentA": "Once the submission is accepted for filing, the FDA begins an in-depth substantive review.", "sentB": "The government may deem manufacturers to have \"caused\" the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label.", "type": 1, "words": ["<tag1>", "Once", "the", "submission", "is", "accepted", "for", "filing,", "the", "FDA", "begins", "an", "in-depth", "substantive", "review.", "<tag2>", "The", "government", "may", "deem", "manufacturers", "to", "have", "\"caused\"", "the", "submission", "of", "false", "or", "fraudulent", "claims", "by,", "for", "example,", "providing", "inaccurate", "billing", "or", "coding", "information", "to", "customers", "or", "promoting", "a", "product", "off-label.", "<tag3>"], "wordsA": ["Once", "the", "submission", "is", "accepted", "for", "filing,", "the", "FDA", "begins", "an", "in-depth", "substantive", "review."], "wordsB": ["The", "government", "may", "deem", "manufacturers", "to", "have", "\"caused\"", "the", "submission", "of", "false", "or", "fraudulent", "claims", "by,", "for", "example,", "providing", "inaccurate", "billing", "or", "coding", "information", "to", "customers", "or", "promoting", "a", "product", "off-label."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p139_s1", "idA": "1316175_17_item1_p121_s4", "sentA": "Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.", "sentB": "The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress.", "type": 1, "words": ["<tag1>", "Only", "one", "patent", "applicable", "to", "an", "approved", "drug", "is", "eligible", "for", "the", "extension", "and", "the", "application", "for", "the", "extension", "must", "be", "submitted", "prior", "to", "the", "expiration", "of", "the", "patent.", "<tag2>", "The", "plan", "for", "the", "research", "was", "published", "in", "2012", "by", "the", "Department", "of", "Health", "and", "Human", "Services,", "the", "Agency", "for", "Healthcare", "Research", "and", "Quality", "and", "the", "National", "Institutes", "for", "Health,", "and", "periodic", "reports", "on", "the", "status", "of", "the", "research", "and", "related", "expenditures", "are", "made", "to", "Congress.", "<tag3>"], "wordsA": ["Only", "one", "patent", "applicable", "to", "an", "approved", "drug", "is", "eligible", "for", "the", "extension", "and", "the", "application", "for", "the", "extension", "must", "be", "submitted", "prior", "to", "the", "expiration", "of", "the", "patent."], "wordsB": ["The", "plan", "for", "the", "research", "was", "published", "in", "2012", "by", "the", "Department", "of", "Health", "and", "Human", "Services,", "the", "Agency", "for", "Healthcare", "Research", "and", "Quality", "and", "the", "National", "Institutes", "for", "Health,", "and", "periodic", "reports", "on", "the", "status", "of", "the", "research", "and", "related", "expenditures", "are", "made", "to", "Congress."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p15_s3", "idA": "1316175_17_item1_p124_s1", "sentA": "During this exclusivity period, competitors are barred from relying on the innovator s safety and efficacy data to gain FDA approval.", "sentB": "Patients are then followed in a 20-week extension period for the collection of longer term safety and efficacy (e.g., growth, maintenance of body weight) data.", "type": 1, "words": ["<tag1>", "During", "this", "exclusivity", "period,", "competitors", "are", "barred", "from", "relying", "on", "the", "innovator", "s", "safety", "and", "efficacy", "data", "to", "gain", "FDA", "approval.", "<tag2>", "Patients", "are", "then", "followed", "in", "a", "20-week", "extension", "period", "for", "the", "collection", "of", "longer", "term", "safety", "and", "efficacy", "(e.g.,", "growth,", "maintenance", "of", "body", "weight)", "data.", "<tag3>"], "wordsA": ["During", "this", "exclusivity", "period,", "competitors", "are", "barred", "from", "relying", "on", "the", "innovator", "s", "safety", "and", "efficacy", "data", "to", "gain", "FDA", "approval."], "wordsB": ["Patients", "are", "then", "followed", "in", "a", "20-week", "extension", "period", "for", "the", "collection", "of", "longer", "term", "safety", "and", "efficacy", "(e.g.,", "growth,", "maintenance", "of", "body", "weight)", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p141_s1", "idA": "1316175_17_item1_p128_s1", "sentA": "A product does not have to be designated as an orphan product to be eligible for the grant program.", "sentB": "A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation s automatic reduction to several government programs.", "type": 1, "words": ["<tag1>", "A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program.", "<tag2>", "A", "Joint", "Select", "Committee", "on", "Deficit", "Reduction,", "tasked", "with", "recommending", "a", "targeted", "deficit", "reduction", "of", "at", "least", "$1.2", "trillion", "for", "the", "years", "2013", "through", "2021,", "was", "unable", "to", "reach", "required", "goals,", "thereby", "triggering", "the", "legislation", "s", "automatic", "reduction", "to", "several", "government", "programs.", "<tag3>"], "wordsA": ["A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program."], "wordsB": ["A", "Joint", "Select", "Committee", "on", "Deficit", "Reduction,", "tasked", "with", "recommending", "a", "targeted", "deficit", "reduction", "of", "at", "least", "$1.2", "trillion", "for", "the", "years", "2013", "through", "2021,", "was", "unable", "to", "reach", "required", "goals,", "thereby", "triggering", "the", "legislation", "s", "automatic", "reduction", "to", "several", "government", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p153_s0", "idA": "1316175_17_item1_p130_s0", "sentA": "The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria.", "sentB": "The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party on its behalf) to, knowingly and willfully offer, solicit, receive, or pay remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward the referral of an individual for or the purchase or recommendation of an item or for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs.", "type": 1, "words": ["<tag1>", "The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "intended", "to", "expedite", "or", "facilitate", "the", "process", "for", "reviewing", "new", "drugs", "and", "biological", "products", "that", "meet", "certain", "criteria.", "<tag2>", "The", "federal", "Anti-Kickback", "Statute", "makes", "it", "illegal", "for", "any", "person,", "including", "a", "prescription", "drug", "manufacturer", "(or", "a", "party", "on", "its", "behalf)", "to,", "knowingly", "and", "willfully", "offer,", "solicit,", "receive,", "or", "pay", "remuneration,", "directly", "or", "indirectly,", "in", "cash", "or", "in", "kind,", "that", "is", "intended", "to", "induce", "or", "reward", "the", "referral", "of", "an", "individual", "for", "or", "the", "purchase", "or", "recommendation", "of", "an", "item", "or", "for", "which", "payment", "may", "be", "made", "under", "federal", "healthcare", "programs", "such", "as", "the", "Medicare", "and", "Medicaid", "programs.", "<tag3>"], "wordsA": ["The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "intended", "to", "expedite", "or", "facilitate", "the", "process", "for", "reviewing", "new", "drugs", "and", "biological", "products", "that", "meet", "certain", "criteria."], "wordsB": ["The", "federal", "Anti-Kickback", "Statute", "makes", "it", "illegal", "for", "any", "person,", "including", "a", "prescription", "drug", "manufacturer", "(or", "a", "party", "on", "its", "behalf)", "to,", "knowingly", "and", "willfully", "offer,", "solicit,", "receive,", "or", "pay", "remuneration,", "directly", "or", "indirectly,", "in", "cash", "or", "in", "kind,", "that", "is", "intended", "to", "induce", "or", "reward", "the", "referral", "of", "an", "individual", "for", "or", "the", "purchase", "or", "recommendation", "of", "an", "item", "or", "for", "which", "payment", "may", "be", "made", "under", "federal", "healthcare", "programs", "such", "as", "the", "Medicare", "and", "Medicaid", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p135_s0", "idA": "1316175_17_item1_p136_s1", "sentA": "Drugs and biological products may be promoted only for the approved indications and in accordance with the provisions of the approved label.", "sentB": "The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer s outpatient drugs furnished to Medicaid patients.", "type": 1, "words": ["<tag1>", "Drugs", "and", "biological", "products", "may", "be", "promoted", "only", "for", "the", "approved", "indications", "and", "in", "accordance", "with", "the", "provisions", "of", "the", "approved", "label.", "<tag2>", "The", "Medicaid", "Drug", "Rebate", "Program", "requires", "pharmaceutical", "manufacturers", "to", "enter", "into", "and", "have", "in", "effect", "a", "national", "rebate", "agreement", "with", "the", "Secretary", "of", "the", "Department", "of", "Health", "and", "Human", "Services", "as", "a", "condition", "for", "states", "to", "receive", "federal", "matching", "funds", "for", "the", "manufacturer", "s", "outpatient", "drugs", "furnished", "to", "Medicaid", "patients.", "<tag3>"], "wordsA": ["Drugs", "and", "biological", "products", "may", "be", "promoted", "only", "for", "the", "approved", "indications", "and", "in", "accordance", "with", "the", "provisions", "of", "the", "approved", "label."], "wordsB": ["The", "Medicaid", "Drug", "Rebate", "Program", "requires", "pharmaceutical", "manufacturers", "to", "enter", "into", "and", "have", "in", "effect", "a", "national", "rebate", "agreement", "with", "the", "Secretary", "of", "the", "Department", "of", "Health", "and", "Human", "Services", "as", "a", "condition", "for", "states", "to", "receive", "federal", "matching", "funds", "for", "the", "manufacturer", "s", "outpatient", "drugs", "furnished", "to", "Medicaid", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p154_s1", "idA": "1316175_17_item1_p143_s1", "sentA": "Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical studies or marketing of the product in those countries.", "sentB": "Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $10,957and $21,916 for each separate false claim, the potential for exclusion from participation in federal healthcare programs and the potential implication of various federal criminal statutes.", "type": 1, "words": ["<tag1>", "Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "of", "a", "product", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "studies", "or", "marketing", "of", "the", "product", "in", "those", "countries.", "<tag2>", "Penalties", "for", "a", "False", "Claims", "Act", "violation", "include", "three", "times", "the", "actual", "damages", "sustained", "by", "the", "government,", "plus", "mandatory", "civil", "penalties", "of", "between", "$10,957and", "$21,916", "for", "each", "separate", "false", "claim,", "the", "potential", "for", "exclusion", "from", "participation", "in", "federal", "healthcare", "programs", "and", "the", "potential", "implication", "of", "various", "federal", "criminal", "statutes.", "<tag3>"], "wordsA": ["Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "of", "a", "product", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "studies", "or", "marketing", "of", "the", "product", "in", "those", "countries."], "wordsB": ["Penalties", "for", "a", "False", "Claims", "Act", "violation", "include", "three", "times", "the", "actual", "damages", "sustained", "by", "the", "government,", "plus", "mandatory", "civil", "penalties", "of", "between", "$10,957and", "$21,916", "for", "each", "separate", "false", "claim,", "the", "potential", "for", "exclusion", "from", "participation", "in", "federal", "healthcare", "programs", "and", "the", "potential", "implication", "of", "various", "federal", "criminal", "statutes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p159_s0", "idA": "1316175_17_item1_p144_s0", "sentA": "In the European Union, our products are subject to extensive regulatory requirements, which provide, among other things, that no medicinal product may be placed on the market of a European Union member state unless a marketing authorization has been issued by the European Medicines Agency or a national competent authority.", "sentB": "HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ( HITECH ), and their respective implementing regulations, which imposes, among other things, specified requirements on covered entities and their business associates, relating to the privacy and security of individually identifiable health information, including mandatory contractual terms and required implementation of technical safeguards of such information.", "type": 1, "words": ["<tag1>", "In", "the", "European", "Union,", "our", "products", "are", "subject", "to", "extensive", "regulatory", "requirements,", "which", "provide,", "among", "other", "things,", "that", "no", "medicinal", "product", "may", "be", "placed", "on", "the", "market", "of", "a", "European", "Union", "member", "state", "unless", "a", "marketing", "authorization", "has", "been", "issued", "by", "the", "European", "Medicines", "Agency", "or", "a", "national", "competent", "authority.", "<tag2>", "HIPAA,", "as", "amended", "by", "the", "Health", "Information", "Technology", "for", "Economic", "and", "Clinical", "Health", "Act", "of", "2009", "(", "HITECH", "),", "and", "their", "respective", "implementing", "regulations,", "which", "imposes,", "among", "other", "things,", "specified", "requirements", "on", "covered", "entities", "and", "their", "business", "associates,", "relating", "to", "the", "privacy", "and", "security", "of", "individually", "identifiable", "health", "information,", "including", "mandatory", "contractual", "terms", "and", "required", "implementation", "of", "technical", "safeguards", "of", "such", "information.", "<tag3>"], "wordsA": ["In", "the", "European", "Union,", "our", "products", "are", "subject", "to", "extensive", "regulatory", "requirements,", "which", "provide,", "among", "other", "things,", "that", "no", "medicinal", "product", "may", "be", "placed", "on", "the", "market", "of", "a", "European", "Union", "member", "state", "unless", "a", "marketing", "authorization", "has", "been", "issued", "by", "the", "European", "Medicines", "Agency", "or", "a", "national", "competent", "authority."], "wordsB": ["HIPAA,", "as", "amended", "by", "the", "Health", "Information", "Technology", "for", "Economic", "and", "Clinical", "Health", "Act", "of", "2009", "(", "HITECH", "),", "and", "their", "respective", "implementing", "regulations,", "which", "imposes,", "among", "other", "things,", "specified", "requirements", "on", "covered", "entities", "and", "their", "business", "associates,", "relating", "to", "the", "privacy", "and", "security", "of", "individually", "identifiable", "health", "information,", "including", "mandatory", "contractual", "terms", "and", "required", "implementation", "of", "technical", "safeguards", "of", "such", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p143_s1", "idA": "1316175_17_item1_p147_s4", "sentA": "In addition, significant uncertainty exists as to the reimbursement status of newly approved health care products.", "sentB": "In addition, effective January 1, 2014, CMS also began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting.", "type": 1, "words": ["<tag1>", "In", "addition,", "significant", "uncertainty", "exists", "as", "to", "the", "reimbursement", "status", "of", "newly", "approved", "health", "care", "products.", "<tag2>", "In", "addition,", "effective", "January", "1,", "2014,", "CMS", "also", "began", "bundling", "the", "Medicare", "payments", "for", "certain", "laboratory", "tests", "ordered", "while", "a", "patient", "received", "services", "in", "a", "hospital", "outpatient", "setting.", "<tag3>"], "wordsA": ["In", "addition,", "significant", "uncertainty", "exists", "as", "to", "the", "reimbursement", "status", "of", "newly", "approved", "health", "care", "products."], "wordsB": ["In", "addition,", "effective", "January", "1,", "2014,", "CMS", "also", "began", "bundling", "the", "Medicare", "payments", "for", "certain", "laboratory", "tests", "ordered", "while", "a", "patient", "received", "services", "in", "a", "hospital", "outpatient", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p135_s1", "idA": "1316175_17_item1_p148_s2", "sentA": "Effective October 1, 2010, the Health Care Reform Law revises the definition of average manufacturer price for reporting purposes, which could increase the amount of Medicaid drug rebates to states once the provision is effective.", "sentB": "Effective in 2010, the ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of AMP, and adding a new rebate calculation for line extensions (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, creating a new methodology by which rebates owed by are calculated for drugs that are inhaled, infused, instilled, implanted or injected, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP.", "type": 1, "words": ["<tag1>", "Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective.", "<tag2>", "Effective", "in", "2010,", "the", "ACA", "made", "several", "changes", "to", "the", "Medicaid", "Drug", "Rebate", "Program,", "including", "increasing", "pharmaceutical", "manufacturers", "rebate", "liability", "by", "raising", "the", "minimum", "basic", "Medicaid", "rebate", "on", "most", "branded", "prescription", "drugs", "from", "15.1%", "of", "average", "manufacturer", "price,", "or", "AMP,", "to", "23.1%", "of", "AMP,", "and", "adding", "a", "new", "rebate", "calculation", "for", "line", "extensions", "(i.e.,", "new", "formulations,", "such", "as", "extended", "release", "formulations)", "of", "solid", "oral", "dosage", "forms", "of", "branded", "products,", "creating", "a", "new", "methodology", "by", "which", "rebates", "owed", "by", "are", "calculated", "for", "drugs", "that", "are", "inhaled,", "infused,", "instilled,", "implanted", "or", "injected,", "as", "well", "as", "potentially", "impacting", "their", "rebate", "liability", "by", "modifying", "the", "statutory", "definition", "of", "AMP.", "<tag3>"], "wordsA": ["Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective."], "wordsB": ["Effective", "in", "2010,", "the", "ACA", "made", "several", "changes", "to", "the", "Medicaid", "Drug", "Rebate", "Program,", "including", "increasing", "pharmaceutical", "manufacturers", "rebate", "liability", "by", "raising", "the", "minimum", "basic", "Medicaid", "rebate", "on", "most", "branded", "prescription", "drugs", "from", "15.1%", "of", "average", "manufacturer", "price,", "or", "AMP,", "to", "23.1%", "of", "AMP,", "and", "adding", "a", "new", "rebate", "calculation", "for", "line", "extensions", "(i.e.,", "new", "formulations,", "such", "as", "extended", "release", "formulations)", "of", "solid", "oral", "dosage", "forms", "of", "branded", "products,", "creating", "a", "new", "methodology", "by", "which", "rebates", "owed", "by", "are", "calculated", "for", "drugs", "that", "are", "inhaled,", "infused,", "instilled,", "implanted", "or", "injected,", "as", "well", "as", "potentially", "impacting", "their", "rebate", "liability", "by", "modifying", "the", "statutory", "definition", "of", "AMP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p135_s2", "idA": "1316175_17_item1_p148_s2", "sentA": "Effective October 1, 2010, the Health Care Reform Law revises the definition of average manufacturer price for reporting purposes, which could increase the amount of Medicaid drug rebates to states once the provision is effective.", "sentB": "The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization as of 2010 and by expanding the population potentially eligible for Medicaid drug benefits (phased-in by 2014).", "type": 1, "words": ["<tag1>", "Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective.", "<tag2>", "The", "ACA", "also", "expanded", "the", "universe", "of", "Medicaid", "utilization", "subject", "to", "drug", "rebates", "by", "requiring", "pharmaceutical", "manufacturers", "to", "pay", "rebates", "on", "Medicaid", "managed", "care", "utilization", "as", "of", "2010", "and", "by", "expanding", "the", "population", "potentially", "eligible", "for", "Medicaid", "drug", "benefits", "(phased-in", "by", "2014).", "<tag3>"], "wordsA": ["Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective."], "wordsB": ["The", "ACA", "also", "expanded", "the", "universe", "of", "Medicaid", "utilization", "subject", "to", "drug", "rebates", "by", "requiring", "pharmaceutical", "manufacturers", "to", "pay", "rebates", "on", "Medicaid", "managed", "care", "utilization", "as", "of", "2010", "and", "by", "expanding", "the", "population", "potentially", "eligible", "for", "Medicaid", "drug", "benefits", "(phased-in", "by", "2014)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p163_s1", "idA": "1316175_17_item1_p148_s4", "sentA": "Substantial new provisions affecting compliance also have been enacted, which may require us to modify our business practices with healthcare practitioners.", "sentB": "It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.", "type": 1, "words": ["<tag1>", "Substantial", "new", "provisions", "affecting", "compliance", "also", "have", "been", "enacted,", "which", "may", "require", "us", "to", "modify", "our", "business", "practices", "with", "healthcare", "practitioners.", "<tag2>", "It", "is", "possible", "that", "governmental", "authorities", "will", "conclude", "that", "our", "business", "practices", "may", "not", "comply", "with", "current", "or", "future", "statutes,", "regulations", "or", "case", "law", "involving", "applicable", "fraud", "and", "abuse", "or", "other", "healthcare", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["Substantial", "new", "provisions", "affecting", "compliance", "also", "have", "been", "enacted,", "which", "may", "require", "us", "to", "modify", "our", "business", "practices", "with", "healthcare", "practitioners."], "wordsB": ["It", "is", "possible", "that", "governmental", "authorities", "will", "conclude", "that", "our", "business", "practices", "may", "not", "comply", "with", "current", "or", "future", "statutes,", "regulations", "or", "case", "law", "involving", "applicable", "fraud", "and", "abuse", "or", "other", "healthcare", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p138_s2", "idA": "1316175_17_item1_p148_s5", "sentA": "We will not know the full effects of the Health Care Reform Law until applicable federal and state agencies issue regulations or guidance under the new law.", "sentB": "As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly eligible entities (with the exception of children s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs.", "type": 1, "words": ["<tag1>", "We", "will", "not", "know", "the", "full", "effects", "of", "the", "Health", "Care", "Reform", "Law", "until", "applicable", "federal", "and", "state", "agencies", "issue", "regulations", "or", "guidance", "under", "the", "new", "law.", "<tag2>", "As", "of", "2010,", "the", "ACA", "expanded", "the", "types", "of", "entities", "eligible", "to", "receive", "discounted", "340B", "pricing,", "although", "under", "the", "current", "state", "of", "the", "law", "these", "newly", "eligible", "entities", "(with", "the", "exception", "of", "children", "s", "hospitals)", "will", "not", "be", "eligible", "to", "receive", "discounted", "340B", "pricing", "on", "orphan", "drugs.", "<tag3>"], "wordsA": ["We", "will", "not", "know", "the", "full", "effects", "of", "the", "Health", "Care", "Reform", "Law", "until", "applicable", "federal", "and", "state", "agencies", "issue", "regulations", "or", "guidance", "under", "the", "new", "law."], "wordsB": ["As", "of", "2010,", "the", "ACA", "expanded", "the", "types", "of", "entities", "eligible", "to", "receive", "discounted", "340B", "pricing,", "although", "under", "the", "current", "state", "of", "the", "law", "these", "newly", "eligible", "entities", "(with", "the", "exception", "of", "children", "s", "hospitals)", "will", "not", "be", "eligible", "to", "receive", "discounted", "340B", "pricing", "on", "orphan", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p143_s0", "idA": "1316175_17_item1_p149_s0", "sentA": "The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries, and included a major expansion of the prescription drug benefit under a new Medicare Part D. Medicare Part D went into effect on January 1, 2006.", "sentB": "The Middle Class Tax Relief and Job Creation Act of 2012 required that the Centers for Medicare Medicaid Services reduce the Medicare clinical laboratory fee schedule by 2% in 2013, which served as a base for 2014 and subsequent years.", "type": 1, "words": ["<tag1>", "The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Medicare", "Part", "D", "went", "into", "effect", "on", "January", "1,", "2006.", "<tag2>", "The", "Middle", "Class", "Tax", "Relief", "and", "Job", "Creation", "Act", "of", "2012", "required", "that", "the", "Centers", "for", "Medicare", "Medicaid", "Services", "reduce", "the", "Medicare", "clinical", "laboratory", "fee", "schedule", "by", "2%", "in", "2013,", "which", "served", "as", "a", "base", "for", "2014", "and", "subsequent", "years.", "<tag3>"], "wordsA": ["The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Medicare", "Part", "D", "went", "into", "effect", "on", "January", "1,", "2006."], "wordsB": ["The", "Middle", "Class", "Tax", "Relief", "and", "Job", "Creation", "Act", "of", "2012", "required", "that", "the", "Centers", "for", "Medicare", "Medicaid", "Services", "reduce", "the", "Medicare", "clinical", "laboratory", "fee", "schedule", "by", "2%", "in", "2013,", "which", "served", "as", "a", "base", "for", "2014", "and", "subsequent", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p160_s0", "idA": "1316175_17_item1_p149_s0", "sentA": "The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries, and included a major expansion of the prescription drug benefit under a new Medicare Part D. Medicare Part D went into effect on January 1, 2006.", "sentB": "The Physician Payments Sunshine Act, enacted as part of the ACA, as amended by the Health Care and Education Reconciliation Act of 2010, which imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children s Health Insurance Program for certain payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members.", "type": 1, "words": ["<tag1>", "The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Medicare", "Part", "D", "went", "into", "effect", "on", "January", "1,", "2006.", "<tag2>", "The", "Physician", "Payments", "Sunshine", "Act,", "enacted", "as", "part", "of", "the", "ACA,", "as", "amended", "by", "the", "Health", "Care", "and", "Education", "Reconciliation", "Act", "of", "2010,", "which", "imposed", "new", "annual", "reporting", "requirements", "for", "certain", "manufacturers", "of", "drugs,", "devices,", "biologics", "and", "medical", "supplies", "for", "which", "payment", "is", "available", "under", "Medicare,", "Medicaid", "or", "the", "Children", "s", "Health", "Insurance", "Program", "for", "certain", "payments", "and", "other", "transfers", "of", "value", "provided", "to", "physicians", "and", "teaching", "hospitals,", "and", "ownership", "and", "investment", "interests", "held", "by", "physicians", "and", "their", "immediate", "family", "members.", "<tag3>"], "wordsA": ["The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Medicare", "Part", "D", "went", "into", "effect", "on", "January", "1,", "2006."], "wordsB": ["The", "Physician", "Payments", "Sunshine", "Act,", "enacted", "as", "part", "of", "the", "ACA,", "as", "amended", "by", "the", "Health", "Care", "and", "Education", "Reconciliation", "Act", "of", "2010,", "which", "imposed", "new", "annual", "reporting", "requirements", "for", "certain", "manufacturers", "of", "drugs,", "devices,", "biologics", "and", "medical", "supplies", "for", "which", "payment", "is", "available", "under", "Medicare,", "Medicaid", "or", "the", "Children", "s", "Health", "Insurance", "Program", "for", "certain", "payments", "and", "other", "transfers", "of", "value", "provided", "to", "physicians", "and", "teaching", "hospitals,", "and", "ownership", "and", "investment", "interests", "held", "by", "physicians", "and", "their", "immediate", "family", "members."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p161_s0", "idA": "1316175_17_item1_p151_s1", "sentA": "For example, a company may be debarred from participation if it is found to have violated federal anti-kickback laws, which could have a significant effect on a company s ability to operate its business.", "sentB": "Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor.", "type": 1, "words": ["<tag1>", "For", "example,", "a", "company", "may", "be", "debarred", "from", "participation", "if", "it", "is", "found", "to", "have", "violated", "federal", "anti-kickback", "laws,", "which", "could", "have", "a", "significant", "effect", "on", "a", "company", "s", "ability", "to", "operate", "its", "business.", "<tag2>", "Analogous", "state", "and", "foreign", "fraud", "and", "abuse", "laws", "and", "regulations,", "such", "as", "state", "anti-kickback", "and", "false", "claims", "laws,", "which", "may", "be", "broader", "in", "scope", "and", "apply", "regardless", "of", "payor.", "<tag3>"], "wordsA": ["For", "example,", "a", "company", "may", "be", "debarred", "from", "participation", "if", "it", "is", "found", "to", "have", "violated", "federal", "anti-kickback", "laws,", "which", "could", "have", "a", "significant", "effect", "on", "a", "company", "s", "ability", "to", "operate", "its", "business."], "wordsB": ["Analogous", "state", "and", "foreign", "fraud", "and", "abuse", "laws", "and", "regulations,", "such", "as", "state", "anti-kickback", "and", "false", "claims", "laws,", "which", "may", "be", "broader", "in", "scope", "and", "apply", "regardless", "of", "payor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p163_s3", "idA": "1316175_17_item1_p151_s1", "sentA": "For example, a company may be debarred from participation if it is found to have violated federal anti-kickback laws, which could have a significant effect on a company s ability to operate its business.", "sentB": "If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions.", "type": 1, "words": ["<tag1>", "For", "example,", "a", "company", "may", "be", "debarred", "from", "participation", "if", "it", "is", "found", "to", "have", "violated", "federal", "anti-kickback", "laws,", "which", "could", "have", "a", "significant", "effect", "on", "a", "company", "s", "ability", "to", "operate", "its", "business.", "<tag2>", "If", "any", "of", "the", "physicians", "or", "other", "healthcare", "providers", "or", "entities", "with", "whom", "we", "expect", "to", "do", "business", "is", "found", "to", "be", "not", "in", "compliance", "with", "applicable", "laws,", "they", "may", "be", "subject", "to", "similar", "actions,", "penalties", "and", "sanctions.", "<tag3>"], "wordsA": ["For", "example,", "a", "company", "may", "be", "debarred", "from", "participation", "if", "it", "is", "found", "to", "have", "violated", "federal", "anti-kickback", "laws,", "which", "could", "have", "a", "significant", "effect", "on", "a", "company", "s", "ability", "to", "operate", "its", "business."], "wordsB": ["If", "any", "of", "the", "physicians", "or", "other", "healthcare", "providers", "or", "entities", "with", "whom", "we", "expect", "to", "do", "business", "is", "found", "to", "be", "not", "in", "compliance", "with", "applicable", "laws,", "they", "may", "be", "subject", "to", "similar", "actions,", "penalties", "and", "sanctions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p134_s0", "idA": "1316175_17_item1_p152_s2", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs.", "type": 1, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "Adoption", "of", "general", "controls", "and", "measures,", "coupled", "with", "the", "tightening", "of", "restrictive", "policies", "in", "jurisdictions", "with", "existing", "controls", "and", "measures,", "could", "limit", "payments", "for", "pharmaceutical", "drugs.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["Adoption", "of", "general", "controls", "and", "measures,", "coupled", "with", "the", "tightening", "of", "restrictive", "policies", "in", "jurisdictions", "with", "existing", "controls", "and", "measures,", "could", "limit", "payments", "for", "pharmaceutical", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p144_s0", "idA": "1316175_17_item1_p154_s0", "sentA": "While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably.", "sentB": "These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.", "type": 1, "words": ["<tag1>", "While", "we", "cannot", "predict", "whether", "any", "proposed", "cost-containment", "measures", "will", "be", "adopted", "or", "otherwise", "implemented", "in", "the", "future,", "the", "announcement", "or", "adoption", "of", "these", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "ability", "to", "obtain", "adequate", "prices", "for", "our", "product", "candidates", "and", "operate", "profitably.", "<tag2>", "These", "laws,", "and", "future", "state", "and", "federal", "healthcare", "reform", "measures", "may", "be", "adopted", "in", "the", "future,", "any", "of", "which", "may", "result", "in", "additional", "reductions", "in", "Medicare", "and", "other", "healthcare", "funding", "and", "otherwise", "affect", "the", "prices", "we", "may", "obtain", "for", "any", "product", "candidates", "for", "which", "we", "may", "obtain", "regulatory", "approval", "or", "the", "frequency", "with", "which", "any", "such", "product", "candidate", "is", "prescribed", "or", "used.", "<tag3>"], "wordsA": ["While", "we", "cannot", "predict", "whether", "any", "proposed", "cost-containment", "measures", "will", "be", "adopted", "or", "otherwise", "implemented", "in", "the", "future,", "the", "announcement", "or", "adoption", "of", "these", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "ability", "to", "obtain", "adequate", "prices", "for", "our", "product", "candidates", "and", "operate", "profitably."], "wordsB": ["These", "laws,", "and", "future", "state", "and", "federal", "healthcare", "reform", "measures", "may", "be", "adopted", "in", "the", "future,", "any", "of", "which", "may", "result", "in", "additional", "reductions", "in", "Medicare", "and", "other", "healthcare", "funding", "and", "otherwise", "affect", "the", "prices", "we", "may", "obtain", "for", "any", "product", "candidates", "for", "which", "we", "may", "obtain", "regulatory", "approval", "or", "the", "frequency", "with", "which", "any", "such", "product", "candidate", "is", "prescribed", "or", "used."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p140_s0", "idA": "1316175_17_item1_p156_s2", "sentA": "A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.", "sentB": "In recent years, additional laws have resulted in direct or indirect reimbursement reductions for certain Medicare providers, including:", "type": 1, "words": ["<tag1>", "A", "member", "state", "may", "approve", "a", "specific", "price", "for", "the", "medicinal", "product", "or", "it", "may", "instead", "adopt", "a", "system", "of", "direct", "or", "indirect", "controls", "on", "the", "profitability", "of", "the", "company", "placing", "the", "medicinal", "product", "on", "the", "market.", "<tag2>", "In", "recent", "years,", "additional", "laws", "have", "resulted", "in", "direct", "or", "indirect", "reimbursement", "reductions", "for", "certain", "Medicare", "providers,", "including:", "<tag3>"], "wordsA": ["A", "member", "state", "may", "approve", "a", "specific", "price", "for", "the", "medicinal", "product", "or", "it", "may", "instead", "adopt", "a", "system", "of", "direct", "or", "indirect", "controls", "on", "the", "profitability", "of", "the", "company", "placing", "the", "medicinal", "product", "on", "the", "market."], "wordsB": ["In", "recent", "years,", "additional", "laws", "have", "resulted", "in", "direct", "or", "indirect", "reimbursement", "reductions", "for", "certain", "Medicare", "providers,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p138_s1", "idA": "1316175_17_item1_p18_s0", "sentA": "Based on the data produced by the SOLUTION study, we plan to amend the SIMPLICITY study to follow similar dosing paradigm as the RESULT study.", "sentB": "The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "data", "produced", "by", "the", "SOLUTION", "study,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "similar", "dosing", "paradigm", "as", "the", "RESULT", "study.", "<tag2>", "The", "required", "340B", "discount", "on", "a", "given", "product", "is", "calculated", "based", "on", "the", "AMP", "and", "Medicaid", "rebate", "amounts", "reported", "by", "the", "manufacturer.", "<tag3>"], "wordsA": ["Based", "on", "the", "data", "produced", "by", "the", "SOLUTION", "study,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "similar", "dosing", "paradigm", "as", "the", "RESULT", "study."], "wordsB": ["The", "required", "340B", "discount", "on", "a", "given", "product", "is", "calculated", "based", "on", "the", "AMP", "and", "Medicaid", "rebate", "amounts", "reported", "by", "the", "manufacturer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p15_s5", "idA": "1316175_17_item1_p19_s2", "sentA": "We currently plan to continue the EASY study until the BLA for Sollpura is approved by the FDA.", "sentB": "Furthermore, the study had been approved by the Cystic Fibrosis Foundation Therapeutics Development Network ( CFFTDN ) Protocol Review Committee, and the European Cystic Fibrosis Society Clinical Trial Network Executive Committee.", "type": 1, "words": ["<tag1>", "We", "currently", "plan", "to", "continue", "the", "EASY", "study", "until", "the", "BLA", "for", "Sollpura", "is", "approved", "by", "the", "FDA.", "<tag2>", "Furthermore,", "the", "study", "had", "been", "approved", "by", "the", "Cystic", "Fibrosis", "Foundation", "Therapeutics", "Development", "Network", "(", "CFFTDN", ")", "Protocol", "Review", "Committee,", "and", "the", "European", "Cystic", "Fibrosis", "Society", "Clinical", "Trial", "Network", "Executive", "Committee.", "<tag3>"], "wordsA": ["We", "currently", "plan", "to", "continue", "the", "EASY", "study", "until", "the", "BLA", "for", "Sollpura", "is", "approved", "by", "the", "FDA."], "wordsB": ["Furthermore,", "the", "study", "had", "been", "approved", "by", "the", "Cystic", "Fibrosis", "Foundation", "Therapeutics", "Development", "Network", "(", "CFFTDN", ")", "Protocol", "Review", "Committee,", "and", "the", "European", "Cystic", "Fibrosis", "Society", "Clinical", "Trial", "Network", "Executive", "Committee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p159_s1", "idA": "1316175_17_item1_p24_s2", "sentA": "Abnormally high elevations of BAFF, B-cells and plasma cells have been associated with several autoimmune diseases, including lupus and IgA nephropathy.", "sentB": "HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties applicable to business associates, and gave state attorneys general new authority to file civil actions for damage or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys fees and costs associated with pursuing federal civil actions.", "type": 1, "words": ["<tag1>", "Abnormally", "high", "elevations", "of", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases,", "including", "lupus", "and", "IgA", "nephropathy.", "<tag2>", "HITECH", "also", "created", "new", "tiers", "of", "civil", "monetary", "penalties,", "amended", "HIPAA", "to", "make", "civil", "and", "criminal", "penalties", "applicable", "to", "business", "associates,", "and", "gave", "state", "attorneys", "general", "new", "authority", "to", "file", "civil", "actions", "for", "damage", "or", "injunctions", "in", "federal", "courts", "to", "enforce", "the", "federal", "HIPAA", "laws", "and", "seek", "attorneys", "fees", "and", "costs", "associated", "with", "pursuing", "federal", "civil", "actions.", "<tag3>"], "wordsA": ["Abnormally", "high", "elevations", "of", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases,", "including", "lupus", "and", "IgA", "nephropathy."], "wordsB": ["HITECH", "also", "created", "new", "tiers", "of", "civil", "monetary", "penalties,", "amended", "HIPAA", "to", "make", "civil", "and", "criminal", "penalties", "applicable", "to", "business", "associates,", "and", "gave", "state", "attorneys", "general", "new", "authority", "to", "file", "civil", "actions", "for", "damage", "or", "injunctions", "in", "federal", "courts", "to", "enforce", "the", "federal", "HIPAA", "laws", "and", "seek", "attorneys", "fees", "and", "costs", "associated", "with", "pursuing", "federal", "civil", "actions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s10", "idA": "1316175_17_item1_p50_s0", "sentA": "There is also a striking geographic variation in the prevalence of IgA nephropathy throughout the world.", "sentB": "Furthermore, serum immunoglobulins IgA, IgG, and IgM, demonstrated marked reduction throughout the treatment period.", "type": 1, "words": ["<tag1>", "There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgA", "nephropathy", "throughout", "the", "world.", "<tag2>", "Furthermore,", "serum", "immunoglobulins", "IgA,", "IgG,", "and", "IgM,", "demonstrated", "marked", "reduction", "throughout", "the", "treatment", "period.", "<tag3>"], "wordsA": ["There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgA", "nephropathy", "throughout", "the", "world."], "wordsB": ["Furthermore,", "serum", "immunoglobulins", "IgA,", "IgG,", "and", "IgM,", "demonstrated", "marked", "reduction", "throughout", "the", "treatment", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s7", "idA": "1316175_17_item1_p53_s1", "sentA": "We also scaled up manufacturing from 300 liters up to 3,000 liters.", "sentB": "Throughout the treatment period and for up to one year of additional follow up off treatment, blisibimod appeared to halt disease progression as measured by the mean estimate of urinary protein:creatinine levels (\"proteinuria\").", "type": 1, "words": ["<tag1>", "We", "also", "scaled", "up", "manufacturing", "from", "300", "liters", "up", "to", "3,000", "liters.", "<tag2>", "Throughout", "the", "treatment", "period", "and", "for", "up", "to", "one", "year", "of", "additional", "follow", "up", "off", "treatment,", "blisibimod", "appeared", "to", "halt", "disease", "progression", "as", "measured", "by", "the", "mean", "estimate", "of", "urinary", "protein:creatinine", "levels", "(\"proteinuria\").", "<tag3>"], "wordsA": ["We", "also", "scaled", "up", "manufacturing", "from", "300", "liters", "up", "to", "3,000", "liters."], "wordsB": ["Throughout", "the", "treatment", "period", "and", "for", "up", "to", "one", "year", "of", "additional", "follow", "up", "off", "treatment,", "blisibimod", "appeared", "to", "halt", "disease", "progression", "as", "measured", "by", "the", "mean", "estimate", "of", "urinary", "protein:creatinine", "levels", "(\"proteinuria\")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p99_s0", "idA": "1316175_17_item1_p54_s3", "sentA": "As a result of the narrow miss we intend to initiate a new Phase 3 study, RESULT, incorporating the learnings from the SOLUTION study.", "sentB": "A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration is required to submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or, if there is no end-of-Phase 2 meeting as early as practicable before the initiation of the Phase 3 or Phase 2/3 study.", "type": 1, "words": ["<tag1>", "As", "a", "result", "of", "the", "narrow", "miss", "we", "intend", "to", "initiate", "a", "new", "Phase", "3", "study,", "RESULT,", "incorporating", "the", "learnings", "from", "the", "SOLUTION", "study.", "<tag2>", "A", "sponsor", "who", "is", "planning", "to", "submit", "a", "marketing", "application", "for", "a", "drug", "that", "includes", "a", "new", "active", "ingredient,", "new", "indication,", "new", "dosage", "form,", "new", "dosing", "regimen", "or", "new", "route", "of", "administration", "is", "required", "to", "submit", "an", "initial", "Pediatric", "Study", "Plan,", "or", "PSP,", "within", "sixty", "days", "of", "an", "end-of-Phase", "2", "meeting", "or,", "if", "there", "is", "no", "end-of-Phase", "2", "meeting", "as", "early", "as", "practicable", "before", "the", "initiation", "of", "the", "Phase", "3", "or", "Phase", "2/3", "study.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "narrow", "miss", "we", "intend", "to", "initiate", "a", "new", "Phase", "3", "study,", "RESULT,", "incorporating", "the", "learnings", "from", "the", "SOLUTION", "study."], "wordsB": ["A", "sponsor", "who", "is", "planning", "to", "submit", "a", "marketing", "application", "for", "a", "drug", "that", "includes", "a", "new", "active", "ingredient,", "new", "indication,", "new", "dosage", "form,", "new", "dosing", "regimen", "or", "new", "route", "of", "administration", "is", "required", "to", "submit", "an", "initial", "Pediatric", "Study", "Plan,", "or", "PSP,", "within", "sixty", "days", "of", "an", "end-of-Phase", "2", "meeting", "or,", "if", "there", "is", "no", "end-of-Phase", "2", "meeting", "as", "early", "as", "practicable", "before", "the", "initiation", "of", "the", "Phase", "3", "or", "Phase", "2/3", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p40_s3", "idA": "1316175_17_item1_p57_s2", "sentA": "Two short-term trials, the Phase 2 Study TC-2A, and the Phase 3 Study 726 evaluated the efficacy of Sollpura in subjects 7 years of age with EPI due to CF.", "sentB": "We anticipate completing the Phase 3 clinical trials with Sollpura (the RESULT and SIMPLICITY studies) in 2018, and process validation for commercial manufacture of Sollpura APIs and drug product in 2019, with a target submission date of the Biologics Licence Application ( BLA ) in 2019.", "type": 1, "words": ["<tag1>", "Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC-2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "Sollpura", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF.", "<tag2>", "We", "anticipate", "completing", "the", "Phase", "3", "clinical", "trials", "with", "Sollpura", "(the", "RESULT", "and", "SIMPLICITY", "studies)", "in", "2018,", "and", "process", "validation", "for", "commercial", "manufacture", "of", "Sollpura", "APIs", "and", "drug", "product", "in", "2019,", "with", "a", "target", "submission", "date", "of", "the", "Biologics", "Licence", "Application", "(", "BLA", ")", "in", "2019.", "<tag3>"], "wordsA": ["Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC-2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "Sollpura", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF."], "wordsB": ["We", "anticipate", "completing", "the", "Phase", "3", "clinical", "trials", "with", "Sollpura", "(the", "RESULT", "and", "SIMPLICITY", "studies)", "in", "2018,", "and", "process", "validation", "for", "commercial", "manufacture", "of", "Sollpura", "APIs", "and", "drug", "product", "in", "2019,", "with", "a", "target", "submission", "date", "of", "the", "Biologics", "Licence", "Application", "(", "BLA", ")", "in", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p51_s0", "idA": "1316175_17_item1_p60_s2", "sentA": "Pairwise comparison of the CFA values showed that statistically greater improvements were observed at the higher doses of Sollpura compared with the lowest dose of 6,500 U. Similar improvements in the CNA, were observed with Sollpura at the two highest dose levels.", "sentB": "There was a statistically-significant steroid sparing effect among subjects randomized to blisibimod wherein 17.2% of subjects in the blisibimod group achieved corticosteroid dose of less than or equivalent to 7.5 mg prednisone compared with 8.9% in the control group (p=0.019).", "type": 1, "words": ["<tag1>", "Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "Sollpura", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U.", "Similar", "improvements", "in", "the", "CNA,", "were", "observed", "with", "Sollpura", "at", "the", "two", "highest", "dose", "levels.", "<tag2>", "There", "was", "a", "statistically-significant", "steroid", "sparing", "effect", "among", "subjects", "randomized", "to", "blisibimod", "wherein", "17.2%", "of", "subjects", "in", "the", "blisibimod", "group", "achieved", "corticosteroid", "dose", "of", "less", "than", "or", "equivalent", "to", "7.5", "mg", "prednisone", "compared", "with", "8.9%", "in", "the", "control", "group", "(p=0.019).", "<tag3>"], "wordsA": ["Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "Sollpura", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U.", "Similar", "improvements", "in", "the", "CNA,", "were", "observed", "with", "Sollpura", "at", "the", "two", "highest", "dose", "levels."], "wordsB": ["There", "was", "a", "statistically-significant", "steroid", "sparing", "effect", "among", "subjects", "randomized", "to", "blisibimod", "wherein", "17.2%", "of", "subjects", "in", "the", "blisibimod", "group", "achieved", "corticosteroid", "dose", "of", "less", "than", "or", "equivalent", "to", "7.5", "mg", "prednisone", "compared", "with", "8.9%", "in", "the", "control", "group", "(p=0.019)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p161_s1", "idA": "1316175_17_item1_p69_s1", "sentA": "Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions.", "sentB": "Such laws are enforced by various state agencies and through private actions.", "type": 1, "words": ["<tag1>", "Our", "potential", "competitors", "include", "large", "pharmaceutical", "and", "biotechnology", "companies,", "specialty", "pharmaceutical", "and", "generic", "drug", "companies,", "academic", "institutions,", "government", "agencies", "and", "research", "institutions.", "<tag2>", "Such", "laws", "are", "enforced", "by", "various", "state", "agencies", "and", "through", "private", "actions.", "<tag3>"], "wordsA": ["Our", "potential", "competitors", "include", "large", "pharmaceutical", "and", "biotechnology", "companies,", "specialty", "pharmaceutical", "and", "generic", "drug", "companies,", "academic", "institutions,", "government", "agencies", "and", "research", "institutions."], "wordsB": ["Such", "laws", "are", "enforced", "by", "various", "state", "agencies", "and", "through", "private", "actions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p161_s4", "idA": "1316175_17_item1_p85_s0", "sentA": "The requirements for filing a provisional patent application are not as strict as those for filing a non-provisional patent application.", "sentB": "Such data privacy and security laws may differ from one another in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.", "type": 1, "words": ["<tag1>", "The", "requirements", "for", "filing", "a", "provisional", "patent", "application", "are", "not", "as", "strict", "as", "those", "for", "filing", "a", "non-provisional", "patent", "application.", "<tag2>", "Such", "data", "privacy", "and", "security", "laws", "may", "differ", "from", "one", "another", "in", "significant", "ways", "and", "often", "are", "not", "preempted", "by", "HIPAA,", "thus", "complicating", "compliance", "efforts.", "<tag3>"], "wordsA": ["The", "requirements", "for", "filing", "a", "provisional", "patent", "application", "are", "not", "as", "strict", "as", "those", "for", "filing", "a", "non-provisional", "patent", "application."], "wordsB": ["Such", "data", "privacy", "and", "security", "laws", "may", "differ", "from", "one", "another", "in", "significant", "ways", "and", "often", "are", "not", "preempted", "by", "HIPAA,", "thus", "complicating", "compliance", "efforts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p142_s0", "idA": "1316175_17_item1_p85_s1", "sentA": "Provisional applications are often used, among other things, to establish an early filing date for a subsequent non-provisional patent application.", "sentB": "The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.", "type": 1, "words": ["<tag1>", "Provisional", "applications", "are", "often", "used,", "among", "other", "things,", "to", "establish", "an", "early", "filing", "date", "for", "a", "subsequent", "non-provisional", "patent", "application.", "<tag2>", "The", "American", "Taxpayer", "Relief", "Act", "of", "2012,", "among", "other", "things,", "reduced", "Medicare", "payments", "to", "several", "providers,", "and", "increased", "the", "statute", "of", "limitations", "period", "for", "the", "government", "to", "recover", "overpayments", "to", "providers", "from", "three", "to", "five", "years.", "<tag3>"], "wordsA": ["Provisional", "applications", "are", "often", "used,", "among", "other", "things,", "to", "establish", "an", "early", "filing", "date", "for", "a", "subsequent", "non-provisional", "patent", "application."], "wordsB": ["The", "American", "Taxpayer", "Relief", "Act", "of", "2012,", "among", "other", "things,", "reduced", "Medicare", "payments", "to", "several", "providers,", "and", "increased", "the", "statute", "of", "limitations", "period", "for", "the", "government", "to", "recover", "overpayments", "to", "providers", "from", "three", "to", "five", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p138_s3", "idA": "1316175_17_item1_p91_s3", "sentA": "Furthermore, we are required to make tiered quarterly royalty payments on net sales, which increase as a percentage from the high single digits to the low double digits as net sales increase.", "sentB": "As 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.", "type": 1, "words": ["<tag1>", "Furthermore,", "we", "are", "required", "to", "make", "tiered", "quarterly", "royalty", "payments", "on", "net", "sales,", "which", "increase", "as", "a", "percentage", "from", "the", "high", "single", "digits", "to", "the", "low", "double", "digits", "as", "net", "sales", "increase.", "<tag2>", "As", "340B", "drug", "pricing", "is", "determined", "based", "on", "AMP", "and", "Medicaid", "rebate", "data,", "the", "revisions", "to", "the", "Medicaid", "rebate", "formula", "and", "AMP", "definition", "described", "above", "could", "cause", "the", "required", "340B", "discount", "to", "increase.", "<tag3>"], "wordsA": ["Furthermore,", "we", "are", "required", "to", "make", "tiered", "quarterly", "royalty", "payments", "on", "net", "sales,", "which", "increase", "as", "a", "percentage", "from", "the", "high", "single", "digits", "to", "the", "low", "double", "digits", "as", "net", "sales", "increase."], "wordsB": ["As", "340B", "drug", "pricing", "is", "determined", "based", "on", "AMP", "and", "Medicaid", "rebate", "data,", "the", "revisions", "to", "the", "Medicaid", "rebate", "formula", "and", "AMP", "definition", "described", "above", "could", "cause", "the", "required", "340B", "discount", "to", "increase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p158_s0", "idA": "1316175_17_item1_p95_s3", "sentA": "We did not incur any termination penalties in connection with the early termination of the Zenyaku Agreement by Zenyaku.", "sentB": "Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly or willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.", "type": 1, "words": ["<tag1>", "We", "did", "not", "incur", "any", "termination", "penalties", "in", "connection", "with", "the", "early", "termination", "of", "the", "Zenyaku", "Agreement", "by", "Zenyaku.", "<tag2>", "Health", "Insurance", "Portability", "and", "Accountability", "Act", "of", "1996,", "or", "HIPAA,", "which", "imposes", "criminal", "and", "civil", "liability", "for", "knowingly", "and", "willfully", "executing,", "or", "attempting", "to", "execute,", "a", "scheme", "to", "defraud", "any", "healthcare", "benefit", "program,", "including", "private", "payors,", "knowingly", "and", "willfully", "embezzling", "or", "stealing", "from", "a", "healthcare", "benefit", "program,", "willfully", "obstructing", "a", "criminal", "investigation", "of", "a", "healthcare", "offense,", "and", "knowingly", "or", "willfully", "falsifying,", "concealing", "or", "covering", "up", "a", "material", "fact", "or", "making", "any", "materially", "false,", "fictitious", "or", "fraudulent", "statement", "in", "connection", "with", "the", "delivery", "of", "or", "payment", "for", "healthcare", "benefits,", "items", "or", "services.", "<tag3>"], "wordsA": ["We", "did", "not", "incur", "any", "termination", "penalties", "in", "connection", "with", "the", "early", "termination", "of", "the", "Zenyaku", "Agreement", "by", "Zenyaku."], "wordsB": ["Health", "Insurance", "Portability", "and", "Accountability", "Act", "of", "1996,", "or", "HIPAA,", "which", "imposes", "criminal", "and", "civil", "liability", "for", "knowingly", "and", "willfully", "executing,", "or", "attempting", "to", "execute,", "a", "scheme", "to", "defraud", "any", "healthcare", "benefit", "program,", "including", "private", "payors,", "knowingly", "and", "willfully", "embezzling", "or", "stealing", "from", "a", "healthcare", "benefit", "program,", "willfully", "obstructing", "a", "criminal", "investigation", "of", "a", "healthcare", "offense,", "and", "knowingly", "or", "willfully", "falsifying,", "concealing", "or", "covering", "up", "a", "material", "fact", "or", "making", "any", "materially", "false,", "fictitious", "or", "fraudulent", "statement", "in", "connection", "with", "the", "delivery", "of", "or", "payment", "for", "healthcare", "benefits,", "items", "or", "services."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p163_s2", "idA": "1316175_17_item1_p97_s2", "sentA": "We do not have in place long term supply agreements with respect to all of the components of any of our pharmaceutical systems, however, and are subject to the risk that we may not be able to procure all required components in adequate quantities with acceptable quality, within acceptable time frames or at reasonable cost.", "sentB": "If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement ,exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.", "type": 1, "words": ["<tag1>", "We", "do", "not", "have", "in", "place", "long", "term", "supply", "agreements", "with", "respect", "to", "all", "of", "the", "components", "of", "any", "of", "our", "pharmaceutical", "systems,", "however,", "and", "are", "subject", "to", "the", "risk", "that", "we", "may", "not", "be", "able", "to", "procure", "all", "required", "components", "in", "adequate", "quantities", "with", "acceptable", "quality,", "within", "acceptable", "time", "frames", "or", "at", "reasonable", "cost.", "<tag2>", "If", "our", "operations", "are", "found", "to", "be", "in", "violation", "of", "any", "of", "these", "laws", "or", "any", "other", "related", "governmental", "regulations", "that", "may", "apply", "to", "us,", "we", "may", "be", "subject", "to", "significant", "civil,", "criminal", "and", "administrative", "penalties,", "damages,", "fines,", "imprisonment,", "disgorgement", ",exclusion", "of", "drugs", "from", "government", "funded", "healthcare", "programs,", "such", "as", "Medicare", "and", "Medicaid,", "reputational", "harm,", "additional", "oversight", "and", "reporting", "obligations", "if", "we", "become", "subject", "to", "a", "corporate", "integrity", "agreement", "or", "similar", "settlement", "to", "resolve", "allegations", "of", "non-compliance", "with", "these", "laws", "and", "the", "curtailment", "or", "restructuring", "of", "our", "operations.", "<tag3>"], "wordsA": ["We", "do", "not", "have", "in", "place", "long", "term", "supply", "agreements", "with", "respect", "to", "all", "of", "the", "components", "of", "any", "of", "our", "pharmaceutical", "systems,", "however,", "and", "are", "subject", "to", "the", "risk", "that", "we", "may", "not", "be", "able", "to", "procure", "all", "required", "components", "in", "adequate", "quantities", "with", "acceptable", "quality,", "within", "acceptable", "time", "frames", "or", "at", "reasonable", "cost."], "wordsB": ["If", "our", "operations", "are", "found", "to", "be", "in", "violation", "of", "any", "of", "these", "laws", "or", "any", "other", "related", "governmental", "regulations", "that", "may", "apply", "to", "us,", "we", "may", "be", "subject", "to", "significant", "civil,", "criminal", "and", "administrative", "penalties,", "damages,", "fines,", "imprisonment,", "disgorgement", ",exclusion", "of", "drugs", "from", "government", "funded", "healthcare", "programs,", "such", "as", "Medicare", "and", "Medicaid,", "reputational", "harm,", "additional", "oversight", "and", "reporting", "obligations", "if", "we", "become", "subject", "to", "a", "corporate", "integrity", "agreement", "or", "similar", "settlement", "to", "resolve", "allegations", "of", "non-compliance", "with", "these", "laws", "and", "the", "curtailment", "or", "restructuring", "of", "our", "operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
